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PROPOSITIONS
1. Blood pressure in older adult populations can be reduced by more than 
10 mmHg when optimizing sodium and potassium intake. 
 (this thesis)
2. Changes in blood pressure are not necessarily accompanied by changes 
in vascular function.
 (this thesis)
3. Waiting for medical ethical approval in infection disease outbreaks is 
unethical.
4. In life sciences, standardized collection, analysis and reporting of trial data 
is required to foster scientific progress.
5. Putting sustainability labels on foods wrongly suggests that unlabeled foods 
in that category are non-sustainable.
  
6. Statutes of limitations for criminal cases are outdated.
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Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality. Annually, 
about 17.5 million people die from CVD, accounting for ~30% of deaths worldwide [1]. 
Elevated blood pressure (BP) is a major risk factor for CVD [2, 3] and the largest single 
contributor to global mortality, according to the World Health Organization [1]. In 2015, BP 
accounted for 9.2% of the Disability Adjusted Life Years (DALYs) in men and 7.8% of DALYs 
in women [4]. BP is a modifiable risk factor that is largely determined by lifestyle factors, 
including diet [5]. Dietary minerals, in particular sodium and potassium, play an important 
role in BP regulation [6]. While adverse effects of sodium and beneficial effects of potassium 
on BP have repeatedly been shown in human intervention studies, less is known about 
other vascular effects of these dietary minerals that could influence CVD risk. The present 
thesis aims at studying the BP effects of sodium and potassium intake in healthy humans 
in a broader (patho)physiological context, focusing also on endothelial function, arterial 
stiffness, body fluid balance and heart rate.  
Sodium and Potassium Intake
The human body needs ~0.5 g/d of sodium for maintaining plasma volume, acid-base 
balance and cellular functions, including smooth muscle cells [7, 8]. Sodium is mostly 
consumed as table salt (sodium chloride) added to foods, with each 2.5 g of salt containing 
1 g of sodium. Around the world people consume on average 9−12 g of salt on a daily basis, 
which is far beyond the recommended maximum intake of 5−6 g/d (1.5−2.4 g of sodium) [9-
12]. In the Netherlands, about 80% of the salt in the diet is added by food manufacturers. An 
additional 5 to 10% is naturally present in foods, and 10 to 15% is added during cooking or 
at the table (i.e. discretionary salt) [13]. Around 90% of sodium consumed is excreted in urine 
[8]. Averaging multiple 24-h urine samples is considered the gold standard for estimating 
an individual’s daily sodium intake. Methods based on reported food intake are inadequate 
because they fail to take discretionary salt use into account [14]. Also, they are hampered by 
the huge variability in sodium content in processed foods, depending on the manufacturer, 
which is not well captured in food composition databases [15]. 
Potassium is an essential nutrient, which is together with sodium involved in the distribution 
of body fluids, regulation of the acid-base balance, nerve impulse transmission and muscle 
contraction [16]. The main dietary sources of potassium are fruit and vegetables, legumes, 
whole grains, and dairy products [17]. Most countries lack specific guidelines for potassium 
intake, but the European Food and Safety Authority considers 3.5 g/d as an Adequate Intake 
for European populations [11]. A study of 21 countries across the world by Van Mierlo et 
al. [18] showed that the mean daily potassium intake ranged from 1.7 g in China to 3.7 g 
in Northern Europe. Adherence to the dietary guidelines, especially for fruit and vegetables, 
would increase current levels of potassium intake in Western populations to US guideline 
4.7 g/d, as was also the target in the well-known DASH trial for hypertension prevention [16, 
18, 19]. Of all potassium consumed, 77−92% of is excreted in urine [20]. As long as there is 
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no widespread use of potassium-containing salt substitutes by consumers or food industry, 
dietary assessment methods that make use of food composition tables can provide rather 
adequate estimations of daily potassium intake [21]. 
BP and Vascular Health
Hypertension, defined as a systolic BP ≥ 140 mmHg, diastolic BP ≥ 90 mmHg or use of 
antihypertensive medication [22], affects ~25% of the world’s adult population [23]. Increasing 
BP increases the risk of cardiovascular morbidity and mortality, starting from levels as low as 
115/75 mmHg [2]. It has been estimated that a population-wide reduction in systolic BP of 3 
mmHg is associated with a ~13% lower risk of stroke death and ~10% lower risk of death from 
ischemic heart disease or other vascular causes in a middle-aged population [2]. Twenty-
four-hour ambulatory BP, which includes repeated readings during day and night that are 
free from white-coat effect, may be superior in predicting cardiovascular morbidity and 
mortality compared to office measurements [24]. 
The endothelium is the thin layer of cells that covers the inner wall of blood vessels. It 
is involved in physiological functions related to vascular health, including regulation of 
vascular tone, coagulation and inflammatory processes [25]. Endothelial cells synthesize 
and release biologically active substances that play a role in these processes. An imbalance 
in these substances may result in endothelial dysfunction, which is characterized by 
impairment of endothelial-dependent vasodilation and proinflammatory, proliferative, 
and procoagulatory features [26]. Higher circulating concentrations of cytokines, adhesion 
molecules and regulators of thrombosis and coagulation markers may reflect dysfunction 
of the endothelium and more inflammatory activity. Endothelium-dependent vasodilation 
can be assessed by the noninvasive measurement of flow-mediated dilation (FMD). Using 
high-resolution ultrasound, this method quantifies the change in diameter of the brachial 
artery in response to reactive hyperemia [27]. FMD is the most accepted and established 
method to study endothelial function, also because it could have predictive value for CVD 
events [28, 29].
Another measure of vascular health is arterial stiffness, which is one of the earliest detectable 
manifestations of adverse structural changes within the vessel wall [30]. Pulse wave velocity 
(PWV) is the direct measure of arterial stiffness [31], and high PWV values have been associated 
with increased risk of CVD [32]. An indirect measure of arterial stiffness is augmentation index, 
which is deduced from a pulse wave analysis of the radial artery.
Sodium, Potassium and BP 
Meta-analyses of randomized controlled trials (RCTs) have repeatedly shown that a 
reduced sodium and increased potassium intake lowers BP [33-38]. In a meta-analysis of 
34 randomized trials with a minimum duration of 4 weeks, He et al. [38] showed reductions 
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of 4.2 mmHg in systolic BP and 2.1 mmHg in diastolic BP for a 75 mmol lower 24-h sodium 
excretion (i.e. 1.7 g sodium or 4.4 g salt per day) in adults not on antihypertensive medication. 
A significant dose-response relation was found, with larger effects in hypertensives than 
normotensives (-5.4 mmHg vs -2.4 mmHg for systolic BP). 
In a meta-analysis of 22 trials by Aburto et al. [37], potassium supplementation (~2 g/d) 
reduced systolic/diastolic BP by 3.5/2.0 mmHg, an effect that was more pronounced in 
hypertensives. No clear dose-response relation was observed. Although not significantly 
different, the BP reduction was 6.9/2.9 mmHg when baseline sodium intake was high (> 
4 g/d) compared to 2.0/2.0 mmHg at lower sodium intake (2−4 g/d). A larger BP response 
after potassium supplementation in populations with a high salt intake was also found in an 
earlier meta-analysis by Whelton et al. [36]. 
Sodium, Potassium and Other Vascular Outcomes
Endothelial function - Limited studies have addressed the effects of sodium and potassium 
intake on endothelial function. RCTs with sodium reductions ranging from 1.4 to 2.3 g/d for 
a period of 2−6 weeks showed improvements in brachial artery FMD of 1.5−2.4% [39-41]. 
Studies on the effects of sodium intake on biochemical markers have primarily focused on 
vasoconstrictor endothelin-1, showing inconclusive results [39, 41-44]. 
Supplemental potassium of 2.5 g/d for 4 weeks improved FMD, with larger effect for potassium 
chloride supplements (2.7%) than for potassium bicarbonate supplements (1.5%) [45]. An 
RCT with a potassium dose of 1.6 g/d for 6 weeks demonstrated no change in FMD [46]. RCTs 
in which potassium was increased for at least 4 weeks showed no effect on endothelin-1 [47], 
soluble adhesion molecules or inflammation marker C-reactive protein [46, 48]. 
Body fluid balance - A key aspect in long-term regulation of BP is fluid balance, which is 
regulated by means of osmoregulation and volume regulation [49]. Body fluid volume and 
electrolyte concentration are maintained within very narrow limits despite wide variations in 
dietary sodium and potassium intake [50]. The mechanisms involved in counterbalancing the 
BP raising effects of sodium have been investigated repeatedly. These mechanisms include 
suppression of the renin-angiotensin aldosterone system, resulting in a decreased tendency 
for sodium reabsorption [51], and stimulation of release of natriuretic peptides that promote 
sodium excretion [52, 53]. The BP-lowering effects of potassium were found to be more 
pronounced at higher levels of sodium intake. During sodium restriction, potassium has less 
effect on BP [37]. This suggests an interaction between potassium intake and sodium- and 
volume status. This interaction, however, has not been well characterized. In particular, the 
humoral mechanisms involved in the BP-lowering effects of potassium supplementation 
have been poorly documented.
11
GENERAL INTRODUCTION
1
Heart rate - Heart rate has been identified as a predictor of cardiovascular morbidity and 
mortality in population-based studies [54-56]. A meta-analysis of 7 prospective cohort 
studies showed that a high resting heart rate was associated with a 40% higher risk of heart 
failure compared to a low resting heart rate [56]. However, to what extent heart rate in healthy 
individuals can be modified by changes in sodium and potassium intake warrants further 
research. 
THESIS OUTLINE
Research on sodium and potassium intake has mainly focused on BP. The aim of this thesis 
is to examine the effects of sodium and potassium intake on BP in healthy individuals in 
the broader context of cardiovascular health, by simultaneously studying the effects on 
vascular function, body fluid balance and heart rate (see Figure 1). In Chapter 2, the effects 
of sodium and potassium supplementation on office BP, 24-h ambulatory BP and arterial 
stiffness are examined in a randomized placebo-controlled crossover study of 36 untreated 
(pre)hypertensive Dutch individuals on a fully controlled diet. In the same study, the effects of 
sodium and potassium supplementation on the functional measure of endothelial function 
(FMD) and on a comprehensive set of biochemical markers of endothelial dysfunction and 
low-grade inflammation are evaluated in the same individuals (Chapter 3). To gain more 
mechanistic insight, the humoral effects of potassium supplementation during sodium-
restriction are assessed using a panel of markers that are involved in osmoregulation and 
volume regulation. In addition, the effects of sodium supplementation, with surmised 
opposite changes in these markers are investigated (Chapter 4). The effects of potassium 
supplementation on heart rate are summarized by means of a meta-analysis of RCTs in 
healthy adults (Chapter 5). The BP effects of sodium and potassium as observed in RCTs may 
not be confirmed in observational research, which could be due to methodological issues. 
Chapter 6 focuses on the assessment of dietary sodium and potassium intake by different 
methods and how that affects BP associations in an observational study in healthy Dutch 
adults. Finally, in Chapter 7 the main findings and their clinical and public health implications 
are discussed. 
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FIGURE 1.
Schematic overview of the vascular effects of sodium and potassium intake that are assessed in this thesis. 
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ABSTRACT
We performed a randomised, placebo-controlled, crossover study to examine the effects 
of sodium and potassium supplementation on blood pressure (BP) and arterial stiffness in 
untreated (pre)hypertensive individuals. During the study, subjects were on a fully controlled 
diet that was relatively low in sodium and potassium. After a 1-week run-in period, subjects 
received capsules with supplemental sodium (3 g d−1, equals 7.6 g d−1 of salt), supplemental 
potassium (3 g d−1) or placebo, for 4 weeks each, in random order. Fasting ofﬁce BP, 24-h 
ambulatory BP and measures of arterial stiffness were assessed at baseline and every 4 
weeks. Of 37 randomised subjects, 36 completed the study. They had a mean pre-treatment 
BP of 145/81 mm Hg and 69% had systolic BP ≥ 140 mm Hg. Sodium excretion was increased 
by 98 mmol per 24 h and potassium excretion by 63 mmol per 24 h during active interventions, 
compared with placebo. During sodium supplementation, ofﬁce BP was signiﬁcantly 
increased by 7.5/3.3 mm Hg, 24-h BP by 7.5/2.7 mm Hg and central BP by 8.5/3.6 mm Hg. 
During potassium supplementation, 24-h BP was signiﬁcantly reduced by 3.9/1.6 mm Hg and 
central pulse pressure by 2.9 mm Hg. Pulse wave velocity and augmentation index were not 
signiﬁcantly affected by sodium or potassium supplementation. In conclusion, increasing 
the intake of sodium caused a substantial increase in BP in subjects with untreated elevated 
BP. Increased potassium intake, on top of a relatively low-sodium diet, had a beneﬁcial effect 
on BP. Arterial stiffness did not materially change during 4-week interventions with sodium 
or potassium.
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INTRODUCTION
Hypertension is a key risk factor for renal and cardiovascular diseases (CVD) [1,2] and affects 
~25% of the world’s adult population [3]. Reducing population blood pressure (BP) through 
beneﬁcial dietary and lifestyle changes may have important effects on CVD prevention. There 
is compelling evidence from randomised controlled trials that sodium reduction lowers BP 
[4-8]. In a meta-analysis of randomised trials with a minimum duration of 4 weeks, He et al. 
[7] showed reductions of 5.4 mm Hg in systolic BP (SBP) and 2.8 mm Hg in diastolic BP (DBP) 
in hypertensives for a 75 mmol lower 24-h sodium excretion (i.e. 1.7 g sodium or 4.4 g salt 
per day), with about half the effect in normotensives. Considering that most populations 
around the world have salt intakes higher than the recommended maximum intake of 5–6 
g d−1 (equals 2.0–2.4 g sodium) [9-11], global reductions in salt intake could substantially 
reduce the burden of CVD [7, 12]. 
Increasing dietary potassium intake may favourably affect CVD risk. van Mierlo et al. [13] 
reported expected reductions of 1.7–3.2 mm Hg in population SBP when current potassium 
intakes in 21 countries (1.7–3.7 g d−1) were increased to 4.7 g d−1, as recommended by the US 
Institute of Medicine [14]. A recent meta-analysis of 21 randomised trials reported 3.5/2.0 
mm Hg lower BP with an increased potassium intake, especially in hypertensives [15]. The 
BP reduction was 6.9/2.9 mm Hg when habitual sodium intake was high (> 4 g d−1), compared 
with 2.0/2.0 mm Hg for sodium intake of 2–4 g d−1. Whether potassium supplementation 
lowers BP in subjects who adhere to the dietary sodium recommendation has not extensively 
been investigated. 
Arterial stiffness is an independent risk factor of CVD [16] and can be assessed non-invasively, 
using pulse wave analysis (PWA), or directly as pulse wave velocity (PWV) [17]. Limited studies 
have examined the effects of sodium or potassium on measures of arterial stiffness, with 
inconclusive results both for sodium [18-25] and potassium [26-29].
We performed a randomised, placebo-controlled, crossover study to examine the effects of 
sodium and potassium supplementation on ofﬁce BP, ambulatory BP and arterial stiffness in 
Dutch subjects with untreated elevated BP. Supplementation took place while subjects were 
on a fully controlled diet that was relatively low in sodium and potassium, with all meals 
provided during the study.
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MATERIALS AND METHODS
Subjects
Potential participants were recruited within a 10-km radius of the research centre from 
December 2011 to April 2012. Subjects ﬁlled out a medical questionnaire, underwent physical 
examination and provided one 24-h urine and a fasting blood sample. Eligible for participation 
were non-smoking men and women, aged 40–80 years, with a fasting supine SBP between 
130 and 159 mm Hg. Subjects with diabetes mellitus or cardiovascular, gastrointestinal, liver 
or renal diseases were excluded based on the questionnaire data and laboratory parameters. 
Other exclusion criteria were body mass index > 40 kg m−2; use of medication known to affect 
the cardiovascular system; use of nutritional supplements; an energy-restricted or medically 
prescribed diet; unstable body weight in past 2 months; alcohol use over 21 (women) or 28 
(men) consumptions per week; and pregnancy or lactation (women). 
The Medical Ethics Committee of Wageningen University approved the study. The trial was 
registered at ClinicalTrials.gov (NCT01575041). The study was conducted from March to 
August 2012 at the research centre of Wageningen University, Wageningen, The Netherlands. 
All subjects gave a written informed consent.
Study Design
We performed a randomised, double-blind, placebo-controlled crossover study, in which 
diet was fully controlled. During the 1-week run-in (to ensure energy balance and reach basal 
BP) and 3 consecutive intervention periods of 4 weeks (not separated by washout) each 
subject consumed a diet that was targeted to provide 2 g of sodium and 2 g of potassium 
per day for a 2500 kcal intake. At the end of the run-in (‘baseline’), subjects were examined 
and randomly allocated to 1 of the 6 possible treatment orders, in strata of sex and SBP 
(130–139 and ≥ 140 mm Hg), by an independent person who used a computer-generated 
table. Treatments included 3 g of added sodium (equals 7.5 g salt) per day, 3 g of added 
potassium per day or placebo. Subjects were examined at baseline and at the end of each 
intervention. Examinations included ambulatory BP monitoring (ABPM), and in a fasting 
state anthropometric measurements, ofﬁce BP, PWA and PWV and a blood sample. Subjects 
collected 24-h urine by discarding the ﬁrst morning urine sample and collecting all urine for 
the next 24 h. Measurements were done at ﬁxed time points of the day throughout the study. 
BP was re-measured 2 weeks after completion of the study, when subjects had returned to 
their usual diet.
Diet and Study Procedures
Individual energy needs were estimated using an FFQ [30], which was ﬁlled out during 
screening, combined with results of the Schoﬁeld equation [31]. The food and beverages that 
were supplied by the research institute covered 90% of daily energy needs. Remaining 10% 
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was chosen by the participant from a limited number of products that were low in sodium 
and potassium. These products and any deviations from the diet were recorded in a diary. 
Subjects were not allowed to add salt or salt-containing seasonings to their food. Maximum 
daily consumption levels were set for coffee (3 cups), alcohol (1 consumption, equalling 10–
15 g of ethanol), fruit (2 portions) and liquorice (3 pieces).
During the trial, duplicates of each daily diet were collected, homogenised and analysed 
for energy, macronutrients and mineral content. The average composition of the diet (see 
Supplementary Table 1) was calculated from these duplicate diets and from free-choice 
items for which nutrient values were obtained from the Dutch food composition table [32]. 
A 2500-kcal diet provided a daily sodium and potassium intake of 2.4 and 2.3 g, respectively. 
We asked the subjects to maintain their usual level of physical activity during the study. 
Subjects were weighed twice a week and if needed, their energy intake was adjusted to keep 
body weight constant.
Experimental Treatment
Sodium and potassium intakes were increased through the daily use of capsules (Microz, 
Geleen, The Netherlands), while subjects were on the study diet. Depending on the 
intervention period, subjects had to ingest 8 sodium chloride capsules (in duplicate analysed 
content: 371 mg sodium per capsule, totalling 2968 mg), 8 potassium chloride capsules (353 
mg potassium per capsule, totalling 2824 mg) or 8 placebo capsules (cellulose), distributed 
over the day with meals. Capsules were matched in size and colour and research staff and 
subjects were blinded to treatment. Compliance was checked through capsule counts and 
subjects’ diaries. Subjects who ingested over 80% of the capsules for a given intervention 
period were considered compliant.
Measurements
Ofﬁce BP and heart rate. Ofﬁce BP and heart rate (HR) measurements were performed 
in a temperature-controlled (20–24 °C) quiet room by 1 trained staff member. BP and HR 
were measured in supine position after at least 10 min rest with 2-min intervals using an 
automated oscillometric device (Dinamap Pro 100, KP Medical, Houten, The Netherlands) 
with an appropriate cuff size on the left upper arm with the arm rested on the bed. The ﬁrst 
measurement was discarded and the 3 subsequent measurements were averaged. Subjects 
remained blinded towards the BP and HR values until the end of the study.
Ambulatory BP and HR. Blinded ambulatory BP and HR monitoring was performed for 24 
h using Spacelabs 90217 devices (Spacelabs Medical Inc. Redmond, WA, USA). Recordings 
were taken every 30 min at daytime (7 AM to 11 PM) and every 60 min at nighttime (11 PM to 
7 AM) on the non-dominant arm ~2 cm above the antecubital fossa. Subjects were asked to 
maintain their normal daily activities during the recording period, to avoid intense exercise 
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and to register their activities in a diary. Subjects were instructed to perform ABPM 1 or 2 
days before the end of each intervention period, at ﬁxed times (i.e. same day of the week 
and time of the day). A weighted 24-h mean ambulatory BP and HR was calculated, as well 
as daytime (8 AM to 22 PM), nighttime (midnight to 6 AM) and early-morning (6 AM to 9 AM) 
means. Ambulatory BP and HR was based on at least 6 daytime and 4 nighttime recordings.
PWA and PWV. Radial artery PWA and carotid-femoral PWV were determined by applanation 
tonometry using the SphygmoCor system (version 8.0; AtCor Medical, Sydney, NSW, Australia) 
by the same staff member each occasion. Central aortic pressures and HR-corrected 
augmentation index (AIx), which are surrogate measures of arterial stiffness, were derived 
from PWA [17]. One subject was excluded in the PWA and PWV analysis as no reliable pressure 
wave could be recorded because of an irregular heartbeat.
Laboratory Analysis
Serum samples were stored at −80 °C until the end of the study for the determination of 
sodium, potassium, triglycerides, total cholesterol, HDL-cholesterol and creatinine. LDL-
cholesterol was calculated from the Friedewald formula [33]. Twenty-four-hour urine samples 
were stored at −80 °C for the determination of sodium, potassium, creatinine (unprocessed 
samples) and calcium and magnesium (acidiﬁed samples). Serum and urinary sodium and 
potassium were determined using the ion-selective electrodes module on the Modular P of 
Roche (Roche Diagnostics, Mannheim, Germany) in a certiﬁed laboratory. Other serum and 
urine parameters were assessed using standard laboratory methods. Inter-assay coefﬁcients 
of variation were < 3% for all biochemical measurements, except for calcium (5.0%).
Statistical Analysis
Double-data entry was performed and data were analysed according to the intention-to-
treat principle, using a predeﬁned protocol. Treatment codes were broken after data-analysis 
results had been veriﬁed by an independent statistician. For each outcome measure, mixed-
effects model with covariance structure compound symmetry was used to estimate the effect 
of the active treatment compared to placebo. The effects on ofﬁce SBP were deﬁned as the 
primary outcomes. Differences in the occurrence of adverse events between treatments were 
assessed by the χ2-test. Sensitivity analysis was conducted by excluding periods in which 
subjects were noncompliant (see Supplementary Table 2).
Values reported in text and tables are means with s.d. or treatment effects with 95% conﬁdence 
interval. Two-sided P-values < 0.05 were regarded as statistically signiﬁcant. Analyses were 
performed using SAS 9.2 software (SAS Institute, Cary, NC, USA).
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RESULTS
Subjects
Figure 1 shows the number of subjects screened, randomised and withdrawn during the 
study. Of 37 randomised Caucasian subjects, one dropped out because of gastrointestinal 
complaints due to capsule use. Baseline characteristics of the 24 men and 12 women who 
completed the study are reported in Table 1. Subjects were on average 65.8 y (range 47–80 y) 
and their body mass index was 27.2 kg m−2.
Sodium and Potassium Excretion
During screening, 24-h urinary excretion was 153.7 mmol for sodium and 81.8 mmol for 
potassium, which were reduced to 90.8 and 49.0 mmol, respectively, after run-in. Twenty-
four-hour urinary sodium excretion was 105.1 mmol on placebo and 202.9 mmol on sodium 
supplementation, a mean difference of 97.6 mmol (equals 2.2 g sodium or 5.7 g salt). Urinary 
potassium excretion was increased from 55.3 mmol on placebo to 118.1 mmol on potassium 
FIGURE 1. Flow chart of a randomized, double-blind, placebo-controlled crossover study in untreated (pre)hyper-
tensive adults. Na, sodium; K, potassium. a One subject withdrew because of gastrointestinal complaints after the 
intake of capsules.
4 K 7 Na
 13 Na 13 Ka 11 Placebo
6 Placebo
6 K 7 Placebo
 7 K
6 Na
6 Placebo 6 Na
83 assessed for eligibility
6 Placebo 4 Na 7 K
2 withdrew during run-in:                         
1 suffered a stroke                                         
1 partner of person with stroke                                   
44 did not meet entry criteria                                       
39 started 1-week run-in           
on study diet
37 randomized to 3 times                 
4-week intervention
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supplementation, i.e. by 62.9 mmol (equals 2.5 g) (Table 2). The molar sodium-to-potassium 
ratio was 2.0 during placebo, 4.0 during sodium supplementation and 0.9 during potassium 
supplementation (ratios based on weight: 1.2, 2.4 and 0.5, respectively).
Ofﬁce BP and HR
During screening, subjects had a mean ofﬁce BP of 145.3/80.6 mm Hg and 69% (25/36) had 
SBP ≥ 140 mm Hg. After run-in, BP was 133.4/75.7 mm Hg. Table 3 shows the treatment 
effects for ofﬁce BP and HR. During sodium supplementation, SBP was increased by 7.5 mm 
Hg (3.8, 11.1), DBP by 3.3 mm Hg (1.5, 5.2) and pulse pressure (PP) by 4.1 mm Hg (1.5, 6.7) 
compared with placebo, with no effect on HR. Potassium supplementation resulted in a 
nonsigniﬁcantly lower SBP of 3.0 mm Hg (−0.6, 6.7), and signiﬁcantly lower PP of 2.8 mm Hg 
(0.1, 5.4) compared with placebo, with no signiﬁcant differences in DBP and HR. Two weeks 
after completion of the study, mean ofﬁce BP was 132.1/74.8 mm Hg (data not shown), which 
was comparable to post-run-in values.
Ambulatory BP and HR
Figure 2 shows the mean unadjusted ambulatory SBP (A) and DBP (B) values, by treatment. 
Sodium supplementation resulted in a higher 24-h SBP of 7.5 mm Hg (4.4, 10.5) and DBP 
of 2.7 mm Hg (1.1, 4.2), compared with placebo. In 78% (28/36) of the subjects, 24-h SBP 
was higher during sodium supplementation than during placebo supplementation (Figure 
3). For SBP, the effect did not essentially differ over the day, but for DBP a larger effect was 
seen during early-morning (4.1 mm Hg). Sodium supplementation did not signiﬁcantly affect 
ambulatory HR (Table 3).
TABLE 1. Baseline characteristics of 36 subjects who completed the study
  Men (n=24) Women (n=12)
Age (y) 66.0 ± 9.3 65.4 ± 8.2
Height (cm) 178.8 ± 8.9 168.8 ± 5.8
Weight (kg) 87.9 ± 19.0 77.2 ± 16.0
BMI (kg m−2) 27.3 ± 4.8 27.0 ± 4.6
Waist circumference (cm) 103.0 ± 15.0 93.8 ± 12.9
Pre-run-in SBP ( mm Hg) 147.7 ± 10.3 140.4 ± 11.7
Pre-run-in DBP (mm Hg) 82.8 ± 7.7  76.2 ± 7.0
Post-run-in SBP (mm Hg) 136.4 ± 14.7 127.5 ± 13.3
Post-run-in DBP (mm Hg) 77.8 ± 8.0 71.4 ± 7.6
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Values are mean ± s.d.
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Potassium supplementation resulted in a lower 24-h SBP of 3.9 mm Hg (0.9, 6.9) and 24-h 
DBP of 1.6 mm Hg (0.1, 3.2) compared with placebo (Figure 2, Table 3). For SBP, the effect 
did not essentially differ over the day, but for DBP no effect was seen during early-morning. 
In 67% (24/36) of the subjects, 24-h SBP was lower during potassium supplementation than 
during placebo supplementation (Figure 3). During potassium supplementation, 24-h HR was 
2.6 beats per minute (1.1, 4.1) higher than during placebo.
PWA and PWV
Sodium supplementation resulted in a signiﬁcantly higher central SBP of 8.5 mm Hg, central 
DBP of 3.6 mm Hg and central PP of 4.8 mm Hg compared with placebo. PWV was unaffected 
by sodium supplementation (Table 3). Potassium supplementation resulted in a signiﬁcantly 
lower central PP of 2.9 mm Hg, and a nonsigniﬁcantly lower central SBP and DBP of 3.0 and 
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FIGURE 2. Unadjusted mean ambulatory systolic (a) and diastolic (b) blood pressure for each hour over 24 h after 
4-week supplementation with sodium, potassium or placebo in 36 untreated (pre)hypertensive adults. DBP, diastolic 
blood pressure; SBP, systolic blood pressure.
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0.2 mm Hg, respectively. PWV was nonsigniﬁcantly decreased by 0.35 m s− 1. Central HR-
corrected AIx was unaffected by sodium or potassium supplementation (Table 3).
Serum and Urine Parameters, and Body Weight
Sodium supplementation resulted in a nonsigniﬁcantly higher serum sodium of 0.39 mmol l−1, 
and signiﬁcantly lower serum potassium of 0.10 mmol l−1, serum creatinine of 3.7 μmol l−1, 
total cholesterol of 0.19 mmol l−1 and LDL-cholesterol of 0.18 mmol l−1, compared with 
placebo. Serum HDL-cholesterol, total-to-HDL-cholesterol ratio and triglycerides did not 
differ signiﬁcantly between sodium and placebo supplementation. Twenty-four-hour 
urinary calcium excretion was signiﬁcantly higher by 1.16 mmol (equals 46.4 mg) during 
sodium supplementation than during placebo. Urinary magnesium and creatinine 
excretion were not signiﬁcantly affected (Table 2). 
FIGURE 3. Effects of 4-week sodium and potassium supplementation on 24-h ambulatory systolic blood pressure in 
36 untreated (pre)hypertensive adults, compared with placebo. SBP, systolic blood pressure.
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Potassium supplementation resulted in a signiﬁcantly lower serum sodium of 0.68 mmol l−1, 
higher serum potassium of 0.13 mmol l−1 and higher urinary creatinine of 0.82 mmol per 24 
h compared with placebo. Other serum and urinary parameters did not differ signiﬁcantly 
(Table 2). Body weight was kept constant during the study through adjustments in caloric 
intake, and did not differ between the intervention periods.
Adverse Events
Reported side effects in subjects’ diaries indicated that 19 persons experienced gastrointestinal 
complaints during sodium, 21 during potassium and 8 during placebo supplementation (P 
= 0.004). Other side effects including dizziness, headache, illness, shortness of breath and 
oedema were not signiﬁcantly different among the 3 treatments.
DISCUSSION
In Dutch adults with untreated elevated BP, increasing the intake of sodium by 3.0 g d−1 
(equals 7.6 g d−1 of salt) strongly raised ofﬁce, ambulatory and central SBP by ~8 mm Hg. 
Increasing the potassium intake by 2.8 g d−1 signiﬁcantly lowered ambulatory SBP by 4 mm 
Hg in these individuals on a relatively low-sodium diet. Measures of arterial stiffness did not 
materially change after 4 weeks of sodium or potassium supplementation.
In most Western societies, mean sodium intakes are above recommended levels [9], whereas 
potassium intakes are relatively low [13]. This could have a major impact on population 
health, including risk of CVD. A 7.5-mm Hg lower SBP, in our study achieved by decreasing 
sodium intake from a level common in Western societies to the recommended level, would 
be associated with a 30% lower risk of stroke mortality and 22% lower risk of ischaemic heart 
disease in a middle-aged population [2]. Increasing the intake of potassium, even when 
subjects adhere to guidelines for dietary salt intake, may further reduce the risk.
A major strength of the present study is the fully controlled diet, which strongly reduced the 
intra-individual variability in BP resulting from dietary inﬂuences (for example, use of alcohol, 
coffee and salt) and thereby increasing power to demonstrate effects on BP. Subjects were 
also instructed to keep other lifestyle behaviours, such as physical activity, constant. Fasting 
BP was repeatedly measured at the research centre using a strict protocol, at ﬁxed times in 
the morning. All subjects underwent ABPM, which is considered a better predictor of CVD than 
ofﬁce BP [34]. Because we provided a (relatively) low-sodium, low-potassium diet, combined 
with capsules that contained ~3 g of sodium or potassium, we were able to achieve large 
contrasts in sodium and potassium intake. Eighty-six percent of the subjects were compliant 
during all periods, as also reﬂected in 24-h urinary excretions.
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Our study showed a 7.5 mm Hg increase in SBP with an increase in 24-h urinary sodium of 98 
mmol. Assuming a linear relation, this is equivalent to an effect of 0.7-0.8 mm Hg per 10 mmol 
change in 24-h urinary sodium. This ﬁnding is comparable to the result of a meta-analysis of 
randomised trials of at least 4 weeks duration, in which a reduction in 24-h urinary sodium of 
75 mmol decreased SBP by 5.4 mm Hg (0.7 mm Hg per 10 mmol) in hypertensives [7]. 
Potassium supplementation in our study increased 24-h urinary potassium by 63 mmol 
and reduced SBP by 3–4 mm Hg. In a meta-analysis of 16 randomised controlled trials [15], 
potassium lowered SBP by ~5 mm Hg in hypertensives. The smaller effect in our study may 
result from the inclusion of prehypertensives (31% of our subjects) who may show smaller 
BP responses. Also, our subjects consumed a relatively low-sodium diet (2.2 g d−1). In the 
meta-analysis, BP reductions after increased potassium intake depended on sodium intake, 
i.e. SBP was reduced by 7 mm Hg for sodium intake of > 4 g d−1 and by 2 mm Hg for sodium 
intake of 2–4 g d−1 [15]. Therefore, the beneﬁcial effect of increased potassium intake on BP in 
individuals with Western, high-salt diets may be greater than observed in the present study.
We found signiﬁcant effects of sodium and potassium on BP, but not on arterial stiffness 
as measured by PWV and the surrogate measure AIx. The differences in several indices of 
central BP may have resulted from changes in brachial artery pressure, which was used in 
the algorithm to estimate the central pressures [17]. Since no effect was found for PWV, a 
direct indicator of arterial stiffness, we consider effects of sodium and potassium on arterial 
stiffness in our study unlikely. The 4-week duration of the intervention periods may have been 
too short to induce changes in the vascular structure. However, short-term interventions 
may affect arterial stiffness by inﬂuencing functional properties, such as vascular tone and 
endothelial function [35]. Moreover, other studies with a 4–6-week duration did ﬁnd effects of 
sodium intake on PWV in (pre)hypertensives [21, 22, 24], although 2 studies in normotensives 
[19, 25] did not. Therefore, further studies of longer duration in subjects with untreated 
hypertension are warranted to assess the effects of sodium intake on arterial stiffness.
For potassium supplementation, limited data are available on the effects of arterial stiffness 
and results are inconsistent. A randomised controlled trial in 42 untreated hypertensives 
showed a signiﬁcant reduction of 0.8 m s−1 in PWV for 2.5 g d−1 higher potassium intake 
[28]. Another trial in 40 subjects at increased CVD risk with the same potassium dose found 
a reduction in PWV of 0.4 m s−1 [27]. A trial in 48 early hypertensives with lower doses of 
potassium, however, found no effect [26]. In our study, PWV was 0.35 m s−1 lower during 
potassium but this ﬁnding was not statistically signiﬁcant, despite a high potassium dose. 
Our study had ample power (> 80%) to detect an effect of 0.7 m s−1 in PWV, which has been 
associated with a 11% lower risk of mortality [16]. 
Sodium supplementation had no signiﬁcant effect on HR. Potassium supplementation, 
however, signiﬁcantly increased ambulatory HR, although no effect was seen for ofﬁce HR. 
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The reason for this ﬁnding remains unclear. During high potassium intake, serum potassium 
was increased by 0.13 mmol l−1 but levels of all participants remained within the normal 
range, not posing them at increased risk for hyperkalaemia or cardiac rhythm disturbances. 
Possibly, decreases in plasma volume contributed to the effect on HR. Another trial in healthy 
humans reporting the effects of 4-week potassium supplementation of 3.9 g d−1, however, 
found no differences in ambulatory HR [29]. Because an effect was found only on 24-h and 
not on ofﬁce HR in our subjects, we cannot exclude the possibility that our ﬁnding was due 
to chance. 
Sodium supplementation resulted in lower total and LDL-cholesterol levels of 3.4 and 4.6%, 
respectively, in our study. Other studies showed raised serum total or LDL-cholesterol during 
sodium restriction or use of thiazide diuretics, which is in line with these ﬁndings [36]. In 
a meta-analysis of sodium interventions that lasted 4 weeks or more, differences in serum 
cholesterol were not signiﬁcant, suggesting a transient response [37]. Urinary calcium 
excretion in our subjects was higher during sodium supplementation, as has also been 
reported by others [38]. When urinary calcium losses occur, calcium mobilisation from 
bone may be increased. It has been suggested that this side effect of high sodium intake, if 
sustained over time, may lead to osteoporosis [38]. 
In conclusion, the current study demonstrates that increasing the intake of sodium from a 
recommended level to a level that is common in Western societies, has a strong adverse 
effect on BP in untreated (pre)hypertensive individuals. Increasing potassium intake, 
however, lowers BP even when people are on a relatively low-sodium diet. Measures of 
arterial stiffness were not materially affected by sodium or potassium supplementation. Our 
ﬁndings support the recommendations to reduce sodium intake and to increase potassium 
intake, which will likely lower BP in older individuals with untreated elevated BP, and the 
burden of CVD in Western societies.
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SUPPLEMENTAL RESULTS 
SUPPLEMENTAL TABLE 1. Composition of the background study diet
Average daily menua Average daily menu, standardised to 2500 kcal
Energy intake (kcal d−1) 2774
Energy intake (MJ d−1) 11.6
Protein (g d−1) 91.2 82.2
Protein (en%) 13.4 13.4
Fat (g d−1) 110.9 100.0
Fat (en%) 35.4 35.4
Carbohydrates (g d−1) 327.9 295.5
Carbohydrates (en%) 48.0 48.0
Cholesterol (mg MJ−1) 23.5 23.5
Dietary fiber (g MJ−1) 2.0 2.0
Alcohol (g d−1) 6.5 5.8
Alcohol (en%) 1.6 1.6
Sodium (mg d−1) 2700 2433
Salt (g d−1) 6.9 6.2
Potassium (mg d−1) 2506 2258
Calcium (mg d−1) 1119 1008
Magnesium (mg d−1) 305 275
a Based on chemical analysis of daily duplicate diets, plus free-choice items for which the nutrient content was ob-
tained from the Dutch food composition table 2011 (NEVO) [1].
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SUPPLEMENTAL TABLE 2. Effects of sodium and potassium supplementation on urinary parameters, blood 
pressure, heart rate and arterial stiffness in 36 untreated (pre)hypertensive adults, after the exclusion of periods 
in which subjects were noncomplianta
Treatment effectb
  Sodium vs placebo P Potassium vs placebo P
Urinary parameters
Sodium (mmol per 24 h)c 100.7 (84.0, 117.3) <0.001 -11.3 (-28.1, 5.5) 0.18
Potassium (mmol per 24 h)d -2.1 (-8.7, 4.6) 0.53 68.8 (62.1, 75.5) <0.001
Office BP and HR 
SBP (mm Hg) 7.2 (3.3, 11.0) <0.001 -3.4 (-7.3, 0.6) 0.092
DBP (mm Hg) 3.4 (1.5, 5.4) <0.001 -0.4 (-2.3, 1.6) 0.72
PP (mm Hg) 3.7 (1.0, 6.5) 0.008 -3.0 (-5.7, -0.2) 0.035
HR (b.p.m.) -0.7 (-2.6, 1.2) 0.46 0.7 (-1.2, 2.6) 0.47
Ambulatory BP and HR
24-h SBP (mm Hg) 7.4 (4.3, 10.5) <0.001 -4.6 (-7.7, -1.5) 0.005
24-h DBP (mm Hg) 2.7 (1.1, 4.3) 0.001 -1.9 (-3.5, -0.2) 0.025
24-h HR (b.p.m.) -1.0 (-2.6, 0.6) 0.23 2.6 (1.0, 4.2) 0.002
Daytime SBP (mm Hg) 7.0 (3.6, 10.5) <0.001 -5.0 (-8.6, -1.5) 0.005
Daytime DBP (mm Hg) 2.2 (0.2, 4.1) 0.029 -1.9 (-3.9, 0.0) 0.052
Daytime HR (b.p.m.) -1.7 (-3.8, 0.3) 0.10 2.8 (0.7, 4.9) 0.010
Nighttime SBP (mm Hg) 7.8 (4.2, 11.4) <0.001 -4.0 (-7.7, -0.4) 0.030
Nighttime DBP (mm Hg) 3.2 (1.2, 5.3) 0.002 -1.7 (-3.8, 0.4) 0.10
Nighttime HR (b.p.m.) -0.5 (-2.4, 1.5) 0.64 1.9 (0.0, 3.8) 0.053
Early-morning SBP (mm Hg) 8.1 (3.7, 12.5) <0.001 -3.9 (-8.3, 0.6) 0.086
Early-morning DBP (mm Hg) 4.6 (1.9, 7.4) 0.001 -0.3 (-3.1, 2.5) 0.82
Early-morning HR (b.p.m.) 0.7 (-2.2, 3.5) 0.65 3.1 (0.2, 6.0) 0.035
PWAe
Central AIx (%)f 0.7 (-0.7, 2.2) 0.32 -0.2 (-1.7, 1.2) 0.75
Central SBP (mm Hg) 8.1 (4.3, 12.0) <0.001 -3.3 (-7.2, 0.6) 0.10
Central DBP (mm Hg) 3.7 (1.8, 5.6) <0.001 -0.2 (-2.2, 1.7) 0.81
Central PP (mm Hg) 4.4 (1.6, 7.1) 0.002 -3.1 (-5.9, -0.3) 0.029
PWV (m s−1)e 0.09 (-0.43, 0.62) 0.73 -0.35 (-0.88, 0.18) 0.19
Abbreviations: AIx, augmentation index; BP, blood pressure; b.p.m., beats per minute; DBP, diastolic blood pressure; 
HR, heart rate; SBP, systolic blood pressure; PP, pulse pressure; PWA, pulse wave analysis; PWV, pulse wave velocity.
a Excluded were two periods of sodium supplementation, three periods of potassium supplementation and one 
period of placebo supplementation. b Data are mean differences (95% CI) obtained from linear mixed-effect models 
for repeated measurements using the compound symmetry covariance structure. c To convert sodium in mmol per 
24 h to mg per 24 h multiply by 23. d To convert potassium in mmol per 24 h to mg per 24 h multiply by 39. e One 
subject was excluded as no reliable pressure wave could be recorded due to an irregular heartbeat. f Adjusted to a 
standard HR of 75 b.p.m.
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ABSTRACT
High Na and low K intakes have adverse effects on blood pressure, which increases the risk 
for CVD. The role of endothelial dysfunction and inﬂammation in this pathophysiological 
process is not yet clear. In a randomised placebo-controlled cross-over study in untreated 
(pre) hypertensives, we examined the effects of Na and K supplementation on endothelial 
function and inﬂammation. During the study period, subjects were provided with a diet that 
contained 2.4 g/d of Na and 2.3 g/d of K for a 10 460 kJ (2500 kcal) intake. After 1-week run-
in, subjects received capsules with supplemental Na (3.0 g/d), supplemental K (2.8 g/d) or 
placebo, for 4 weeks each, in random order. After each intervention, circulating biomarkers 
of endothelial function and inﬂammation were measured. Brachial artery ﬂow-mediated 
dilation (FMD) and skin microvascular vasomotion were assessed in sub-groups of twenty-
two to twenty-four subjects. Of thirty-seven randomised subjects, thirty-six completed the 
study. Following Na supplementation, serum endothelin-1 was increased by 0.24 pg/ml (95% 
CI 0.03, 0.45), but no change was seen in other endothelial or inﬂammatory biomarkers. FMD 
and microvascular vasomotion were unaffected by Na supplementation. K supplementation 
reduced IL-8 levels by 0.28 pg/ml (95% CI 0.03, 0.53), without affecting other circulating 
biomarkers. FMD was 1.16% (95% CI 0.37, 1.96) higher after K supplementation than after 
placebo. Microvascular vasomotion was unaffected. In conclusion, a 4-week increase in 
Na intake increased endothelin-1, but had no effect on other endothelial or inﬂammatory 
markers. Increased K intake had a beneﬁcial effect on FMD and possibly IL-8, without affecting 
other circulating endothelial or inﬂammatory biomarkers.
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INTRODUCTION
Excess Na intake and low K intake have been associated with detrimental effects on blood 
pressure (BP) and CVD risk [1, 2], as recently conﬁrmed by us in thirty-six adults who had a 
7.5/2.7 mmHg higher 24 h BP after Na supplementation and 3.9/1.6 mmHg lower 24 h BP after 
K supplementation [3]. The vascular endothelium has been suggested to play a key role in 
BP homeostasis [4]. However, limited well-controlled studies have examined the effects of Na 
and K intake on endothelial function. 
Endothelial function can be measured by circulating blood biomarkers that are expressed 
by activation of the endothelium [5]. For Na intake, randomised controlled trials with an 
intervention duration of 4 weeks or more mainly focused on the vasoconstrictor endothelin-1 
and showed inconsistent results [6-10]. Similar studies on K intake showed no effect on 
endothelin-1 [11] or on soluble adhesion molecules [12, 13]. Effects of Na and K intake on 
low-grade inﬂammation, closely related to endothelial function [14], are largely unknown. 
High-sensitivity C-reactive protein (CRP) did not respond to the intake of Na [8-10] or K [12, 
13] in randomised controlled trials. Flow-mediated dilation (FMD), the dilation of conduit 
arteries in response to blood ﬂow-induced increases in shear stress, is a functional biomarker 
of endothelial function [15]. In randomised controlled trials, modest Na reductions ranging 
from 1.4 to 2.3 g/d for 2–6 weeks improved brachial artery FMD by 1.5–2.4% [6, 8, 16]. FMD has 
also been shown to improve after increased K intake of 2.5 g/d for 4 weeks [17]. A randomised 
controlled trial with a lower dose of K (i.e. 1.6 g/d) for 6 weeks demonstrated no effect [12]. 
Microvascular vasomotion, the periodic oscillations of microvessel diameter, is thought to 
be partly dependent on endothelial function [18]. Microvascular vasomotion, assessed via 
spectral analysis of skin laser Doppler ﬂowmetry (LDF) tracing, has not yet been studied in 
relation to Na and K intakes.
In a double-blind placebo-controlled cross-over study, we performed a comprehensive 
assessment of Na and K supplementation on endothelial function and low-grade 
inﬂammation in subjects with untreated elevated BP. In addition, we assessed microvascular 
vasomotion as an exploratory secondary outcome.
METHODS
Study Population
The details of this study have been published previously [3]. Potential subjects were recruited 
from within a 10 km radius of the research centre through subject email databases and 
advertisements. Non-smoking men and women, aged between 40 and 80 years, with a fasting 
supine systolic BP (SBP) between 130 and 159 mmHg were eligible to participate. Exclusion 
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criteria included a history of diabetes mellitus or cardiovascular, gastrointestinal, liver or 
renal diseases based on questionnaire data and laboratory parameters; BMI > 40 kg/m2; use 
of medication known to affect the cardiovascular system; use of nutritional supplements; an 
energy-restricted or medically prescribed diet; unstable body weight in the past 2 months; 
alcohol use over 21 units for women and 28 units for men/week (1 unit equalling 10–15 g of 
ethanol); and pregnant or lactating women. 
Of the thirty-nine subjects who started the 1-week run-in, thirty-seven were randomised. One 
randomised subject dropped out because of gastrointestinal complaints due to the capsules, 
leaving thirty-six subjects who completed the study. This study was conducted according 
to the guidelines laid down in the Declaration of Helsinki, and all the procedures involving 
human subjects were approved by the Medical Ethics Committee of Wageningen University. 
Written informed consent was obtained from all the subjects. The study was registered at 
ClinicalTrials.gov (registration no. NCT01575041).
Study Design
The study was a randomised, double-blind, placebo-controlled cross-over trial in which 
diet was fully controlled, as described previously [3]. In brief, during the 1-week run-in and 
three consecutive intervention periods of 4 weeks, not separated by washout, subjects were 
provided with a relatively low-Na, low-K diet that contained 2.4 g/d of Na and 2.3 g/d of K 
for a 10 460 kJ (2500 kcal) intake. At the end of the run-in (baseline), subjects were randomly 
allocated to one of the six possible treatment orders, based on sex and SBP (130–139 and 
≥ 140 mmHg). Treatments were daily consumption of eight sodium chloride capsules (Na: 
3.0 g), eight potassium chloride capsules (K: 2.8 g) and eight placebo (cellulose) capsules 
(Microz), for 4 weeks each, in random order. Body weight was kept constant during the study 
period through adjustments in energy intake, and subjects were asked to maintain their 
usual level of physical activity. 
At baseline and at the end of each intervention period, subjects underwent 24 h ambulatory 
BP monitoring and collected 24 h urine by discarding the ﬁrst morning urine and 
collecting all urine secretions for the next 24 h. Subjects also underwent anthropometric 
measurements, blood sampling, and ofﬁce BP, FMD and microvascular vasomotion 
assessment. The measurements were taken following an overnight fast (from 20.00 hours) 
at ﬁxed time points in the morning, in a temperature-controlled (20–24°C) quiet room at 
the research centre.
Measurements
Biochemical analysis
Fasting blood samples collected in EDTA- and sodium citrate-containing tubes were 
centrifuged at 1550 g for 15 min at 4 and 20°C, respectively. Blood samples collected in 
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heparin-coated tubes were centrifuged at 800 g for 20 min at 4°C. Aliquots were stored at 
−80ºC until the end of the study for analysis. Concentrations of soluble E-selectin, soluble 
thrombomodulin, soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular 
adhesion molecule-1 (sICAM-1), CRP, serum amyloid A, TNF-α, monocyte chemoattractant 
protein-1, IL-1β, IL-6 and IL-8 were measured in EDTA plasma using a multi-array detection 
system (SECTOR Imager 2400; Meso Scale Discovery) in the laboratory of the Maastricht 
University Medical Center, as previously described [19]. Endothelin-1 and von Willebrand 
factor (vWf) were determined by ELISA in the laboratory of the Maastricht University Medical 
Center from EDTA plasma and citrate plasma, respectively. Levels of vWf were expressed as 
a percentage of vWf detected in pooled citrated plasma of healthy volunteers [19]. Heparin 
plasma levels of nitric oxide (NO) were determined at the RIKILT Institute of Food Safety by 
estimating NO by the chemiluminescence formed after the release of NO from NO2, NO2− and 
nitrosated and nitrosylated species, as described previously [20]. Intra-assay CV were <10% 
for all biomarker measurements, except for IL-1β (10.4%). Inter-assay CV were <10% for all 
biomarker measurements, except for sVCAM-1 (12.8%), IL-1β (12.4%) and NO (18.6%). Na and 
K levels were determined in 24 h urine samples in a certiﬁed laboratory using ion-selective 
electrodes module on the Modular P of Roche.
Flow-mediated dilation and blood pressure
FMD was measured by a trained staff member according to established guidelines [21]. 
After rest of at least 20 min in the supine position, longitudinal ultrasonographic images 
of the right brachial artery were continuously recorded. Baseline arterial diameter 
was recorded for 3 min, after which a pressure cuff on the forearm was inﬂated to 200 
mmHg for 5 min to induce reactive hyperaemia. After cuff release, images were recorded 
for 5 min for the determination of the maximum arterial diameter. Images were processed 
automatically using custom-written software (DuplexFMD, Department of Biomedical 
Engineering, Maastricht University). FMD was calculated as the percentage change in arterial 
diameter from baseline to the maximum value after cuff release. Endothelium-independent 
dilation (EID) was assessed as the maximum change in arterial diameter over a 5 min period 
following sublingual administration of nitroglycerin (400 μg). Before data analysis, recordings 
of insufﬁcient quality due to movements of subjects or unclear images of the arterial wall 
were excluded, leaving twenty-two subjects for the analysis of FMD for Na v. placebo 
supplementation and twenty-four subjects for K v. placebo supplementation.
Ofﬁce brachial BP was measured in the supine position after at least 10 min of rest using 
an automated oscillometric device (Dinamap Pro 100). Ambulatory BP monitoring was 
performed for 24 h using Spacelabs 90217 devices (Spacelabs Medical Inc.), as described 
previously [3].
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Microvascular vasomotion 
Skin blood ﬂow was measured using an LDF system (PeriFlux 5000; Perimed) with a laser 
Doppler probe (PF 457; Perimed) at approximately 2 cm distal to the wrist on the back of 
the left hand. Subjects were in the supine position, and after a rest of at least 20 min skin 
temperature was set at 30°C and skin blood ﬂow was recorded. Spectral analysis was 
performed using Fast-Fourier transform analysis of skin LDF (Perisoft for Windows version 2.5; 
Perimed) to determine the power spectral density of the LDF signal. The power density was 
calculated in the total frequency spectrum of 0.01–1.60 Hz and in ﬁve frequency sub-intervals 
to determine the contribution of oscillations of endothelial (0.01–0.02 Hz), neurogenic (0.02–
0.06 Hz), myogenic (0.06–0.15 Hz), respiratory (0.15–0.40 Hz) and heart beat origin (0.40–1.60 
Hz) to microvascular vasomotion [22]. Data were expressed as arbitrary perfusion units. 
Recordings of insufﬁcient quality due to movements of subjects were excluded before data 
analysis, leaving twenty-three subjects for the analysis of Na v. placebo supplementation and 
twenty-three subjects for K v. placebo supplementation.
Statistical Analysis
Data were analysed according to the intention-to-treat principle, using a predeﬁned 
statistical analysis plan. FMD was deﬁned as the primary outcome. The present study had 
80% power to detect a FMD difference of 1.0% for a SD of 1.7% and a two-sided α of 0.05. 
Circulating biomarkers with a skewed distribution were transformed taking the natural 
logarithm. After analyzing biomarkers individually, overall Z scores were created for a 
set of biomarkers of endothelial function and of low-grade inﬂammation (Supplemental 
Methods) [19]. For each outcome measure, a mixed-effects model with covariance structure 
compound symmetry was used to estimate the effect of the active treatment compared 
with placebo. ‘Treatment’ and ‘period’ were included as ﬁxed effects and ‘subject’ as the 
random effect. In the sensitivity analysis, analyses were repeated after the exclusion of 
intervention periods in which subjects were non-compliant. Values reported in text and 
tables are expressed as mean with standard deviation, median with interquartile range 
for skewed variables or treatment effect with 95% CI. Two-sided P values < 0.05 were 
considered statistically signiﬁcant. Analyses were performed using SAS software version 
9.2 (SAS Institute).
RESULTS
Subjects and Compliance
Baseline characteristics of the twenty-four men and twelve women who completed the 
study are reported in Table 1. Subjects were on average 65.8 years old and their BMI was 27.2 
kg/m2. During screening, their 24 h urinary excretion was 153.7 (SD 63.6) mmol for Na and 
81.8 (SD 25.6) mmol for K. This decreased to 90.8 (SD 26.6) mmol and 49.0 (SD 13.4 mmol), 
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respectively, after 1-week run-in. Subjects had a mean ofﬁce SBP/diastolic BP of 145.3/80.6 
mmHg, and 69% of them (25/36) had an SBP ≥ 140 mmHg during screening. BP was 133.4/75.7 
mmHg after the 1-week run-in period on the low-Na, low-K diet. Baseline characteristics of 
the subjects with FMD or vasomotion data did not essentially differ from the overall study 
population (Supplemental Tables 1 and 2, respectively). Based on returned capsules and 
diary entries, 86% (31/36) of the subjects were compliant, ingesting over 80% of the capsules 
during each intervention period.
Sodium Supplementation
Na supplementation increased urinary Na excretion by 97.6 mmol/24 h (95% CI 81.0, 114.1; 
P < 0.001) and 24 h SBP by 7.5 mmHg (95% CI 4.4, 10.5; P < 0.001) compared with placebo 
(Table 2). After Na supplementation, endothelin-1 levels were 0.24 pg/ml (95% CI 0.03, 0.45; P 
= 0.023) higher compared with placebo. Other individual biomarkers of endothelial function 
and the aggregate Z score of endothelial function (0.080; 95% CI −0.029, 0.189; P = 0.15) 
did not change. In addition, markers of low-grade inﬂammation and the aggregate Z score 
(−0.047; 95% CI −0.189, 0.094; P = 0.51) were unaffected. Differences in FMD are depicted in 
Figure 1, with, on average, no effect of Na supplementation on FMD (0.06%; 95% CI −0.75, 
0.86; P = 0.89). Moreover, EID (−0.01%; 95% CI −1.77, 1.75; P = 0.99) was unaffected. No effects 
of Na supplementation were seen on the power densities of the different frequency intervals 
determining microvascular vasomotion (Table 2).
TABLE 1. Baseline characteristics of the 36 subjects who completed the study
Total (n=36) Men (n=24) Women (n=12)
Age, y 65.8 ± 8.8 66.0 ± 9.3 65.4 ± 8.2
Height, cm 175.5± 9.3 178.8 ± 8.9 168.8 ± 5.8
Weight, kg 84.3 ± 18.5 87.9 ± 19.0 77.2 ± 16.0
Body mass index, kg/m² 27.2 ± 4.7 27.3 ± 4.8 27.0 ± 4.6
Waist circumference, cm 99.9 ± 14.8 103.0 ± 15.0 93.8 ± 12.9
Pre-run-in sodium excretion, mmol/24h 153.7 ± 63.6 160.2 ± 71.4 140.8 ± 44.1
Pre-run-in potassium excretion, mmol/24h 81.8 ± 25.6 82.2 ± 28.7 81.0 ± 19.3
Post-run-in sodium excretion, mmol/24h 90.8 ± 26.6 98.3 ± 26.3 75.9 ± 20.8
Post-run-in potassium excretion, mmol/24h 49.0 ± 13.4 50.5 ± 13.6 46.0 ± 13.0
Pre-run-in SBP, mmHg 145.3 ± 11.2 147.7 ± 10.3 140.4 ± 11.7
Pre-run-in DBP, mmHg 80.6 ± 8.0 82.8 ± 7.7 76.2 ± 7.0
Post-run-in SBP, mmHg 133.4 ± 14.7 136.4 ± 14.7 127.5 ± 13.3
Post-run-in DBP, mmHg 75.7 ± 8.3 77.8 ± 8.0 71.4 ± 7.6
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure. 
Values are mean ± SD.
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CHAPTER 3
Potassium Supplementation
K supplementation increased urinary K excretion by 62.9 mmol/24 h (95% CI 54.9, 70.8; P 
< 0.001) and decreased 24 h SBP by 3.9 mmHg (95% CI 0.9, 6.9; P = 0.013), compared with 
placebo (Table 3). K supplementation resulted in a lower IL-8 of 0.28 pg/ml (95% CI 0.03, 
0.53; P = 0.031). In the sensitivity analysis, after the exclusion of intervention periods in which 
subjects were non-compliant, the effect on IL-8 was no longer signiﬁcant (−0.24 pg/ml; 95% 
CI −0.50, 0.03, P = 0.080). K supplementation had no effect on other individual biomarkers, 
FIGURE 1. Effects of 4-week sodium (a) and potassium (b) supplementation on flow-mediated dilation (FMD) in 
untreated pre-hypertensive and hypertensive adults, compared with placebo.
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on the Z score of endothelial function (0.007; 95% CI −0.102, 0.115; P = 0.90) or low-grade 
inﬂammation (−0.032; 95% CI −0.173, 0.109; P = 0.66). However, in the sensitivity analysis, K 
supplementation increased vWf by 12.5% (95% CI 1.0, 23.9, P = 0.033) compared with placebo. 
FMD was 1.16% (95% CI 0.37, 1.96; P = 0.005) higher after K supplementation compared with 
placebo, with FMD being improved in 83% (20/24) of the subjects after K supplementation 
compared with placebo (Figure 1). K supplementation had no effect on EID (0.51%; 95% 
CI −1.17, 2.19; P = 0.54). The power densities of the frequency intervals related to activities 
determining vasomotion were unaffected (Table 3). 
DISCUSSION
In untreated pre-hypertensive and hypertensive adults on a fully controlled diet that was 
relatively low in Na and K, 4 weeks of Na supplementation had no effect on endothelial function 
or low-grade inﬂammation, except for an increase in endothelin-1. K supplementation 
lowered the inﬂammatory marker IL-8 and increased the functional biomarker FMD.
A major strength of the present study is the comprehensive assessment of endothelial function 
and low-grade inﬂammation by an extensive set of circulating biomarkers, the functional 
biomarker FMD and microvascular vasomotion. All measurements were performed in a 
fasting state at ﬁxed times of the day using a strict protocol. We used high-sensitivity assay 
techniques, and eleven circulating biomarkers were assessed simultaneously to minimise 
between-assay variation. Our study had limited variability in diet and lifestyle behaviours 
due to the provision of a fully controlled diet and the instruction to keep other lifestyle 
factors such as physical activity constant. In addition, a large contrast in Na and K intake was 
achieved, the compliance was high and the drop-out rate was low. Moreover, although the 
number of subjects in this study was limited, the study had ample power (80%) to show a 
clinically relevant effect on FMD of 1.0% [23, 24].
Our study showed that for an increase in Na intake of 2.2 g/d (based on urinary excretions), 
the potent vasoconstrictor and pro-inﬂammatory peptide endothelin-1 increased by 0.24 
pg/ml. Other circulating biomarkers of endothelial function and low-grade inﬂammation 
were unaffected. These ﬁndings are in line with the results of a randomised controlled trial, 
in which lowering Na intake moderately for 6 weeks resulted in a decrease in endothelin-1 
and no changes in ICAM-1, VCAM-1 and E-selectin [6]. Other randomised controlled trials also 
indicated lower levels of endothelin-1 at lower Na intakes, but ﬁndings were not signiﬁcant 
[7, 9]. In contrast, in seventeen adults with moderately elevated BP, endothelin-1 levels were 
higher after 4 weeks of Na restriction than after normal Na intake (6.3 v. 5.9 pg/ml); however, 
this was not statistically signiﬁcant [8]. Although not as comprehensively assessed as in 
our study, other randomised controlled trials with a 4-week intervention also observed no 
signiﬁcant effects of Na intake on inﬂammatory markers [8–10].
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We found no effect of Na supplementation on FMD. Other cross-over studies demonstrated 
improvements in FMD of 1.5–2.4% after Na reductions for 2–6 weeks [6, 8, 16]. In these studies, 
in contrast to our study, K intake was not reduced. Moreover, our subjects had, on average, 
a high baseline brachial artery diameter and a low FMD compared with these studies. We 
excluded FMD recordings of low quality, but baseline characteristics of the subjects included 
in the FMD analysis were similar to all thirty-six subjects and randomisation was maintained.
In our study, doubling the intake of K from 2.2 to 4.6 g/d had no effect on circulating 
biomarkers of endothelial function, whereas the inﬂammatory marker IL-8 was reduced. 
Other randomised controlled trials with durations of 4 weeks or more also observed no effect 
of increased K intake on endothelial biomarkers [11–13]. To our knowledge, in randomised 
controlled trials, the effects of supplemental K on inﬂammatory biomarkers have only 
been investigated by measuring high-sensitivity CRP, which, in line with our study, was not 
affected [12, 13]. As other cytokines did not change, we cannot exclude the possibility that 
our ﬁndings for IL-8 were per chance because of the large number of outcomes that we 
examined. Moreover, in the sensitivity analysis, the effect on IL-8 was no longer signiﬁcant 
after the exclusion of intervention periods in which subjects were non-compliant.
The functional biomarker FMD was improved by 1.16% following K supplementation, which 
may contribute to cardiovascular risk reduction. In the meta-analyses, each 1% increase in 
FMD was associated with a 8–13% lower risk of cardiovascular events [23, 24]. A randomised 
controlled trial investigating the effects of increased K intake using potassium chloride 
supplements revealed in forty-two untreated hypertensives a signiﬁcant increase of 2.7% in 
FMD for an increased urinary K excretion of 45 mmol/24 h [17]. This study also showed a 1.5% 
increase in FMD after 4-week supplemental potassium bicarbonate. In contrast, increasing 
K intake for 6 weeks through potassium citrate supplements and fruit and vegetables with a 
maximum increase in urinary K of 27 mmol/24 h resulted in no effect on FMD in forty-eight 
early hypertensives [12]. Possibly, a minimum dose of K is required to improve FMD. Skin 
microvascular vasomotion, which is thought to be partly dependent on endothelial function, 
was unaffected by K supplementation. It is uncertain to what extent endothelial function of 
the microvessel is similar to that of macrovessels (e.g. brachial artery). Moreover, our data 
on microvascular vasomotion should be considered exploratory, and need conﬁrmation by 
others using similar methods.
In the present cross-over study, we have previously shown that 24 h BP was 7.5/2.7 mmHg 
higher after Na supplementation and 3.9/1.6 mmHg lower after K supplementation [3]. The 
results of the present investigation suggest that supplemental Na for 4 weeks can increase BP 
without altering endothelial function. The endothelium may play a role in the BP effects of K. 
However, we saw no effect of K intake on the circulating biomarkers of endothelial function, 
while FMD was affected. Endothelial function is a complex process involving a number of 
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factors and it needs to be determined which factors are directly related to K intake-induced 
changes in FMD. Furthermore, we cannot conclude whether the improvement in endothelial 
function preceded or followed BP reduction, or whether these changes are independent.
In conclusion, a 4-week increase in Na intake had, besides an increase in endothelin-1, 
no effect on endothelial function and low-grade inﬂammation in subjects with untreated 
elevated BP. Increasing K intake improved endothelial function as assessed by FMD, but did 
not affect other indicators of endothelial function or low-grade inﬂammation. This suggests 
that K intake may have protective effects on endothelial function. Other studies replicating 
these ﬁndings and further studies about the mechanisms underlying the effect of K intake on 
endothelial function are warranted.
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SUPPLEMENTAL METHODS
Calculation of Overall Z Scores for Endothelial Function and Low-Grade Inflammation
To reduce the influences of biological variability of each individual measure, we created 
overall Z scores for both endothelial function and low-grade inflammation. These overall 
Z scores were calculated as follows: first, for each individual biomarker a Z score was 
calculated according to the formula: (individual value – study population mean after placebo 
supplementation) / study population standard deviation after placebo supplementation. 
The overall Z score for either endothelial function or low-grade inflammation was then 
calculated by averaging the individual Z scores [1]. The endothelial function Z score consisted 
of the biomarkers endothelin-1, soluble E-selectin, soluble thrombomodulin, von Willebrand 
factor, soluble vascular cellular adhesion molecule-1 and soluble intercellular adhesion
molecule-1. The low-grade inflammation overall Z score consisted of soluble intercellular 
adhesion molecule-1, C-reactive protein, serum amyloid A, TNF-α, monocyte chemoattractant 
protein-1, IL-1β, IL-6 and IL-8. Soluble intercellular adhesion molecule-1 was included in 
both overall Z scores, because monocytes and the endothelium express soluble intercellular 
adhesion molecule-1 [2]. Nitric oxide was not included in the endothelial function Z score, 
because plasma nitric oxide levels may not always represent endothelium-derived nitric 
oxide [3].
SUPPLEMENTAL RESULTS
SUPPLEMENTAL TABLE 1. Baseline characteristics of subjects in flow-mediated dilation analysisa
Sodium vs placebo (n=22) Potassium vs placebo (n=24)
Men/women 15/7 17/7
Age (y) 62.8 ± 8.5 63.8 ± 8.8
Height (cm) 177.7 ± 8.2 177.5 ± 7.9
Weight (kg) 88.0 ± 18.9 86.9 ± 18.4
Body mass index (kg/m²) 27.7 ± 4.8 27.4 ± 4.7
Waist circumference (cm) 101.9 ± 15.9 101.5 ± 15.3
Pre-run-in office SBP (mmHg) 142.9 ± 11.6 143.7 ± 11.6
Pre-run-in office DBP (mmHg) 80.0 ± 7.8 79.8 ± 7.6
Post-run-in office SBP (mmHg) 129.2 ± 15.6 130.8 ± 16.3
Post-run-in office DBP (mmHg) 74.0 ± 7.8 74.3 ± 7.5
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure. Values are mean ± SD. a Flow-mediated 
dilation recordings of insufficient quality were excluded, leaving 22 subjects for analysis of flow-mediated dilation 
for sodium versus placebo supplementation and 24 subjects for potassium versus placebo supplementation.
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SUPPLEMENTAL TABLE 2. Baseline characteristics of subjects in vasomotion analysisa
Sodium vs placebo (n=23) Potassium vs placebo (n=23)
Men/women 16/7 16/7
Age (y) 64.5 ± 9.6 64.0 ± 9.2
Height (cm) 176.6 ± 10.5 177.0 ± 10.6
Weight (kg) 85.6 ± 18.4 86.3 ± 18.2
Body mass index (kg/m²) 27.2 ± 4.1 27.3 ± 4.1
Waist circumference (cm) 101.2 ± 14.0 101.3 ± 14.0
Pre-run-in office SBP (mmHg) 146.3 ± 11.7 146.2 ± 11.6
Pre-run-in office DBP (mmHg) 80.9 ± 9.0 81.3 ± 8.9
Post-run-in office SBP (mmHg) 133.0 ± 16.5 132.7 ± 16.0
Post-run-in office DBP (mmHg) 75.6 ± 9.0 75.9 ± 9.2
Values are mean ± SD. Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure. a Vasomotion 
recordings of insufficient quality were excluded, leaving 23 subjects for analysis of vasomotion for sodium versus 
placebo supplementation and 23 subjects for potassium versus placebo supplementation.
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ABSTRACT
Objective
Lifestyle measures including dietary sodium restriction and increased potassium intake are 
recognized to lower blood pressure (BP). Potassium was found to be effective in reducing BP 
at higher levels of sodium intake, but to have little effect when sodium intake is restricted. 
The humoral mechanisms underlying these sodium intake dependent effects of potassium 
are unknown. We investigated the effects of potassium supplementation on top of a fully 
controlled sodium-restricted diet on markers of osmoregulation and volume regulation.
Methods
In this post-hoc analysis, we included 35 (pre)hypertensive individuals participating in a 
randomized, double-blind, placebo-controlled crossover trial. Individuals received capsules 
containing sodium [3.0 g (130 mmol)/day], potassium [2.8 g (72 mmol)/day], or placebo 
for three four-week periods. Linear mixed-effect models were used to estimate the effects 
of potassium supplementation compared with placebo. Skewed data were ln-transformed 
before analysis.
Results
Increased potassium intake was associated with a significant decrease in 24-h BP (-3.6/-1.6 
mmHg). Furthermore, we found a significant decrease in ln MRproANP {-0.08 [95% confidence 
interval (95% CI)] (-0.15, -0.01) pmol/l, P = 0.03} and significant increases in 24-h heart rate [2.5 
(0.9, 4.0) bpm, P = 0.002], ln plasma copeptin [0.11 (0.01, 0.20) pmol/l, P=0.02], ln renin [0.34 
(0.08, 0.60) μIU/ml, P = 0.01], and ln aldosterone [0.14 (0.07, 0.22) nmol/l, P < 0.001] compared 
with placebo.
Conclusions
We found that potassium has BP-lowering effects during sodium restriction. These BP-
lowering effects, however, seem mitigated by several counter regulatory mechanisms (i.e. 
increased secretion of vasopressin, stimulation of RAAS, and increased heart rate) that were 
activated to maintain volume homeostasis and counterbalance the decrease in BP.
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INTRODUCTION
Given the high prevalence of hypertension and the concomitant increased risks for 
cardiovascular and renal disease [1, 2], hypertension is an important worldwide public-
health challenge [3]. Lifestyle measures including dietary sodium restriction and increased 
potassium intake are recognized to lower blood pressure (BP) and cardiovascular risk [4–6].
A key aspect in long-term regulation of BP is fluid balance, which is precisely regulated by 
means of osmoregulation and volume regulation. Any increase in plasma osmolarity, which 
is mainly determined by the plasma sodium concentration, is normally counterbalanced 
by an increase in vasopressin to maintain osmotic homeostasis [7]. Multiple effectors are 
involved in volume regulation including the renin–angiotensin–aldosterone system (RAAS) 
that stimulates sodium reabsorption [8], natriuretic peptides that promote sodium excretion 
[9], and vasopressin that stimulates water reabsorption in the kidneys [7, 10].
Previous studies, including meta-analyses of randomized controlled trials, have suggested that 
the BP-lowering effects of potassium are more pronounced at higher levels of sodium intake [6, 
11, 12]. During sodium restriction, potassium intake was found to have little or no effect on BP 
[13]. To date, it is not known whether a modest BP-lowering effect of potassium supplementation 
during sodium restriction is biologically plausible. Also, the humoral mechanisms involved in the 
BP-lowering effects of potassium supplementation have poorly been described. Therefore, our 
aim was to investigate whether there could be biological plausibility for a modest BP-lowering 
effect of potassium supplementation during sodium restriction. To this end, we investigated 
the humoral effects of potassium supplementation during a fully controlled sodium-restricted 
diet using a panel of markers that are involved in osmoregulation and volume regulation. 
We additionally investigated the effects of sodium supplementation, with surmised opposite 
changes in markers of osmoregulation and volume regulation.
MATERIALS AND METHODS
Study Protocol and Individuals
The current study is a post-hoc analysis of a randomized, double-blind, placebo-controlled 
crossover trial in which individuals were on a fully controlled diet for a period of 13 weeks, 
as described previously [14]. The study was designed to examine the effects of sodium and 
potassium supplementation on BP and arterial stiffness in untreated (pre)hypertensive 
individuals (i.e. individuals with a fasting office SBP between 130 and 159 mmHg) [14]. In 
brief, at the end of a one-week run-in period (‘baseline’), individuals were randomized to 
take eight sodium chloride capsules [i.e. 3.0 g (130 mmol) sodium], eight potassium chloride 
capsules [i.e. 2.8 g (72 mmol) potassium] or eight placebo capsules (cellulose) daily, for four 
weeks each, while they were provided with the fully controlled diet. The fully controlled diet 
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provided on average 2.4 g (104 mmol) of sodium, based on the recommended maximum 
sodium intake of 2.0 – 2.4 g per day (which equals 87 – 104 mmol sodium or 5 – 6 g salt per 
day) [15, 16], and 2.3 g (59 mmol) of potassium per day for a 2500-kcal intake. Individuals 
were weighed twice a week and if needed, their energy intake was adjusted to keep body 
weight constant.
Nonsmoking men and women aged 40 – 80 years, who had a fasting office SBP between 
130 and 159 mmHg were eligible for the study. Exclusion criteria were a history of diabetes 
mellitus, cardiovascular, gastrointestinal, liver, or renal diseases; BMI more than 40 kg/m2; 
use of medication known to affect the cardiovascular system; use of nutritional supplements; 
an energy-restricted or medically prescribed diet; unstable body weight in the preceding two 
months; alcohol use over 21 (women) or 28 (men) consumptions per week; and pregnant 
or lactating women. Of the 37 Whites that were included and randomized in the study, 36 
completed the study. One individual withdrew because of experiencing gastrointestinal 
complaints. Given the effects of trauma or severe infection on plasma copeptin [17], one 
individual was excluded from all analyses because of severe trauma during the placebo 
study period and one individual was excluded only from analyses on the effects of potassium 
because of severe infection during the potassium intervention period. Written informed 
consent was obtained from all participants. The study was approved by the Medical Ethics 
Committee of Wageningen University and was in adherence to the Declaration of Helsinki. 
The trial was registered at ClinicalTrials.gov (registration no. NCT01575041).
Measurements
At baseline and at the end of each four-week intervention, participants collected a 24-h urine 
sample and underwent 24-h ambulatory BP and heart rate monitoring (Spacelabs 90127 
devices; Spacelabs Medical Inc. Redmond, Washington, USA). At the research center, in a 
fasting state, anthropometrics and BP were measured, and blood was sampled. Individuals 
rested at least 10 min before office brachial BP was assessed in the supine position with an 
automated oscillometric device (Dinamap Pro 100; KP Medical, Houten, The Netherlands).
Serum and urinary sodium and potassium concentrations were measured using the ion-
selective electrodes module on the Roche Modular P (Roche Diagnostics, Mannheim, 
Germany); plasma copeptin and MR-proANP using an automated sandwich immunoassay 
(KRYPTOR; BRAHMS GmbH, Hennigsdorf/Berlin, Germany); plasma NT-proBNP using the 
Roche Modular E170 (Roche Diagnostics, Mannheim, Germany); and plasma renin and 
aldosterone concentrations using an automated sandwich immunochemiluminescent assay 
(LIAISON, Diasorin; DiaSorin Ltd, Schiphol Rijk, The Netherlands). Other serum and urinary 
parameters were assessed using standard laboratory methods. Serum osmolarity was 
calculated using the Eq. 1.9 * ([Na] + [K]) + [glucose] + 0.5 * [urea] + 5 [18]. The creatinine-
based Chronic Kidney Disease Epidemiology Collaboration equation was used to estimate 
glomerular filtration rate [19].
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Statistical Analysis
Analyses were performed using SAS 9.2 software (SAS Institute, Cary, North Carolina, USA) and 
SPSS version 22.0 for Windows (IBM Corporation, Chicago, Illinois, USA). Data are reported as 
mean with standard deviation for variables with a normal distribution or geometric mean 
with 95% confidence interval for variables with a skewed distribution. Nominal data are 
presented as the number of individuals with percentage [n (%)]. A two-sided P-value less than 
0.05 was considered to indicate statistical significance. To estimate the effects of potassium 
and sodium supplementation compared with placebo on clinical parameters, we used linear 
mixed-effect models for repeated measurements, using the compound symmetry covariance 
structure with ‘treatment’ and ‘period’ as fixed effects and ‘individual’ as random effect. 
Skewed data were logarithmically transformed before statistical analysis.
RESULTS
Baseline Characteristics
During screening, mean 24-h urinary sodium excretion was 152 mmol (i.e. 3.5 g sodium or 
8.7 g of salt), which reduced to 91 mmol after one-week run-in (i.e. baseline). Mean 24-h 
potassium excretion during screening was 82 mmol (i.e. 3.2 g potassium), which reduced 
to 49 mmol after run-in. Average office BP was 146/81 mmHg during screening and 134/76 
mmHg after the one-week run-in period on controlled diet. Baseline characteristics of the 
study participants are shown in Table 1.
Effects of Potassium and Sodium Supplementation
The effects of potassium and sodium supplementation on clinical parameters are shown in 
Table 2. After four weeks of potassium supplementation, 24-h BP and plasma MR-proANP 
decreased significantly, whereas plasma copeptin, renin, aldosterone, serum urea, and 24-h 
heart rate increased significantly compared with placebo (Table 2). After four weeks of sodium 
supplementation, we found significant increases in 24-h BP and plasma concentrations of 
copeptin and natriuretic peptides (i.e. NT-proBNP and MR-proANP), whereas plasma renin 
and aldosterone concentrations decreased significantly compared with placebo (Table 2).
The percentage change in several markers for osmoregulation and volume regulation after 
potassium and sodium supplementation compared with placebo are depicted in Figure 1. 
Changes in serum osmolarity and serum sodium concentrations were minor (i.e. ranging 
between -2.0 and +1.7% for serum osmolarity and -2.1 and +2.1% for serum sodium; Figure 1). 
The percentage change in serum potassium, BP, and heart rate were more pronounced and 
interindividual variability was higher, but all percentage changes remained within the range 
of -20 to +25% (Figure 1). The changes in plasma copeptin, NT-proBNP, MR-proANP, renin, and 
aldosterone were much more pronounced, with distinct interindividual differences (Figure 1).
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TABLE 1. Baseline characteristics of the study participants
  All participantsa (n=35)
Demographics
Male sex [n, (%)] 23 (66)
Age (years) 66 ± 9
Clinical measurements
BMI (kg/m²) 27.4 ± 4.7
Body weight (kg) 84.9 ± 18.5
SBP (mmHg) 134 ± 15
DBP (mmHg) 76 ± 8
Heart rate (bpm) 61 ± 6
Fasting serum/plasma parameters
Sodium (mmol/L) 143 ± 2
Potassium (mmol/L) 4.3 ± 0.3
Serum osmolarity (mmol/L) 294 ± 3
Total cholesterol to HDL ratio 3.9 ± 1.0
Renal function parameters
Serum urea (mmol/L) 5.4 ± 1.0
Serum creatinine (μmol/L) 81 ± 13
eGFR (mL/min per 1.73m²) 79 ± 12
ACR (mg/mmol) 0.41 (0.28-0.59)
Urinary parameters
Sodium excretion (mmol/24 h)b 91 ± 27
Potassium excretion (mmol/24 h)c 49 ± 14
Abbreviations: ACR, urinary albumin to creatinine ratio; bpm, beats per minute, 
eGFR, estimated glomerular filtration rate. a Data are presented as mean ± SD, geom-
etric mean (95% confidence interval), or number (percentage). b To convert sodium in 
mmol/24 h to mg/24 h multiply by 23. c To convert potassium in mmol/24 h to mg/24 
h multiply by 39.
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DISCUSSION
The present study is, to the best of our knowledge, the first to investigate the humoral effects of 
potassium supplementation during sodium restriction and provides a biologically plausible 
explanation for the diminished BP-lowering effects of potassium supplementation during 
sodium restriction. In this post-hoc analysis of a fully controlled dietary intervention study, 
we found that BP decreased significantly after four weeks of potassium supplementation, 
indicating that potassium has BP-lowering effects, albeit relatively small, during sodium 
restriction. The BP-lowering effects of potassium during sodium restriction seem mitigated by 
activation of several counter regulatory mechanisms (i.e. increased secretion of vasopressin, 
stimulation of RAAS, and increased heart rate) in order to maintain volume homeostasis and 
counterbalance the decrease in BP.
The BP-lowering effects of potassium have been established in several randomized clinical 
trials [6, 14]. Potassium is suggested to exert its BP-lowering effects, at least in part, through 
Potassium supplementation
-20 -10 0 10 20 30
24-h heart rate
24-h DBP
24-h SBP
Serum potassium
Serum sodium
Serum osmolarity
Percentage change compared with placebo
Sodium supplementation
-20 -10 0 10 20 30
24-h heart rate
24-h DBP
24-h SBP
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Serum sodium
Serum osmolarity
Percentage change compared with placebo
Potassium supplementation
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MR-proANP
NT-proBNP
Copeptin
*
Percentage change compared with placebo
Sodium supplementation
-10
0 0
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NT-proBNP
Copeptin
Percentage change compared with placebo
FIGURE 1. Effects of potassium and sodium supplementation on markers of osmoregulation and volume regulation 
in 35 (pre)hypertensive subjects. 
*3 data points (percentage change in renin after potassium supplementation of 281, 380, and 569%, respectively) 
are outside the x-axis limits.
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stimulation of natriuresis [20, 21]. A dietary potassium load was reported to induce a rapid 
natriuresis [22, 23], which is most likely explained by deactivation of the NaCl cotransporter 
that occurs independent of plasma aldosterone concentrations [23]. Moreover, potassium 
was reported to be more effective in reducing BP at higher levels of sodium intake [6, 
11]. High potassium intake is suggested to blunt the BP increasing effects of high sodium 
intake [24], which could be explained by enhanced natriuretic effects of potassium during 
high sodium intake [22]. A previous randomized crossover trial that examined the effects of 
increased potassium intake on top of a sodium-restricted diet (i.e., 70 mmol/24 h) showed 
little or no effect of potassium on BP in individuals with mild or moderate hypertension [13]. 
It was hypothesized that potassium has either less of a natriuretic effect or less effect on 
renin suppression when sodium intake is restricted [13]. In the present study, we found a 
significant decrease in BP after potassium supplementation, indicating that potassium can 
have BP-lowering effects when sodium intake is restricted. Because the BP-lowering effects 
of potassium are suggested to depend on the level of sodium intake [6, 11], differences in 
background sodium intake (i.e. ~100 mmol/24 h in the present study versus ~70 mmol/ 24 
h in the study of Smith et al. [13]) may explain the differences in the observed effects of 
potassium supplementation on BP.
Interestingly, the BP-lowering effects of potassium during sodium restriction seem mitigated 
by counter regulatory effects of hormones involved in maintenance of volume and BP 
homeostasis. In line, we found significant increases in both plasma renin and aldosterone. 
In hyperkalemia, aldosterone secretion is increased, while secretion of renin and angiotensin 
II is suppressed, resulting in electrochemical sodium reabsorption that promotes kaliuresis 
[25]. In contrast, secretion of both renin and aldosterone is increased in effective circulating 
volume depletion, in which aldosterone and angiotensin II act synergistically to promote 
maximal sodium reabsorption [25]. The significant increase in serum urea is likely to 
correspond with increased tubular sodium reabsorption, because reabsorption of filtered 
urea is passively linked to that of sodium and water [7]. In addition, we found a significant 
increase in plasma copeptin, a surrogate for vasopressin. Vasopressin stimulates water 
reabsorption, which raises the extracellular volume toward normal [17]. Furthermore, 
we found a significant increase in 24-h heart rate, which may indicate that the decrease 
in effective circulating volume is counterbalanced by an increase in heart rate to increase 
cardiac output.
The effects of increased sodium intake on RAAS and natriuretic peptides are well known. 
In line with previous studies, we found that increased sodium intake is associated with 
suppression of RAAS [26, 27] and increases in natriuretic peptides [7, 26]. However, limited 
data are available on the effects of increased dietary sodium intake on copeptin, or 
vasopressin, concentrations. In line with a recent study of Tasevska et al. [28], we found that 
increased sodium intake was associated with an increase in plasma copeptin concentrations.
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We found that percentage changes in serum sodium concentration after sodium and 
potassium supplementation, compared with placebo, are minor (i.e. less than 2%). This 
suggests that, in line with a recent study of Zhang et al. [29], serum sodium concentrations 
are tightly regulated around a subject-specific set point.
We acknowledge that this study has several limitations. The main limitation of the present 
study is the relatively small sample size. However, the fact that we found anticipated effects 
of sodium supplementation and opposing effects of potassium intake makes our data 
robust. Furthermore, we studied relatively short-term effects of potassium and sodium 
intake on osmoregulation and volume regulation in (pre)hypertensive individuals. It would 
be of interest to investigate whether long-term effects of potassium and sodium intake on 
osmoregulation and volume regulation would alter the risk of cardiovascular and renal 
disease end points. A major strength of our study is the fully controlled diet, which strongly 
reduced the intraindividual variability resulting from dietary influences (for example, use 
of alcohol, coffee, and salt) and thereby increasing the power to demonstrate effects that 
are exclusively attributable to potassium and sodium intake. The power of our study is 
furthermore strengthened by its design as a crossover study, allowing paired data analysis.
In conclusion, in this post-hoc analysis of a fully controlled dietary intervention study, we 
demonstrated that potassium has BP-lowering effects during sodium restriction. These BP-
lowering effects of potassium, however, seem mitigated by activation of several counter 
regulatory mechanisms (i.e. increased secretion of vasopressin, stimulation of RAAS, and 
increased heart rate) to maintain volume homeostasis and counterbalance the decrease in 
BP. Our study provides biological plausibility for the observation that BP-lowering effects of 
potassium supplementation are diminished during sodium restriction.
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ABSTRACT
Background and aims
Increasing the intake of potassium has been shown to lower blood pressure, but whether it 
also affects heart rate (HR) is largely unknown. We therefore assessed the effect of potassium 
supplementation on HR in a meta-analysis of randomized controlled trials.
Methods and results
We searched PubMed (1966–October 2014) for randomized, placebo-controlled trials 
in healthy adults with a minimum duration of two weeks in which the effect of increased 
potassium intake on HR was assessed. In addition, reference lists from meta-analysis papers 
on potassium and blood pressure were hand-searched for publications. Two investigators 
independently extracted the data. We performed random effects meta-analyses, subgroup 
and meta-regression analyses for characteristics of the study (e.g. design, intervention 
duration, potassium dose and salt type, change in potassium excretion, sodium excretion 
during intervention) and study population (e.g. gender, age, hypertensive status, pre-
study HR, pre-study potassium excretion). A total of 22 trials (1086 subjects), with a median 
potassium dose of 2.5 g/day (range: 0.9–4.7 g/day), and median intervention duration of 4 
weeks (range: 2–24 weeks) were included. The meta-analysis showed no overall effect of 
increased potassium intake on HR (0.19 bpm, 95% CI: –0.44, 0.82). Stratiﬁed analyses yielded 
no signiﬁcant effects of potassium intake on HR in subgroups, and there was no evidence for 
a dose-response relationship in meta-regression analyses.
Conclusion
A chronic increase in potassium intake with supplemental doses of 2–3 g/day is unlikely to 
affect HR in apparently healthy adults.
77
POTASSIUM AND HEART RATE
5
INTRODUCTION
Elevated resting heart rate (HR) has been identiﬁed as a predictor of cardiovascular morbidity 
and mortality in population-based studies [1–3]. In a meta-analysis of 7 prospective cohort 
studies a high resting HR was associated with a 40% higher risk of heart failure compared to a 
low resting HR [3]. HR can be affected by cardiac drug therapy, e.g. use of beta-blockers [3–8], 
and by non-pharmacological factors such as stress [9], physical activity [10–12], smoking 
[13], and alcohol use [14, 15]. To what extent HR can be modiﬁed by diet, however, is largely 
unknown. García-López et al. [16] showed that baseline adherence to the Mediterranean diet, 
characterized by high consumption of fruits and vegetables, olive oil, legumes, whole grain 
cereals, moderate consumption of ﬁsh, poultry and dairy products, and low consumption 
of red and processed meats, was associated with a lower average HR. No association was 
found for repeated measurements of adherence during follow up and no difference in HR was 
observed among the dietary intervention groups in the PREDIMED trial [16]. Mozaffarian et al. 
[17], however, showed in a meta-analysis of 30 randomized controlled trials (RCTs) that ﬁsh 
oil signiﬁcantly reduced HR by 1.6 beats per minute (bpm), particularly in subjects with high 
pre-study HR and after longer treatment duration.
Increased potassium intake favorably affects BP. A meta-analysis of 21 RCTs in healthy adults 
showed a 3.5 mmHg lower systolic BP and 2.0 mmHg lower diastolic BP after potassium 
supplementation (~2 g/day), an effect that was most pronounced in hypertensives and in 
those with a high sodium intake [18]. In a recent crossover study, we found a 4.0/1.7 mmHg 
lower 24-h BP in 36 subjects with untreated elevated BP who received 3 g/day of potassium 
for 4 weeks on top of a fully controlled, reduced-sodium diet (2.4 g per 2500 kcal) [19]. In that 
study, we noted that potassium supplementation signiﬁcantly increased 24-h HR by 2.6 bpm, 
without affecting resting ofﬁce HR. In a 4-week trial in 21 healthy adults with a high sodium 
intake, however, no effect of 4 g/day of potassium on 24-h HR was seen [20]. 
To clarify the role of potassium intake in determining HR, and possible interaction with sodium 
intake or other factors, we performed a meta-analysis of RCTs of potassium supplementation 
and HR (mostly as a secondary study outcome) in healthy adults.
METHODS
Search Strategy
A systematic literature search was performed for RCTs of potassium supplementation 
evaluating the effect on HR or BP in PubMed (1966 through 31 October 2014), using terms 
and algorithms as presented in Supplemental Table 1. References from previous meta-
analyses and reviews evaluating the effect of potassium on BP were screened for additional 
publications. No restrictions were imposed on language.
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Study Selection
An overview of the study selection is given in Figure 1. After screening titles and abstracts, 
full-text articles were screened according to predeﬁned criteria. Inclusion criteria were 
(1) randomized design; (2) effect of increased potassium intake on HR or BP assessed; 
(3) placebo-controlled study; (4) subjects of 18 years or older; (5) apparently healthy 
individuals; (6) treatment effect could be appointed to increased potassium intake alone; 
and (7) intervention period was 2 weeks or longer. After excluding duplicate publications, 
34 potential relevant studies remained. If not reported, authors were contacted to provide 
HR data. For 12 studies HR data were not obtained, either because (1) no HR measurements 
were performed [21–23]; (2) HR data were not accessible [24–28]; or (3) no contact could be 
established with the author [29–32], leaving 22 RCTs [19, 20, 33–52] that were eligible and 
included in the meta-analysis.
Data Extraction and Risk of Bias Assessment
Two investigators (LG and FJMM) extracted the following data from each study using a 
standardized extraction sheet: study design; primary outcome of the study; intervention 
duration; potassium type and dose; data on potassium and sodium excretion; method of 
HR assessment; data on HR and variance measures; and data on BP. Data on sample size 
and characteristics of the study population including mean baseline age, sex, hypertensive 
status, and use of antihypertensive medications were also collected. When the outcome was 
measured multiple times, data from the latest time point were extracted. Discrepancies were 
resolved by discussion with a third investigator (JMG). When data were missing, authors were 
requested or data were calculated using published data. None of the 22 RCTs reported the HR 
effect estimate with the standard error (SE) of this treatment effect. For 5 RCTs [19, 45, 48, 50, 
52], HR effects with SEs were available upon author request. For 17 RCTs [20, 33–44, 46, 47, 49, 
51], the HR effect and SE were calculated using published data, of which for one RCT [44] HR 
data were derived from graphs. If pre-study characteristics were missing, placebo values were 
extracted if the protocol aimed to maintain usual dietary patterns during the study period. 
Eventually, for one study [34] data on pre-study HR, for two studies [42, 49] data on potassium 
excretion after potassium supplementation, and for one study [42] data on sodium excretion 
after potassium supplementation were missing. Mean age was not reported for one study [39] 
and we took the midpoint of the age range. 
We assessed the risk of bias of the included studies as being low, unclear, or high using the 
Cochrane Collaboration’s tool [53], taking into account method of sequence generation, 
allocation concealment, blinding of participants and personnel, blinding of outcome 
assessment and incomplete outcome data. Selective reporting was not taken into account, 
because authors were requested for additional HR data equalizing and minimalizing 
reporting bias between all studies. Studies considered to be high in risk of bias were the 
studies graded as high in risk for the method of sequence generation, allocation concealment 
and additionally in one of the blinding procedures or incomplete outcome data.
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FIGURE 1. Flow chart of study selection.
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Statistical Analysis
Our primary outcome was the effect of potassium supplementation on HR, as compared to 
a placebo-controlled situation. For crossover RCTs, the treatment effect was calculated as 
HR after potassium intervention minus HR after placebo intervention. For parallel RCTs, the 
treatment effect was calculated as the HR change from baseline to end in the potassium 
intervention group minus the HR change from baseline to end in the control group. If not 
obtained, the SE of the HR effect was estimated following the method as described by 
Streppel et al. [54]. For this estimation, a correlation of 0.50 between baseline and end 
HR (parallel design) or HR after intervention and placebo period (crossover design) was 
assumed, according to Follmann et al. [55]. Considering a correlation coefﬁcient of 0.00 and 
less conservative correlation coefﬁcients of 0.65 and 0.80 yielded similar results. For one 
parallel RCT [41] only SEs for baseline HR were reported and it was assumed that end SEs 
were similar. An overview of the methods to impute SE is given in the supplemental material.
Meta-analyses were performed in STATA (version 11.0; STATA Corp, College Station, TX) through 
the use of random-effects model which takes both within and between study variance into 
account [56], with each study weighted by the inverse of its variance. Heterogeneity between 
studies was evaluated with the I2 test statistic and the Cochran’s Q-test [57].
For RCTs with different types of potassium-salts [43, 47, 51], the potassium-chloride data 
were included in the main meta-analyses. When HR was measured in various body positions 
[19, 33, 36, 37, 41, 43, 45, 46, 50], HR data in supine position were included, or if not available 
we used seated, standing, or 24-h ambulatory monitoring measurements, consecutively.
To investigate potential sources of heterogeneity and to explore effect modiﬁcation, we 
conducted predeﬁned stratiﬁed and meta-regression analyses for study design (parallel vs 
crossover), gender (men vs women vs mixed), age (≤ 45 vs > 45 years), hypertensive status of the 
study population (normotensive vs hypertensive [SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg] 
vs mixed), intervention duration (≤ 4 vs > 4 weeks), potassium dose (≤ 2.5 vs > 2.5 g/day), 
potassium salt type (potassium chloride vs potassium citrate vs potassium bicarbonate), HR 
measurement (ofﬁce supine vs ofﬁce standing vs ofﬁce seated vs 24-h ambulatory), pre-study 
HR (≤ 70 bpm vs > 70 bpm), pre-study potassium excretion (≤ 65 vs > 65 mmol/24 h), urinary 
potassium excretion during potassium intervention (≤ 120 vs > 120 mmol/24 h), change in 
potassium excretion (≤ 50 vs > 50 mmol/24 h), urinary sodium excretion during potassium 
intervention (≤ 140 vs > 140 mmol/24 h) and reduction in SBP (≤ 3 mmHg vs > 3 mmHg). 
In the stratiﬁcation analyses of potassium salt type and HR measurement, some RCTs were 
included in multiple subgroups, because in these RCTs [43, 47, 51] multiple potassium-salt 
types were administered or HR was measured in multiple positions [19, 33, 36, 37, 41, 43, 45, 
46, 50], respectively. For subgroup analysis, a minimum of three studies was required per 
strata.
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We performed sensitivity analysis by excluding one study at a time from the analysis. We 
planned to do a sensitivity analysis to examine the effect of removing studies at high risk 
of bias from the analysis, but none of the studies appeared to be high in risk. Publication 
bias was assessed using funnel plots and Egger’s test [58]. Two- sided p-values < 0.05 were 
regarded as statistically signiﬁcant.
RESULTS
Study Characteristics
Table 1 provides an overview of 22 included RCTs (5 parallel, 17 crossover) of potassium 
supplementation and HR, which had a duration of 2–24 weeks (median: 4 weeks.) The 
overall meta-analysis included 1086 subjects (64% men) with a mean pre-study HR of 70 
bpm and BP of 143/89 mmHg (Supplemental Table 2). Subjects received potassium doses 
between 0.9 and 4.7 g/day (median: 2.5 g/day), with resulting changes in urinary potassium 
excretion between 17 and 108 mmol/24 h (median: 53 mmol/24 h). The effect of potassium 
supplementation on SBP ranged from –13.7 mmHg to +2.0 mmHg (median: –3.0 mmHg). 
None of the 22 studies were considered to be high in risk of bias (Supplemental Table 3).
Effect on Heart Rate
The meta-analysis showed no overall effect of increased potassium intake on HR (0.19 
bpm, 95% CI: –0.44, 0.82; P = 0.56), and there was no evidence for heterogeneity (I2 = 0, P 
= 0.56) (Figure 2). Table 2 shows the results of the stratiﬁed and meta-regression analyses, 
and in Supplemental Table 4 the descriptive characteristics of the subgroups are given. 
HR was reduced by 0.50 bpm in short-term RCTs (≤ 4 weeks), and increased by 0.85 bpm 
in longer-term RCTs, but the estimates were not statistically signiﬁcant. Moreover, meta-
regression analysis indicated no linear relationship of intervention duration with the effect 
on HR (β = 0.08 bpm per one week increase in intervention duration; P = 0.19) (Table 2 
and Supplemental Figure 1). Stratiﬁed analyses also suggested a difference in effect (P for 
interaction = 0.050) for pre-study HR: in subjects with a lower HR (≤ 70 bpm), potassium 
supplementation increased HR by 0.70 bpm, whereas in subjects with a higher HR (> 70 
bpm) potassium reduced HR by 0.85 bpm, albeit these effects were not signiﬁcant. Moreover, 
meta-regression analysis indicated no linear relationship of pre-study HR with the effect 
on HR (Table 2 and Supplemental Figure 2). In the stratiﬁcation for the way in which HR 
measurement was performed, potassium intake tended to increase 24-h ambulatory HR 
by 0.99 bpm, but results were only based on 4 studies and not statistically signiﬁcant (P = 
0.26) (Supplemental Figure 3). The effect of potassium on HR was not associated with the 
concomitant 24-h urinary sodium excretion (β = 0.07 bpm per 10 mmol/24 h, P = 0.50; 
Table 2 and Supplemental Figure 4). The effect of potassium on HR was inversely related 
to SBP reduction (β = –0.24 bpm per mmHg, P = 0.019; Table 2 and Supplemental Figure 5). 
82
CHAPTER 5
TA
BL
E 
1.
 O
ve
rv
ie
w
 o
f 2
2 
ra
nd
om
iz
ed
 c
on
tr
ol
le
d 
tr
ia
ls
 e
va
lu
at
in
g 
th
e 
ef
fe
ct
 o
f i
nc
re
as
ed
 p
ot
as
si
um
 in
ta
ke
 o
n 
he
ar
t r
at
e 
Au
th
or
Ye
ar
Co
un
tr
y
Tr
ia
l 
de
si
gn
Du
ra
tio
n 
(w
ee
ks
)
N
o.
 o
f 
su
bj
ec
ts
M
en
 (%
)
M
ea
n 
ag
e 
(y
r)
H
yp
er
te
ns
iv
e
Do
se
 
(g
/d
ay
)
Ty
pe
 K
a
H
Rb
 m
ea
su
re
m
en
t
Tr
ea
tm
en
t e
ffe
ct
 
H
R 
± 
SE
 (b
pm
)
Ba
rd
en
 e
t a
l. 
[3
7]
19
86
Au
st
ra
lia
XO
4
43
0
32
N
o
3.
1
K-
ch
lo
rid
e
O
ffi
ce
 su
pi
ne
-1
.3
 ±
 2
.3
c
O
ffi
ce
 st
an
di
ng
-1
.6
 ±
 2
.3
c
Be
rr
y 
et
 a
l. 
[5
0]
20
10
U
K
XO
6
48
48
45
M
ix
ed
1.
6
K-
ci
tra
te
O
ffi
ce
 su
pi
ne
0.
9 
± 
0.
9
24
-h
 a
m
bu
la
to
ry
0.
2 
± 
1.
0
Fo
th
er
by
 a
nd
 P
ot
te
r [
46
]
19
92
U
K
XO
4
18
28
75
Ye
s
2.
3
K-
ch
lo
rid
e
O
ffi
ce
 su
pi
ne
-1
.0
 ±
 2
.4
c
O
ffi
ce
 st
an
di
ng
-2
.0
 ±
 2
.5
c
24
-h
 a
m
bu
la
to
ry
-1
.0
 ±
 2
.3
c
Gi
js
be
rs
 e
t a
l. 
[1
9]
20
14
Th
e 
N
et
he
rla
nd
s
XO
4
36
67
66
M
ix
ed
2.
8
K-
ch
lo
rid
e
O
ffi
ce
 su
pi
ne
0.
6 
± 
0.
9
24
-h
 a
m
bu
la
to
ry
2.
6 
± 
0.
8
Gr
ah
am
 e
t a
l. 
[5
2]
20
13
N
or
th
 Ir
el
an
d
XO
6
40
80
55
M
ix
ed
2.
5
K-
ch
lo
rid
e
O
ffi
ce
 su
pi
ne
1.
1 
± 
1.
1
Gr
ob
be
e 
et
 a
l. 
[4
0]
19
87
Th
e 
N
et
he
rla
nd
s
XO
6
40
85
24
Ye
s
2.
8
U
ns
pe
ci
fie
d
O
ffi
ce
 su
pi
ne
2.
0 
± 
2.
0c
H
e 
et
 a
l. 
[5
1]
20
10
U
K
XO
4
42
71
51
Ye
s
2.
5
K-
ch
lo
rid
e
O
ffi
ce
 se
at
ed
0.
0 
± 
1.
3c
K-
bi
ca
rb
on
at
e
0.
0 
± 
1.
3c
M
ac
Gr
eg
or
 e
t a
l. 
[3
3]
19
82
U
K
XO
4
23
52
45
Ye
s
2.
5
K-
ch
lo
rid
e
O
ffi
ce
 su
pi
ne
-1
.0
 ±
 2
.0
c
O
ffi
ce
 st
an
di
ng
-1
.0
 ±
 2
.0
c
M
at
lo
u 
et
 a
l. 
[3
8]
19
86
So
ut
h-
Af
ric
a
XO
6
32
0
51
Ye
s
2.
5
K-
ch
lo
rid
e
O
ffi
ce
 se
at
ed
-2
.0
 ±
 2
.0
c
M
at
th
es
en
 e
t a
l. 
[2
0]
20
12
De
nm
ar
k
XO
4
21
43
26
N
o
3.
9
K-
ch
lo
rid
e
24
-h
 a
m
bu
la
to
ry
0.
0 
± 
2.
8c
M
ul
le
n 
an
d 
O
’C
on
no
r [
43
]
19
90
U
SA
XO
2
24
10
0
25
N
o
2.
9
K-
ch
lo
rid
e
O
ffi
ce
 su
pi
ne
-1
.0
 ±
 2
.0
c
O
ffi
ce
 st
an
di
ng
-1
.0
 ±
 3
.0
c
K-
ci
tra
te
O
ffi
ce
 su
pi
ne
-2
.0
 ±
 2
.0
c
O
ffi
ce
 st
an
di
ng
-4
.0
 ±
 3
.0
c
N
ai
sm
ith
 a
nd
 B
ra
sc
hi
 [4
9]
20
03
U
K
P
6
59
56
43
M
ix
ed
0.
9
K-
ch
lo
rid
e
O
ffi
ce
 se
at
ed
-1
.0
 ±
 1
.5
c
O
ve
rla
ck
 e
t a
l. 
[4
4]
19
91
Ge
rm
an
y
XO
8
12
67
37
Ye
s
4.
7
M
ix
 o
f 
K-
ci
tra
te
 a
nd
 
bi
ca
rb
on
at
e
O
ffi
ce
 su
pi
ne
2.
0 
± 
3.
3c
O
ve
rla
ck
 e
t a
l. 
[4
7]
19
95
Ge
rm
an
y
XO
8
25
72
48
M
ix
ed
4.
7
K-
ch
lo
rid
e
O
ffi
ce
 se
at
ed
2.
3 
± 
1.
7c
K-
ci
tra
te
3.
4 
± 
1.
5c
Po
ul
te
r a
nd
 S
ev
er
 [3
9]
19
86
Ke
ny
a
XO
2
19
10
0
33
N
o
2.
5
K-
ch
lo
rid
e
O
ffi
ce
 se
at
ed
2.
2 
± 
2.
3c
Si
an
i e
t a
l. 
[4
1]
19
87
Ita
ly
P
15
37
62
45
Ye
s
1.
9
U
ns
pe
ci
fie
d
O
ffi
ce
 su
pi
ne
5.
1 
± 
3.
9c
O
ffi
ce
 st
an
di
ng
0.
8 
± 
4.
5c
Sm
ith
 e
t a
l. 
[3
4]
19
85
U
K
XO
4
20
55
53
Ye
s
2.
5
K-
ch
lo
rid
e
O
ffi
ce
 su
pi
ne
-1
.0
 ±
 3
.1
c
Su
nd
ar
 e
t a
l. 
[3
5]
19
85
In
di
a
P
4
50
58
46
M
ix
ed
2.
3
M
ix
 o
f 
K-
ch
lo
rid
e 
an
d 
bi
ca
rb
on
at
e
O
ffi
ce
 su
pi
ne
-3
.0
 ±
 1
.1
c
Sv
et
ke
y 
et
 a
l. 
[4
2]
19
87
U
SA
P
8
10
1
85
51
Ye
s
4.
7
K-
ch
lo
rid
e
O
ffi
ce
 se
at
ed
0.
0 
± 
2.
4c
Va
ld
és
 e
t a
l. 
[4
5]
19
91
Ch
ile
XO
4
24
54
50
Ye
s
2.
5
K-
ch
lo
rid
e
O
ffi
ce
 su
pi
ne
-0
.1
 ±
 1
.5
O
ffi
ce
 st
an
di
ng
1.
3 
± 
1.
3
W
he
lto
n 
et
 a
l. 
[4
8]
19
95
U
SA
P
24
35
3
72
43
N
o
2.
3
K-
ch
lo
rid
e
O
ffi
ce
 se
at
ed
1.
1 
± 
1.
0
Zo
cc
al
i e
t a
l. 
[3
6]
19
85
Sc
ot
la
nd
XO
2
19
53
38
Ye
s
3.
9
K-
ch
lo
rid
e
O
ffi
ce
 su
pi
ne
0.
0 
± 
2.
0c
Ab
br
ev
ia
tio
ns
: K
: p
ot
as
si
um
; H
R:
 h
ea
rt
 ra
te
; S
E:
 s
ta
nd
ar
d 
er
ro
r; 
P:
 p
ar
al
le
l; 
XO
: c
ro
ss
ov
er
; U
K:
 U
ni
te
d 
Ki
ng
do
m
; U
SA
: U
ni
te
d 
St
at
es
 o
f A
m
er
ic
a.
 a 
Fo
r s
tu
di
es
 e
va
lu
at
in
g 
di
ffe
re
nt
 
ty
pe
s o
f p
ot
as
si
um
 sa
lts
, p
ot
as
si
um
 c
hl
or
id
e 
da
ta
 w
er
e 
in
cl
ud
ed
 in
 th
e 
m
ai
n 
m
et
a-
an
al
ys
es
. b
 Fo
r s
tu
di
es
 m
ea
su
rin
g 
H
R 
in
 va
rio
us
 b
od
y 
po
si
tio
ns
, H
R 
da
ta
 in
 su
pi
ne
 p
os
iti
on
 w
er
e 
in
cl
ud
ed
 a
bo
ve
 se
at
ed
, s
ta
nd
in
g,
 a
nd
 2
4-
hr
 a
m
bu
la
to
ry
 m
on
ito
rin
g,
 c
on
se
cu
tiv
el
y.
 c S
E 
w
as
 e
st
im
at
ed
 fo
llo
w
in
g 
th
e 
m
et
ho
d 
of
 S
tr
ep
pe
l e
t a
l. 
[5
4]
 (s
ee
 S
up
pl
em
en
ta
l M
et
ho
ds
).
83
POTASSIUM AND HEART RATE
5
TA
BL
E 
1.
 O
ve
rv
ie
w
 o
f 2
2 
ra
nd
om
iz
ed
 c
on
tr
ol
le
d 
tr
ia
ls
 e
va
lu
at
in
g 
th
e 
ef
fe
ct
 o
f i
nc
re
as
ed
 p
ot
as
si
um
 in
ta
ke
 o
n 
he
ar
t r
at
e 
Au
th
or
Ye
ar
Co
un
tr
y
Tr
ia
l 
de
si
gn
Du
ra
tio
n 
(w
ee
ks
)
N
o.
 o
f 
su
bj
ec
ts
M
en
 (%
)
M
ea
n 
ag
e 
(y
r)
H
yp
er
te
ns
iv
e
Do
se
 
(g
/d
ay
)
Ty
pe
 K
a
H
Rb
 m
ea
su
re
m
en
t
Tr
ea
tm
en
t e
ffe
ct
 
H
R 
± 
SE
 (b
pm
)
Ba
rd
en
 e
t a
l. 
[3
7]
19
86
Au
st
ra
lia
XO
4
43
0
32
N
o
3.
1
K-
ch
lo
rid
e
O
ffi
ce
 su
pi
ne
-1
.3
 ±
 2
.3
c
O
ffi
ce
 st
an
di
ng
-1
.6
 ±
 2
.3
c
Be
rr
y 
et
 a
l. 
[5
0]
20
10
U
K
XO
6
48
48
45
M
ix
ed
1.
6
K-
ci
tra
te
O
ffi
ce
 su
pi
ne
0.
9 
± 
0.
9
24
-h
 a
m
bu
la
to
ry
0.
2 
± 
1.
0
Fo
th
er
by
 a
nd
 P
ot
te
r [
46
]
19
92
U
K
XO
4
18
28
75
Ye
s
2.
3
K-
ch
lo
rid
e
O
ffi
ce
 su
pi
ne
-1
.0
 ±
 2
.4
c
O
ffi
ce
 st
an
di
ng
-2
.0
 ±
 2
.5
c
24
-h
 a
m
bu
la
to
ry
-1
.0
 ±
 2
.3
c
Gi
js
be
rs
 e
t a
l. 
[1
9]
20
14
Th
e 
N
et
he
rla
nd
s
XO
4
36
67
66
M
ix
ed
2.
8
K-
ch
lo
rid
e
O
ffi
ce
 su
pi
ne
0.
6 
± 
0.
9
24
-h
 a
m
bu
la
to
ry
2.
6 
± 
0.
8
Gr
ah
am
 e
t a
l. 
[5
2]
20
13
N
or
th
 Ir
el
an
d
XO
6
40
80
55
M
ix
ed
2.
5
K-
ch
lo
rid
e
O
ffi
ce
 su
pi
ne
1.
1 
± 
1.
1
Gr
ob
be
e 
et
 a
l. 
[4
0]
19
87
Th
e 
N
et
he
rla
nd
s
XO
6
40
85
24
Ye
s
2.
8
U
ns
pe
ci
fie
d
O
ffi
ce
 su
pi
ne
2.
0 
± 
2.
0c
H
e 
et
 a
l. 
[5
1]
20
10
U
K
XO
4
42
71
51
Ye
s
2.
5
K-
ch
lo
rid
e
O
ffi
ce
 se
at
ed
0.
0 
± 
1.
3c
K-
bi
ca
rb
on
at
e
0.
0 
± 
1.
3c
M
ac
Gr
eg
or
 e
t a
l. 
[3
3]
19
82
U
K
XO
4
23
52
45
Ye
s
2.
5
K-
ch
lo
rid
e
O
ffi
ce
 su
pi
ne
-1
.0
 ±
 2
.0
c
O
ffi
ce
 st
an
di
ng
-1
.0
 ±
 2
.0
c
M
at
lo
u 
et
 a
l. 
[3
8]
19
86
So
ut
h-
Af
ric
a
XO
6
32
0
51
Ye
s
2.
5
K-
ch
lo
rid
e
O
ffi
ce
 se
at
ed
-2
.0
 ±
 2
.0
c
M
at
th
es
en
 e
t a
l. 
[2
0]
20
12
De
nm
ar
k
XO
4
21
43
26
N
o
3.
9
K-
ch
lo
rid
e
24
-h
 a
m
bu
la
to
ry
0.
0 
± 
2.
8c
M
ul
le
n 
an
d 
O
’C
on
no
r [
43
]
19
90
U
SA
XO
2
24
10
0
25
N
o
2.
9
K-
ch
lo
rid
e
O
ffi
ce
 su
pi
ne
-1
.0
 ±
 2
.0
c
O
ffi
ce
 st
an
di
ng
-1
.0
 ±
 3
.0
c
K-
ci
tra
te
O
ffi
ce
 su
pi
ne
-2
.0
 ±
 2
.0
c
O
ffi
ce
 st
an
di
ng
-4
.0
 ±
 3
.0
c
N
ai
sm
ith
 a
nd
 B
ra
sc
hi
 [4
9]
20
03
U
K
P
6
59
56
43
M
ix
ed
0.
9
K-
ch
lo
rid
e
O
ffi
ce
 se
at
ed
-1
.0
 ±
 1
.5
c
O
ve
rla
ck
 e
t a
l. 
[4
4]
19
91
Ge
rm
an
y
XO
8
12
67
37
Ye
s
4.
7
M
ix
 o
f 
K-
ci
tra
te
 a
nd
 
bi
ca
rb
on
at
e
O
ffi
ce
 su
pi
ne
2.
0 
± 
3.
3c
O
ve
rla
ck
 e
t a
l. 
[4
7]
19
95
Ge
rm
an
y
XO
8
25
72
48
M
ix
ed
4.
7
K-
ch
lo
rid
e
O
ffi
ce
 se
at
ed
2.
3 
± 
1.
7c
K-
ci
tra
te
3.
4 
± 
1.
5c
Po
ul
te
r a
nd
 S
ev
er
 [3
9]
19
86
Ke
ny
a
XO
2
19
10
0
33
N
o
2.
5
K-
ch
lo
rid
e
O
ffi
ce
 se
at
ed
2.
2 
± 
2.
3c
Si
an
i e
t a
l. 
[4
1]
19
87
Ita
ly
P
15
37
62
45
Ye
s
1.
9
U
ns
pe
ci
fie
d
O
ffi
ce
 su
pi
ne
5.
1 
± 
3.
9c
O
ffi
ce
 st
an
di
ng
0.
8 
± 
4.
5c
Sm
ith
 e
t a
l. 
[3
4]
19
85
U
K
XO
4
20
55
53
Ye
s
2.
5
K-
ch
lo
rid
e
O
ffi
ce
 su
pi
ne
-1
.0
 ±
 3
.1
c
Su
nd
ar
 e
t a
l. 
[3
5]
19
85
In
di
a
P
4
50
58
46
M
ix
ed
2.
3
M
ix
 o
f 
K-
ch
lo
rid
e 
an
d 
bi
ca
rb
on
at
e
O
ffi
ce
 su
pi
ne
-3
.0
 ±
 1
.1
c
Sv
et
ke
y 
et
 a
l. 
[4
2]
19
87
U
SA
P
8
10
1
85
51
Ye
s
4.
7
K-
ch
lo
rid
e
O
ffi
ce
 se
at
ed
0.
0 
± 
2.
4c
Va
ld
és
 e
t a
l. 
[4
5]
19
91
Ch
ile
XO
4
24
54
50
Ye
s
2.
5
K-
ch
lo
rid
e
O
ffi
ce
 su
pi
ne
-0
.1
 ±
 1
.5
O
ffi
ce
 st
an
di
ng
1.
3 
± 
1.
3
W
he
lto
n 
et
 a
l. 
[4
8]
19
95
U
SA
P
24
35
3
72
43
N
o
2.
3
K-
ch
lo
rid
e
O
ffi
ce
 se
at
ed
1.
1 
± 
1.
0
Zo
cc
al
i e
t a
l. 
[3
6]
19
85
Sc
ot
la
nd
XO
2
19
53
38
Ye
s
3.
9
K-
ch
lo
rid
e
O
ffi
ce
 su
pi
ne
0.
0 
± 
2.
0c
Ab
br
ev
ia
tio
ns
: K
: p
ot
as
si
um
; H
R:
 h
ea
rt
 ra
te
; S
E:
 s
ta
nd
ar
d 
er
ro
r; 
P:
 p
ar
al
le
l; 
XO
: c
ro
ss
ov
er
; U
K:
 U
ni
te
d 
Ki
ng
do
m
; U
SA
: U
ni
te
d 
St
at
es
 o
f A
m
er
ic
a.
 a 
Fo
r s
tu
di
es
 e
va
lu
at
in
g 
di
ffe
re
nt
 
ty
pe
s o
f p
ot
as
si
um
 sa
lts
, p
ot
as
si
um
 c
hl
or
id
e 
da
ta
 w
er
e 
in
cl
ud
ed
 in
 th
e 
m
ai
n 
m
et
a-
an
al
ys
es
. b
 Fo
r s
tu
di
es
 m
ea
su
rin
g 
H
R 
in
 va
rio
us
 b
od
y 
po
si
tio
ns
, H
R 
da
ta
 in
 su
pi
ne
 p
os
iti
on
 w
er
e 
in
cl
ud
ed
 a
bo
ve
 se
at
ed
, s
ta
nd
in
g,
 a
nd
 2
4-
hr
 a
m
bu
la
to
ry
 m
on
ito
rin
g,
 c
on
se
cu
tiv
el
y.
 c S
E 
w
as
 e
st
im
at
ed
 fo
llo
w
in
g 
th
e 
m
et
ho
d 
of
 S
tr
ep
pe
l e
t a
l. 
[5
4]
 (s
ee
 S
up
pl
em
en
ta
l M
et
ho
ds
).
84
CHAPTER 5
However, after excluding the study of Sundar et al. [35], the relationship was no longer 
present (β = –0.10 bpm per mmHg, P = 0.43). When single studies were excluded from the 
overall analysis, the overall HR effect ranged from 0.08 bpm (95% CI: –0.60, 0.75; P = 0.83) 
when the study of Whelton et al. [48] was excluded to 0.49 bpm (95% CI: –0.17, 1.15; P = 0.15) 
when the study of Sundar et al. [35] was excluded. The funnel plot (Supplemental Figure 6) 
and the Egger’s test (P = 0.94) indicated no evidence of publication bias.
FIGURE 2. Forest plot of 22 randomized controlled trials evaluating the effect of potassium on heart rate. Black 
bullets indicate the point estimate for each trial, with the horizontal lines representing the 95% CIs. The size of the 
square is proportional to the weight of the study, using a random-effects model. The overall pooled treatment ef-
fect is indicated by the dotted line and the width of the diamond corresponds with the 95% CI of the overall effect. 
Abbreviation: HR, heart rate.
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TABLE 2. Effect of potassium supplementation on HR according to predefined study characteristics
  Number
of studies
Effect on HR (bpm) Heterogeneity test P for 
interactionEstimate (95% CI) P I2 (%) P
Overall 22 0.19 (-0.44, 0.82) 0.56 0.0 0.56
Study design
Parallel 5 -0.38 (-2.56, 1.80) 0.73 60.0 0.041 0.22
Crossover 17 0.47 (-0.28, 1.21) 0.22 0.0 0.96
Gender
Men 2 0.38 (-2.73, 3.48) 0.81 7.9 0.30 ref
Women 2 -1.71 (-4.64, 1.21) 0.25 0.0 0.82 0.43
Mixed 18 0.28 (-0.39, 0.94) 0.41 0.0 0.48 0.94
Per% men 22 0.03 (0.00, 0.07) 0.087
Agea
≤ 45 years 12 0.56 (-0.36, 1.48) 0.24 0.0 0.86 0.36
> 45 years 10 -0.18 (-1.25, 0.89) 0.74 25.6 0.21
Per 5 years 22 -0.01 (-0.36, 0.34) 0.96
Hypertensive population
No 5 0.56 (-0.86, 1.98) 0.44 0.0 0.71 ref
Mixed 6 0.13 (-1.28, 1.53) 0.86 59.2 0.13 0.82
Yesb 11 -0.03 (-1.24, 1.18) 0.96 0.0 0.91 0.54
Intervention durationa
≤ 4 weeks 12 -0.50 (-1.40, 0.40) 0.28 0.0 0.65 0.055
> 4 weeks 10 0.85 (-0.04, 1.74) 0.060 0.0 0.71
Per week 22 0.08 (-0.04, 0.21) 0.19
Potassium dosea
≤ 2.5 grams/day 12 0.04 (-0.90, 0.99) 0.93 23.6 0.21 0.71
> 2.5 grams/day 10 0.38 (-0.69, 1.46) 0.49 0.0 0.85
Per gram/day 22 0.34 (-0.56, 1.24) 0.44
Potassium salt typec
Potassium chloride 17 0.30 (-0.44, 1.03) 0.43 0.0 0.96 ref
Potassium citrate 3 1.01 (-1.46, 3.48) 0.42 57.2 0.097 0.34
Potassium bicarbonate 1 0.00 (-2.59, 2.59) 0.99
HR measurement
Office supine 14 0.04 (-0.80, 0.89) 0.92 8.8 0.36 ref
Office standing 7 -0.11 (-1.65, 1.44) 0.89 0.0 0.86 0.82
Office seated HR 7 0.45 (-0.67, 1.56) 0.43 0.0 0.56 0.64
24-hr ambulatory HR 4 0.99 (-0.73, 2.71) 0.26 46.5 0.13 0.29
Pre-study HRd
≤ 70 bpm 13 0.70 (-0.08, 1.49) 0.077 0.0 0.91 0.050
> 70 bpm 8 -0.85 (-2.12, 0.42) 0.19 17.1 0.30
Per 5 bpm 21 -0.53 (-1.14, 0.08) 0.086
Pre-study potassium excretione
≤ 65 mmol/24h 10 -0.32 (-1.67, 1.02) 0.64 28.6 0.18 0.31
> 65 mmol/24h 9 0.48 (-0.44, 1.39) 0.31 0.0 0.82
Per 5 mmol/24h 19 0.16 (-0.16, 0.48) 0.31
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DISCUSSION
In this meta-analysis of 22 RCTs, increasing potassium intake for at least two weeks had no 
effect on resting HR in apparently healthy adults. To our knowledge, this is the ﬁrst meta-
analysis evaluating the effects of an increased potassium intake on HR, based on double-
blind, placebo-controlled trials with a high internal validity. None of the RCTs, however, 
examined HR as the primary outcome of interest and it may therefore be that these studies 
were underpowered to ﬁnd an effect on HR. There was no evidence for publication bias, as 
indicated by the funnel plot that showed reasonable symmetry. For 5 published RCTs, we 
obtained data on HR after contacting the authors. However, the SEs of treatment effects, 
which were needed to compute weighing factors, had to be imputed for 17 RCTs. We assumed 
a correlation of 0.50 between baseline and end HR (parallel design) or HR after intervention 
and placebo period (crossover design), according to Follmann et al. [55]. This assumption 
may have inﬂuenced our pooled estimate, as the weight of the individual studies in the meta-
TABLE 2. Continued
  Number
of studies
Effect on HR (bpm) Heterogeneity test P for 
interactionEstimate (95% CI) P I2 (%) P
Potassium excretion during 
potassium interventionf
≤ 120 mmol/24h 12 0.07 (-0.92, 1.06) 0.89 29.6 0.16 0.62
> 120 mmol/24h 8 0.50 (-0.77, 1.78) 0.44 0.0 0.89
Per 10 mmol/24h 20 0.15 (-0.13, 0.44) 0.28
Change in potassium 
excretiong
≤ 50 mmol/24h 10 0.16 (-0.98, 1.29) 0.79 34.7 0.13
> 50 mmol/24h 10 0.34 (-0.70, 1.38) 0.52 0.0 0.84 0.87
Per 10 mmol/24h 20 0.11 (-0.23, 0.45) 0.51
Sodium excretion during 
potassium interventionh
≤ 140 mmol/24h 9 -0.07 (-1.24, 1.10) 0.91 30.1 0.18 0.58
> 140 mmol/24h 12 0.42 (-0.49, 1.34) 0.36 0.0 0.76
Per 10 mmol/24h 21 0.07 (-0.14, 0.27) 0.50
Reduction in SBPa
≤ 3.0 mmHg 12 0.63 (-0.19, 1.46) 0.13 0.0 0.98 0.13
> 3.0 mmHg 10 -0.39 (-1.65, 0.88) 0.55 31.6 0.16
Per mmHg 22 -0.24 (-0.43, -0.04) 0.019
Abbreviations: HR, heart rate; SBP, systolic blood pressure a Cut-off point is based on median. b SBP ≥ 140 mmHg and/
or DBP ≥ 90 mmHg. c Studies using another potassium salt [35, 44] or not reporting which type of potassium salt used 
[40, 41] are excluded.d Data on pre-study HR is missing for Smith et al. [34]. e Data on pre-study potassium excretion 
is missing for Smith et al. [34], Berry et al. [50], and Svetkey et al. [42].f Data on potassium excretion during potassium 
intervention is missing for Naismith and Braschi [49], and Svetkey et al. [42]. g Data on the change in potassium ex-
cretion is missing for Naismith and Braschi [49], and Svetkey et al. [42].h Data on sodium excretion during potassium 
intervention is missing for Svetkey et al. [42].
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analysis is based on its SE. Also the precision of the pooled estimate may have been affected, 
as it is partly determined by the precision of the individual studies. However, similar results 
were obtained when correlation coefﬁcients of 0.00, 0.65 or 0.80 were used.
In a recent potassium trial at our research center, we found a 4-mmHg lower 24-h systolic 
BP in healthy adults with untreated elevated BP [19], in line with previous meta-analyses of 
RCTs [18]. In that study, we also found a substantial and signiﬁcant 2.6-bpm increase in 24-h 
HR [19]. Based on these ﬁndings, we hypothesized that an increase in HR may be caused 
by a shift in plasma electrolyte balance after increased potassium intake [59, 60] or that it 
could be a compensatory response to a reduction in effective circulating volume [61, 62]. 
The latter, however, was not conﬁrmed by results from the present meta-analysis, because 
HR responses stratiﬁed by the magnitude of SBP reduction were small and not signiﬁcantly 
different. Moreover, the effect of potassium on HR was not inﬂuenced by concomitant 24-h 
urinary sodium excretion. The observed increase in 24-h HR in our recent potassium trial, 
therefore, may be considered a chance ﬁnding.
The effect of BP lowering therapies on HR have been of concern in other studies. Robinson et 
al. [63] evaluated the effects of glucagon-like peptide-1 agonists in a meta-analysis of 32 RCTs 
with a minimum duration of 12 weeks. Compared to placebo, HR was increased signiﬁcantly 
by 1.9 bpm, with a decrease in SBP of 1.8 mmHg. Based on a literature review, Toal et al. [64] 
reported in hypertensive populations small mean increases in HR (< 1 bpm) after at least 
one week of treatment with the calcium-channel blockers amlodipine and nifedipine. During 
the intervention with the calcium-channel blockers, increases in plasma norepinephrine, a 
marker of sympathetic nervous system activity, were observed [64]. These studies imply that 
BP reducing agents can adversely affect HR. Possibly, BP and HR are differently regulated by 
these agents than by potassium.
Subgroup analyses suggested an increased HR of 0.85 bpm of potassium supplementation 
in studies with an intervention duration of more than four weeks. Although, continuously no 
relationship was found between intervention duration and the potassium-induced effect on 
HR, it may be that potassium supplementation for a longer duration adversely affects HR. 
Studies with a longer intervention duration are needed to further explore this.
Resting HR may predict cardiovascular morbidity and mortality [1–3]. After a median follow 
up duration of 12 years, an increase in resting HR of 15 bpm was independently associated 
with a 24% and 32% higher cardiovascular mortality risk in 10 519 healthy men and 11 334 
healthy women, respectively [1]. Another population-based study showed similar results: a 
10 bpm increase in resting HR was associated with a 16% higher cardiovascular mortality 
risk in 6518 healthy subjects followed for 18 years [2]. Based on these epidemiological data, 
a persistent increase in HR of 1 bpm, which was the maximum effect observed in our meta-
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analysis after stratiﬁcation, is not expected to increase cardiovascular mortality risk by more 
than 3% over a period of 10 years. 
From this meta-analysis, we conclude that increasing the intake of potassium by 2–3 g/day 
does not adversely affect HR in apparently healthy individuals. Potential adverse effects of 
potassium supplementation on HR in the long-term, albeit expected to be small, warrant 
further investigation.
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SUPPLEMENTAL METHODS 
Imputing SE of the Treatment Effect for Crossover Trials
When SE of HR after intervention and placebo period are given, the following formula is used 
to obtain the SE of the HR treatment effect in crossover trials:
 = 
SE(d) = 
N treatment
SE(xi ) =  
SE(xi) = 
N
i
 
SE(d) =
SE(d) 
(SE xi 
base)2 + (SE xi 
end)2 - (2x   x(SE xi 
base) x (SE xi 
end))
(SD xi 
base)2 + (SD xi 
end)2 - (2x  x(SD xi 
base) x (SD xi end))
(SE x T)2 + (SE x P)2
(SE x post-T2) + (SE x post-P2) - (2xpx(SE x post-T) x (SE x post-P))
(SD x post-T2) + (SD x post-P2) - (2xpx(SDx post-T) x (SD x post-P))
SE(xpost-T) = standard error at the end of the treatment period
SE(xpost-P) = standard error at the end of the control period
ρ = correlation coefficient, according to Follmann et al. [1] we assumed a correlation of 0.50 
between HR after intervention and control period
SE(d) = standard error of the treatment effect
 
When SD of HR after intervention and placebo period are given, the following formula is used 
to obtain the SE of the HR treatment effect in crossover trials:
 = 
SE(d) = 
N treatment
SE(xi ) =  
SE(xi) = 
N
i
 
SE(d) =
SE(d) 
(SE xi 
base)2 + (SE xi 
end)2 - (2x   x(SE xi 
base) x (SE xi 
end))
(SD xi 
base)2 + (SD xi 
end)2 - (2x  x(SD xi 
base) x (SD xi end))
(SE x T)2 + (SE x P)2
(SE x post-T2) + (SE x post-P2) - (2xpx(SE x post-T) x (SE x post-P))
(SD x post-T2) + (SD x post-P2) - (2xpx(SDx post-T) x (SD x post-P))
SD(xpost-T) = standard deviation at the end of the treatment period
SD(xpost-P) = standard deviation at the end of the control period
ρ = correlation coefficient, according to Follmann et al. [1] we assumed a correlation of 0.50 
between HR after intervention and control period
N treatment = number of subjects in treatment period
SE(d) = standard error of the treatment effect
Imputing SE of the Treatment Effect for Parallel Trials 
1. Calculation of the SE of the difference in HR in both the treatment and control group
When SE of baseline and end measurements are given, the following formula is used to 
obtain the SE of HR change in both the treatment and control group:
 = 
SE(d) = 
N treatment
SE(xi ) =  
SE(xi) = 
N
i
 
SE(d) =
SE(d) 
(SE xi 
base)2 + (SE xi 
end)2 - (2x   x(SE xi 
base) x (SE xi 
end))
(SD xi 
base)2 + (SD xi 
end)2 - (2x  x(SD xi 
base) x (SD xi end))
(SE x T)2 + (SE x P)2
(SE x post-T2) + (SE x post-P2) - (2xpx(SE x post-T) x (SE x post-P))
(SD x post-T2) + (SD x post-P2) - (2xpx(SDx post-T) x (SD x post-P))
SE(x base) = standard error at the baseline 
SE(x end) = standard error at the end
ρ = correlation coefficient, according to Follmann et al. [1] we assumed a correlation of 0.50 
between baseline and end HR 
SE(xi ) = standard error of the difference
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When SD of baseline and end measurements are given, the following formula is used to 
obtain the SE of HR in both the treatment and control group:
 
 = 
SE(d) = 
N treatment
SE(xi ) =  
SE(xi) = 
N
i
 
SE(d) =
SE(d) 
(SE xi 
base)2 + (SE xi 
end)2 - (2x   x(SE xi 
base) x (SE xi 
end))
(SD xi 
base)2 + (SD xi 
end)2 - (2x  x(SD xi 
base) x (SD xi end))
(SE x T)2 + (SE x P)2
(SE x post-T2) + (SE x post-P2) - (2xpx(SE x post-T) x (SE x post-P))
(SD x post-T2) + (SD x post-P2) - (2xpx(SDx post-T) x (SD x post-P))
SD(x base) = standard error at the baseline
SD(x end) = standard error at the end
ρ = correlation coefficient, according to Follmann et al. [1] we assumed a correlation of 0.50 
between baseline and end HR
Ni = number of subjects in the group
SE(x i ) = standard error of the difference
2. Calculation of the SE of the HR treatment effect for parallel trials
When the SE of HR change in both the treatment and control group are reported or estimated 
(see formulae at point 1), the following formula is used to obtain the SE of the HR treatment 
effect:
 = 
SE(d) = 
N treatment
SE(xi ) =  
SE(xi) = 
N
i
 
SE(d) =
SE(d) 
(SE xi 
base)2 + (SE xi 
end)2 - (2x   x(SE xi 
base) x (SE xi 
end))
(SD xi 
base)2 + (SD xi 
end)2 - (2x  x(SD xi 
base) x (SD xi end))
(SE x T)2 + (SE x P)2
(SE x post-T2) + (SE x post-P2) - (2xpx(SE x post-T) x (SE x post-P))
(SD x post-T2) + (SD x post-P2) - (2xpx(SDx post-T) x (SD x post-P))
SE(xT) = standard error of the difference in the treatment group
SD(xP) = standard error at the difference in the control group
SE(d) = standard error of the treatment effect
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SUPPLEMENTAL RESULTS
SUPPLEMENTAL TABLE 1. Search terms and number of citations retrieved via PubMed
Step Search terms # Citationsa
1 Potassium[MeSH] OR Potassium[tiab] OR potassium*[tiab] 169.746
2 Diet[MeSH] OR Dietary Supplements[MeSH] OR diet*[tiab] OR supplement* [tiab] 
OR tablet[tiab] OR capsule[tiab] OR intake*[tiab] OR consumption[tiab]
913.385
3 Blood Pressure[MeSH] OR Hypertension[MeSH] OR Heart Rate[MeSH] OR 
pressure*[tiab] OR Hypertension[tiab] OR heart rate[tiab] OR pulse[tiab] 
1.143.429
4 Randomized controlled trial[pt] OR clinical trial[pt] OR random*[tiab] OR trial[tiab] 
OR placebo[tiab] OR intervention[tiab] OR group[tiab]
2.989.201
5 #1 AND #2 AND #3 AND #4 1.592
a Search conducted at 31 October 2014.
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SUPPLEMENTAL TABLE 2. Descriptives of the 22 randomized controlled trials evaluating 
the effect of an increased potassium intake on heart ratea
  Mean ± SDb
Design, no. of RCTs
Parallel 5
Crossover 17
Total no. of subjects 1086
Men 698
Women 399
Age (years) 44.6 ± 12.5
Pre-study HR (bpm)c 70.2 ± 5.4
Pre-study SBP (mmHg) 142.7 ± 19.3
Pre-study DBP (mmHg) 88.5 ± 12.3
Intervention duration (weeks)d 4 (2 - 24)
Potassium dose (grams/day)d 2.5 (0.9 - 4.7)
Potassium type, no. of RCTs
Potassium chloride 17
Potassium citrate 1
Mix of potassium chloride and bicarbonate 1
Mix of potassium citrate and bicarbonate 1
Unspecified 2
HR measurement, no. of RCTs
Office supine HR 14
Office seated HR 7
24-hr ambulatory HR 1
Antihypertensive medication use during study, no. of RCTs
No 18
Yes, treated during study when necessary 1
Not reported 3
Abbreviations: DBP, diastolic blood pressure; HR, heart rate; no, number; RCTs, 
randomized controlled trials; SBP, systolic blood pressure. a Descriptives are based on 
the study data included in the primary meta-analysis. b Unless indicated otherwise. c Data 
on pre-study HR is missing for Smith et al. [2]. d Value is median (range).
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SUPPPLEMENTAL TABLE 3. Risk of bias assessmenta of the 22 randomized controlled trials evaluating the effect of 
an increased potassium intake on heart rate
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Barden et al. [3] ? ? ? ? +
Berry et al. [4] + + + + +
Fotherby and Potter [5] ? ? + + +
Gijsbers et al. [6] + + + + +
Graham et al. [7] + + + + +
Grobbee et al. [8] ? ? + ? ?
He et al. [9] + + + + +
MacGregor et al. [10] ? ? + ? +
Matlou et al. [11] ? ? - + +
Matthesen et al. [12] + + ? ? -
Mullen and O’Connor [13] ? ? + + -
Naismith and Braschi [14] + + + + +
Overlack et al. [15] ? ? - + +
Overlack et al. [16] ? ? - + ?
Poulter and Sever [17] ? ? ? ? -
Siani et al. [18] ? + + + ?
Smith et al. [2] ? ? + + +
Sundar et al. [19] ? ? ? ? ?
Svetkey et al. [20] + + + + +
Valdés et al. [21] ? ? + ? ?
Whelton et al. [22] ? ? + + +
Zoccali et al. [23] ? ? - ? +
a Studies are low (+), unclear (?) or high (-) at risk of bias.
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CHAPTER 5
SUPPLEMENTAL FIGURE 1. Meta-regression of 22 randomized controlled trials exploring the relationship of potas-
sium intervention duration with the effect on heart rate. Every circle indicates the point estimate for each trial. The 
size of the circle is proportional to the weight of the study, using a random-effects model. The dotted line is the linear 
regression line based on the weighted estimates of all included studies. Abbreviation: HR, heart rate.
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5
SUPPLEMENTAL FIGURE 2. Meta-regression of 21a randomized controlled trials exploring the relationship of 
pre-study heart rate with the effect on heart rate. Every circle indicates the point estimate for each trial. The size 
of the circle is proportional to the weight of the study, using a random-effects model. The dotted line is the linear 
regression line based on the weighted estimates of all included studies. a Data on pre-study heart rate is missing for 
Smith et al. [2]. Abbreviation: HR, heart rate.
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SUPPLEMENTAL FIGURE 3. Forest plot of 22 randomized controlled trials evaluating the effect of potassium sup-
plementation on heart rate, stratified by heart rate measurement. Number of observations exceeds 22, because in 
some trials heart rate was measured in multiple positions. Black bullets indicate the point estimate for each trial, 
the horizontal lines represent the 95% CIs. The size of the square is proportional to the weight of the study, using a 
random-effects model. The stratum-specific treatment effect is indicated by the diamond, and its width corresponds 
with the 95% CI. Abbreviation: HR, heart rate.
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5
SUPPLEMENTAL FIGURE 4. Meta-regression of 21a randomized controlled trials exploring the relationship of uri-
nary sodium excretion during potassium intervention with the effect on heart rate. Every circle indicates the point 
estimate for each trial. The size of the circle is proportional to the weight of the study, using a random-effects model. 
The dotted line is the linear regression line based on the weighted estimates of all included studies. a Data on sodium 
excretion during potassium intervention is missing for Svetkey et al. [20]. Abbreviation: HR, heart rate.
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SUPPLEMENTAL FIGURE 5. Meta-regression of 22 randomized controlled trials exploring the relationship of the 
reduction in systolic blood pressure with the effect on heart rate. Every circle indicates the point estimate for each 
trial. The size of the circle is proportional to the weight of the study, using a random-effects model. The dotted line is 
the linear regression line based on the weighted estimates of all included studies. Abbreviation: HR, heart rate; SBP, 
systolic blood pressure.
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5
SUPPLEMENTAL FIGURE 6. Funnel plot of 22 randomized controlled trials evaluating the effect of potassium sup-
plementation on heart rate. Every bullet indicates the effect on heart rate and SE for each trial. The overall effect of 
potassium on heart rate is indicated with the vertical line and the dotted lines represent the pseudo-95% confidence 
limits. Abbreviation: HR, heart rate; SE, standard error
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ABSTRACT
Sodium intake raises blood pressure (BP), while potassium intake lowers it, as has repeatedly 
been demonstrated in randomized controlled trials. In observational studies these BP 
associations may be less clear because of inaccurate assessment of habitual dietary intake. 
In a cross-sectional study (NQplus) of 993 Dutch individuals, not on antihypertensive 
medication, we obtained BP associations for sodium and potassium intake based on data 
from different dietary assessment methods. Sodium and potassium intakes were estimated 
from two non-consecutive 24-h urinary samples, two non-consecutive web-based 24-h 
recalls, and a validated 180-item food frequency questionnaire (FFQ). The average daily 
sodium and potassium intakes in our cohort were 4.0 and 3.9 grams, respectively, based on 
urinary excretions after correction for non-urinary losses. BP was on average 125/74 mmHg 
and 16% had a systolic BP ≥ 140 mmHg. In multivariable linear regression models, sodium 
intake was not associated with systolic or diastolic BP for any of the dietary assessment 
methods including urinary sodium excretion (all P > 0.08). Potassium intake based on two 
24-h urinary excretions was associated with a 1.6 mmHg (95% CI 0.3, 2.9; P = 0.016) lower 
systolic BP per gram per day after adjusting for age, sex, body mass index, highest completed 
education, smoking status, physical activity, alcohol intake and urinary creatinine. A similar, 
though non-significant, association was observed for potassium intake estimated by FFQ 
(-1.4 mmHg; 95% CI -2.9, 0.0; P = 0.057). Potassium intake estimated from web-based 24-h 
recalls was not associated with BP. We conclude that dietary assessment methods, including 
two 24-h urinary samples, are inadequate for studying the association of sodium intake with 
BP in cross-sectional studies. For potassium, however, two 24-h urinary collections and a 180-
item FFQ seem appropriate, with associations being in the order of magnitude as observed in 
randomized controlled trials. 
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INTRODUCTION
Accurate assessment of habitual dietary intake in large populations is a challenging task in 
nutritional epidemiology, because invalid or imprecise information on dietary intake may 
alter the direction of diet-disease associations or yield false null results [1]. This may be 
especially the case for sodium, a nutrient that is added in variable amounts to foods and 
for which intake can vary largely from day to day within one individual. From randomized 
controlled trials we know that blood pressure (BP) increases after increasing sodium intake 
and decreases after increasing potassium intake [2-4]. Recent meta-analyses of randomized 
controlled trials with a duration of at least four weeks have shown a ~2.0 mmHg higher 
systolic BP for each 1 g/d increase in sodium intake [2], and a ~1.6 mmHg lower systolic BP 
for each 1 g/d increase in potassium intake [4].
Inconsistent associations with BP have been reported in cross-sectional studies, especially 
for sodium [5-7], which may be related to the method for measuring habitual sodium and 
potassium intake. Dietary assessment methods that are based on self-report, including the 
24-h dietary recall and the food-frequency questionnaire (FFQ), are prone to misreporting 
and recall bias [8]. Furthermore, inaccurate or incomplete data in food composition tables 
may hamper the valid estimation of specific nutrient intakes [9]. Also, sodium added during 
cooking or at the table (i.e. discretionary salt) is difficult to measure. The purpose of this study 
was to evaluate whether dietary assessment methods would influence the associations 
of sodium and potassium intake with BP in observational studies. For this, we compared 
different methods in a single Dutch cohort, including two non-consecutive 24-h urinary 
excretions (considered as the most objective measure), two non-consecutive web-based 
24-h recalls, and a 180-item FFQ.
METHODS
Study Design and Participants
The present analysis was carried out in the Nutrition Questionnaires plus (NQplus) study, an 
observational study that was set up to validate different dietary assessment methods and 
to assess associations of diet with intermediate health outcomes. Eligible for participation 
were men and women aged 20 to 70 years from Wageningen and its surroundings, The 
Netherlands, who were able to speak and write Dutch. The NQplus study was approved by 
the Medical Ethics Committee of Wageningen University and conducted in accordance with 
the principles of the Declaration of Helsinki. Written informed consent was obtained from all 
participants. Between May 2011 and February 2013, 2048 persons entered the study. Baseline 
measurements included physical examination, 24-h urine collection, questionnaires on 
demographic and lifestyle factors, and a 180-item FFQ. Measurements were repeated one 
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year later. In the two years after baseline, participants were repeatedly invited to fill out web-
based 24-h dietary recalls. For the present study on sodium, potassium and BP, we selected 
1233 participants with BP data at baseline and year 1, reliable FFQ data (energy intakes men 
800-4200 kcal, women 500-3500 kcal), two urine collections, and at least two web-based 
24-h recalls. We excluded 12 pregnant women and 228 participants on antihypertensive 
medication (including Anatomical Therapeutic Chemical codes: C02, C03, C07, C08 and C09) 
at baseline or year 1, resulting in 993 participants for analysis. 
24-h Urinary Sodium and Potassium
Participants were provided with instructions for 24-h urine collections. They received two 
3-liter bottles, each containing 25 g of the preservative lithium dihydrogenphosphate, and 
three 80-mg para-aminobenzoid acid (PABA) tablets to ingest at mealtimes during the course 
of the urine collection. The 24-h urine collection started after discarding the first voiding 
on the morning of the collection day and included the first voiding on the morning of the 
following day. At the study center, the urine collections were mixed, weighted, aliquoted and 
stored at -80ºC until further analysis.
Urinary sodium and potassium concentrations were measured with an ion-selective 
electrode module on a Roche 917 analyser, and were multiplied by collected urine volume 
to obtain 24-h excretion values. Intakes of sodium and potassium were calculated taking into 
account extra-renal and faecal losses of 14% for sodium [10] and 19% for potassium [11]. 
Urinary creatinine concentrations were measured at 520 nm on the Synchron LX20 by the 
modified Jaffé procedure using a commercial kit. PABA was used to check the completeness 
of the urine collections and was measured using the HPLC method [12].  
Web-Based 24-h Recalls
Unannounced email invitations were sent to the participants to self-administer a recall over 
the previous day in the web-based program Compl-eat (www.compleat.nl). Invitations were 
valid for 24 hours, and if denied, the recall was randomly rescheduled within 3-10 days. 
Compl-eat is based on the five-step multiple pass method, which is a validated technique 
to increase the accuracy of recalls [13-16]. Portion sizes were reported in commonly used 
household measures, natural portions, and weight in grams or volume in liters. Discretionary 
salt use was not estimated. Average daily intakes of sodium, potassium, alcohol and total 
energy were calculated using the Dutch food composition database of 2011 [17].
FFQ
A 180-item semi-quantitative FFQ, which was self-administered and filled out online using 
the open-source survey tool LimesurveyTM (LimeSurvey Project Team / Carsten Schmitz. 
Hamburg, Germany), was used to assess habitual dietary intake. The FFQ was validated for 
the intake of energy, fats, dietary fiber and selected vitamins. The estimated mean energy 
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intake by the FFQ appeared to be accurate [18], and in comparison with the mean of 
three 24-h recalls, the FFQ showed an acceptable to good ranking for most nutrients [19]. 
The reference period for the FFQ was one month, and portion sizes were estimated using 
commonly used household measures. The FFQ was not developed to estimate salt intake, 
and hence discretionary salt use was not estimated. The Dutch food composition table of 
2011 was used to compute the intake of sodium, potassium, alcohol and total energy [17]. 
BP
Brachial BP measurements were performed by trained research assistants according to a 
standard protocol. BP was measured in lying position after at least 10 minutes of rest with 
2-minute intervals using an automated oscillometric device (IntelliSense HEM-907, Omron 
Health Care, USA) with an appropriate cuff size on the left upper arm. The first measurement 
was discarded and the five subsequent measurements were averaged. 
Covariates
Height was measured to the nearest 0.5 centimeter using a stadiometer (SECA, Germany) 
and weight was measured to the nearest 0.1 kg on a digital scale (SECA, Germany or Tanita 
Corporation, The Netherlands) in light indoor clothing without shoes. Body mass index 
(BMI) was calculated as weight (kg) divided by height squared (m2). General and lifestyle 
questionnaires at baseline included information on age (years), sex, education (low/
intermediate/high), smoking (never/former/current), diabetes (yes/no), and history of 
cardiovascular disease (yes/no). Physical activity was assessed using the Short QUestionnaire 
to Assess Health enhancing physical activity (SQUASH) [20], and was categorized according 
to the average time spent per week doing leisure-time physical activities with a moderate 
to vigorous intensity ( ≥ 4 metabolic equivalents [METs] if aged 18 to 55 years and ≥ 3 METs if 
aged > 55 years). 
Data Analysis
In order to estimate habitual intake, we averaged baseline and year 1 urinary excretions, and 
averaged data from two web-based 24-h recalls. Median (interquartile range) number of days 
between two urine collections was 393 (363-430); between two web-based 24-h recalls 112 
(52-191); and between baseline urinary collection and first web-based 24-h recall 132 (29-
223). BP values obtained at baseline and year 1 were also averaged. 
Continuous variables are presented as mean ± SD, or median with interquartile ranges 
(Q1-Q3) if not normally distributed. Categorical variables are presented as numbers and 
percentages. Partial Spearman correlation coefficients for the sodium and potassium intake 
estimates between the different methods were calculated, adjusting for sex. The associations 
of sodium and potassium intake with systolic and diastolic BP were estimated by means of 
multivariable linear regression models, and findings are reported as adjusted beta regression 
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coefficients per gram sodium or potassium per day with 95% confidence intervals. In model 
1, estimates were adjusted for age and sex. In model 2, additional adjustments were made 
for body mass index (kg/m2), highest completed education (low (e.g. primary education); 
intermediate (e.g. higher secondary education) and high (e.g. higher vocational education 
and university)), smoking status (never, former, current), leisure-time physical activity with 
moderate to vigorous intensity (0-200, >200-≤400, >400 min/week), and alcohol intake (for 
men: 0, >0-≤20, >20 g/day; for women: 0, >0-≤10, >10 g/day). Alcohol intake was estimated 
from FFQ or from two web-based 24-h recalls, depending on the dietary assessment method 
under study. In models of urinary sodium and potassium, we adjusted using alcohol data 
estimated by FFQ. Missing indicators were used for smoking status (2.7% missing) and 
physical activity (5.6% missing). In model 3, we further adjusted for potassium intake in the 
analysis of sodium intake, and vice versa; for urinary creatinine in the analyses of urinary 
sodium and potassium; and for total energy intake estimated from web-based 24-h recalls 
or FFQ, depending on the method under study. In analysis of sodium and potassium intakes 
based on repeated measurements (i.e. two urinary excretions and two web-based 24-h 
recalls), betas from linear regression analyses were multiplied by the inverse of the intra-
class correlation (ICC) coefficient (ICC) to correct for random error [21]. ICC for two repeated 
measurements was calculated according to the following formula: 
ICC=                between-person variance
             between-person variance+(within-person variance/2))
We performed sensitivity analyses by excluding participants with incomplete 24-h urines, as 
indicated by a urinary PABA recovery < 78% [12], leaving 694 participants. All analyses were 
done with SAS statistical software version 9.3 (SAS Institute Inc.). A two-sided P-value below 
0.05 was considered statistically significant.
RESULTS
Participants 
Baseline characteristics of the 495 men and 498 women are listed in Table 1. Participants 
were on average 53 years and their body mass index was 25.4 kg/m². Furthermore, 54% of 
the participants were classified as highly educated. Mean systolic/diastolic BP was 125/74 
mmHg, with women having lower values (119/72 mmHg) than men (131/76 mmHg). Of all 
participants, 14 (1.4%) had a history of cardiovascular disease and 162 (16%) had a systolic 
BP ≥ 140 mmHg.
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Sodium and Potassium Intake
Average sodium intake was 4.0 ± 1.3 g/d based on two 24-h urinary excretions after accounting 
for non-urinary losses. Based on self-reports, which do not take salt added during cooking 
or at the table into account, sodium intake was 2.3 ± 0.9 g/d when estimated from two web-
based 24-h recalls, and 2.1 ± 0.7 g/d when estimated from FFQ data (Table 2). 24-h urinary 
sodium correlated weakly with sodium intake estimated from web-based 24-h recalls (sex-
adjusted r = 0.15) or FFQ (r = 0.17). A higher correlation for sodium was observed between the 
web-based 24-h recall and FFQ (r = 0.40) (Table 3).
Average potassium intake was 3.9 ± 1.0 g/d based on two 24-h urinary excretions after 
accounting for non-urinary losses; 3.2 ± 0.9 g/d based on two web-based 24-h recalls; and 
3.3 ± 0.8 g/d based on FFQ data (Table 2). Twenty-four-hour urinary potassium showed a 
correlation of 0.35 with potassium from web-based 24-h recalls, and 0.37 with potassium 
from FFQ. The correlation between web-based 24-h recalls and FFQ was 0.47 (Table 3).
TABLE 1. Characteristics of 993 Dutch participants from the NQplus study, by sexa
Men Women
Participants, n 495 498
Age, y 55 ± 10 50 ± 11
Body mass index, kg/m² 26.0 ± 3.3 24.8 ± 4.0
Systolic BP, mmHg 131 ± 13 119 ± 14
Diastolic BP, mmHg 76 ± 10 72 ± 10
Smoking status, n (%)
Never 229 (47.3) 299 (62.0)
Former 212 (43.8) 152 (31.5)
Current 43 (8.9) 31 (6.4)
Education, n (%)
Low 71 (14.3) 80 (16.1)
Middle 146 (29.5) 158 (31.7)
High 278 (56.2) 260 (52.2)
Physical activity, min/week 366 (210-600) 290 (150-510)
Energy intake based on 24-h recalls, kcal/d 2196 ± 631 1754 ± 488
Energy intake based on FFQ, kcal/d 2277 ± 586 1823 ± 459
Urinary creatinine, mmol/24h 14.8 ± 2.6 10.1 ± 2.2
History of cardiovascular disease, n (%) 11 (2.2) 3 (0.6)
Diabetes mellitus, n (%) 10 (2.0) 6 (1.2)
Abbreviations: BP, blood pressure; FFQ, food-frequency questionnaire. a Data are presented as n (%), mean ± SD, or 
median (interquartile range).
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Association of Sodium and Potassium Intake with BP
Sodium intake, based on urinary excretions, web-based 24-h recalls or FFQ, was not associated 
with systolic and diastolic BP after adjusting for covariates (Table 4). Systolic BP estimates 
ranged from -1.3 to +0.5 mmHg (all P > 0.3) and diastolic BP estimates from -1.8 to -0.5 mmHg 
(all P > 0.08) per gram per day of sodium, depending on the method of assessment. Similar 
results were found in those with complete urine collection (Supplemental Table 1). 
TABLE 2. Mean intake for sodium and potassium based on two 24-h urinary samples, two web-based 24-h recalls, 
and food-frequency questionnaire in 993 Dutch participants 
  Two 24-h urinary 
excretionsa
Two web-based 
24-h recallsb
FFQb
Total
Sodium intake, g/d 4.0 ± 1.3 2.3 ± 0.9 2.1 ± 0.7
Potassium intake, g/d 3.9 ± 1.0 3.2 ± 0.9 3.3 ± 0.8
Men
Sodium intake, g/d 4.5 ± 1.2 2.6 ± 1.0 2.4 ± 0.7
Potassium intake, g/d 4.2 ± 1.0 3.4 ± 1.0 3.6 ± 0.9
Women
Sodium intake, g/d 3.4 ± 1.0 2.1 ± 0.8 1.9 ± 0.6
Potassium intake, g/d 3.6 ± 1.0 2.9 ± 0.8 3.1 ± 0.7
Abbreviations: FFQ, food-frequency questionnaire. Values are means ± standard deviations. a Corrected for non-uri-
nary losses of 14% for sodium [10] and 19% for potassium [11]. b Salt added during cooking or at the table were not 
taken into account.
TABLE 3. Sex-adjusted Spearman correlation coefficients (r) between two 24-h urinary excretions, two web-
based 24-h recalls, and food-frequency questionnaire for estimated sodium and potassium intake in 993 Dutch 
participants 
  r (95% CI) P
Sodium intake
Two 24-h urinary excretionsa and two web-based 24-h recalls 0.15 (0.09, 0.21) <0.001
Two 24-h urinary excretionsa and FFQb 0.17 (0.11, 0.23) <0.001
Two web-based 24-h recallsb and FFQb 0.40 (0.34, 0.45) <0.001
Potassium intake 
Two 24-h urinary excretionsc and two web-based 24-h recalls 0.35 (0.29, 0.40) <0.001
Two 24-h urinary excretionsc and FFQ 0.37 (0.21, 0.42) <0.001
Two web-based 24-h recalls and FFQ 0.47 (0.42, 0.52) <0.001
Abbreviation: FFQ, food-frequency questionnaire. a Corrected for non-urinary losses of 14% [10]. b Salt added during 
cooking or at the table were not taken into account. c Corrected for non-urinary losses of 19% [11].
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Twenty-four-hour urinary potassium was inversely associated with BP, with each 1 g/d higher 
potassium intake associated with a 1.6 mmHg (95% CI 0.3, 2.9; P = 0.016) lower systolic BP 
and 1.5 mmHg (95% CI 0.5, 2.4; P = 0.002) lower diastolic BP after adjusting for covariates. 
Potassium intake estimated by FFQ showed a similar, though borderline significant, 
association with systolic BP (-1.4 mmHg per 1 g/d increment; 95% CI -2.9, 0.0; P = 0.057), and 
a significant association with diastolic BP (-1.1 mmHg per 1 g/d increment; 95% CI -2.1, -0.1; P 
= 0.033) after adjusting for covariates. Potassium intake estimated from two web-based 24-h 
recalls was not associated with BP (Table 5). Similar results for urinary potassium were found 
in those with complete urine collection. However, the association between potassium intake 
estimated from FFQ data and systolic BP became stronger (-2.6 mmHg per 1 g/d; 95% CI -4.3, 
-0.8; P = 0.004 (Supplemental Table 2).
DISCUSSION
In this cross-sectional analysis of 993 untreated Dutch individuals, BP was unrelated to 
sodium intake estimated from different dietary assessment methods. For potassium intake 
estimated from two 24-h urine collections or FFQ, however, an inverse association was found. 
BP was not associated with potassium intake estimated from web-based 24-h recalls.
TABLE 4.  Association between different assessments of sodium intake and blood pressure in 993 Dutch participants
  Two 24-h urine collectionsa Two web-based 24-h recallsa FFQ
β per 1 g/d 
increment (95% CI)
P   β per 1 g/d 
increment (95% CI)
P β per 1 g/d 
increment (95% CI)
P
Systolic BP, mmHg
Model 1b 2.0 (0.9, 3.2) <0.001 -1.7 (-4.0, 0.7) 0.16 -1.0 (-2.1, 0.2) 0.10
Model 2c 0.5 (-0.7, 1.7) 0.39 -1.7 (-4.0, 0.6) 0.14 -0.8 (-1.9, 0.3) 0.17
Model 3d 0.5 (-0.8, 1.8) 0.46 -1.3 (-4.3, 1.7) 0.38 0.4 (-1.7, 2.4) 0.73
Diastolic BP, mmHg
Model 1b 0.6 (-0.2, 1.5) 0.15 -1.8 (-3.5, -0.1) 0.042 -1.1 (-2.0, -0.3) 0.009
Model 2c -0.8 (-1.6, 0.1) 0.068 -2.1 (-3.7, -0.4) 0.014 -1.0 (-1.8, -0.2) 0.014
Model 3d -0.5 (-1.4, 0.5) 0.32 -1.8 (-3.9, 0.4) 0.11 -1.3 (-2.7, 0.2) 0.086
Abbreviations: BP, blood pressure; FFQ, food-frequency questionnaire. a Estimates have been corrected for random 
error as explained in the text. b Adjusted for age and sex. c Model 1 covariates plus body mass index (kg/m2), hig-
hest completed education (low, intermediate, high), smoking status (never, former, current), physical activity (0-200, 
>200-≤400, >400 min/week), and alcohol intake (for men: 0, >0-≤20, >20 g/d; for women: 0, >0-≤10, >10 g/d). d Model 2 
covariates plus potassium intake based on the method by which sodium intake was assessed, and urinary creatinine 
for estimates based on two 24-h urine collections and total energy intake for estimates based on web-based 24-h 
recalls and food-frequency questionnaire.
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The causal relations of sodium and potassium with BP have repeatedly been demonstrated 
in randomized controlled trials. Meta-analyses have shown a ~2 mmHg increase in systolic 
BP per gram of sodium intake [2], and ~1.6 mmHg decrease in systolic BP per gram of 
potassium intake [4]. In a recent trial in 36 untreated (pre)hypertensive adults from the 
same target population as the NQplus cohort, 24-h systolic BP increased by ~2.5 mmHg per 
gram of sodium and decreased by ~1.3 mmHg per gram of potassium, respectively [22]. The 
~1.5 mmHg lower systolic BP in the present cross-sectional study per gram of potassium 
estimated from 24-h urine or FFQ is in line with these findings [4, 22]. Potassium intake based 
on two 24-h recalls, which was modestly correlated with urinary (r = 0.35) and FFQ potassium 
(r = 0.47), was not associated with BP. Participants filled in the 24-h recalls using a web-based 
tool. This tool is based on the five-step multiple pass method, a proven technique to increase 
the accuracy of recalls [13-16]. The web-based method as such, however, has not yet been 
validated. 
In our cross-sectional study, we could not confirm the BP effect of sodium as established 
in randomized controlled trials [2, 3]. This discrepancy is likely caused by the difficulty 
in accurately assessing habitual sodium intake [1, 9]. Two non-consecutive 24-h urine 
collections or recalls could be insufficient to characterize an individual for habitual sodium 
intake. Averaging multiple timed 24-h urinary excretions with checks for completeness of 
collections is considered as the most accurate method to assess habitual sodium intake, 
TABLE 5. Association between different assessments of potassium intake and blood pressure in 993 Dutch 
participants
  Two 24-h urine collectionsa Two web-based 24-h recallsa FFQ
β per 1 g/d 
increment (95% CI)
P   β per 1 g/d 
increment (95% CI)
P β per 1 g/d 
increment (95% CI)
P
Systolic BP, mmHg
Model 1b -0.5 (-1.8, 0.7) 0.38 -1.5 (-3.3, 0.2) 0.091 -1.4 (-2.3, -0.5) 0.003
Model 2c -1.0 (-2.1, 0.2) 0.11 -0.9 (-2.7, 0.8) 0.31 -1.2 (-2.1, -0.3) 0.009
Model 3d -1.6 (-2.9, -0.3) 0.016 -0.3 (-2.7, 2.1) 0.81 -1.4 (-2.9, 0.0) 0.057
Diastolic BP, mmHg
Model 1b -1.2 (-2.1, -0.3) 0.009 -1.3 (-2.7, 0.0) 0.045 -1.1 (-1.7, -0.4) 0.002
Model 2c -1.5 (-2.4, -0.7) <0.001 -0.8 (-2.1, 0.4) 0.20 -0.9 (-1.6, -0.3) 0.006
Model 3d -1.5 (-2.4, -0.5) 0.002 0.0 (-1.8, 1.7) 0.98 -1.1 (-2.2, -0.1) 0.033
Abbreviations: BP, blood pressure; FFQ, food-frequency questionnaire. a Estimates have been corrected for random 
error as explained in the text. b Adjusted for age and sex. c Model 1 covariates plus body mass index (kg/m2), hig-
hest completed education (low, intermediate, high), smoking status (never, former, current), physical activity (0-200, 
>200-≤400, >400 min/week), and alcohol intake (for men: 0, >0-≤20, >20 g/d; for women: 0, >0-≤10, >10 g/d). d Model 2 
covariates plus sodium intake based on the method by which potassium intake was assessed, and urinary creatinine 
for estimates based on two 24-h urine collections and total energy intake for estimates based on web-based 24-h 
recalls and food-frequency questionnaire.
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as it includes discretionary salt and it takes into account the high day-to-day variation of 
sodium intake [9]. The web-based 24-h recalls and FFQ in our study were not designed to 
estimate sodium intake and included no question about discretionary salt. Furthermore, 
assessment of habitual sodium intake by self-reports is prone to error due to reliance on 
food composition tables, which are often incomplete or do not accurately capture the highly 
variable content of sodium across similar foods of different brands [23]. 
Underreporting is also a problem in self-report methods [1]. These methodological issues in 
assessing sodium intake by self-reports are reflected in our study by the large underestimation 
of sodium intake by the web-based recalls and the FFQ (1.5-2.1 g/d) compared to the urinary 
excretions and the low correlations observed between sodium intake based on self-reports 
and urinary excretions (r = 0.15-0.17). For potassium intake, the underestimation was less (0.5-
0.8 g/d) and the correlations were higher (r = 0.35-0.37). In line with our findings, Freedman 
et al. [24] showed in their pooled analysis of five US validation studies that 24-h recalls 
and FFQ capture sodium intake less well than potassium intake. Dietary potassium has a 
lower day-to-day variability compared to sodium [25], likely because the food content of 
potassium is less variable. Potassium is naturally present in higher amounts in foods such as 
fruits, vegetables, legumes and dairy products, and less often added during food processing 
[26]. Estimating habitual intake based on only two urinary samples may therefore be more 
accurate for potassium than for sodium.
A major strength of this study is the extensive dietary information obtained through various 
methods. This includes 24-h urine collections, and the use of PABA to exclude incomplete 
urine collections in sensitivity analyses. We were able to correct our estimates for random 
error because of repeated 24-h urine collections and 24-h recalls. A limitation of our study 
is the cross-sectional design, which could give rise to reverse causality bias when studying 
sodium and potassium intake in relation to BP. However, we excluded individuals on 
antihypertensive treatment who could have changed their diets (e.g. reduction in salt use) 
because of their increased cardiovascular risk. Also, our study was carried out in volunteers 
who were on average highly educated, which limits the generalizability of our results. Our 
results for potassium intake based on self-reports may be less accurate in populations with 
lower level of education and/or more obesity. 
In conclusion, in this cross-sectional analysis we observed no association of sodium 
intake with BP for any of the dietary assessment methods used, including 24-h urines. BP 
associations for potassium intake estimated from 24-h urine and FFQ, however, were in line 
with known effects from randomized controlled trials. Thus, observational studies may yield 
reliable results for potassium intake in relation to BP, whereas the results for sodium intake 
will likely be biased towards the null.
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SUPPLEMENTAL RESULTS
SUPPLEMENTAL TABLE 1. Association between different assessments of sodium intake and blood pressure in 694 
Dutch participants with complete 24-h urine collections
  Two 24-h urine collectionsa Two web-based 24-h recallsa FFQ
β per 1 g/d 
increment (95% CI)
P   β per 1 g/d 
increment (95% CI)
P β per 1 g/d 
increment (95% CI)
P
Systolic BP, mmHg
Model 1b 1.8 (0.5, 3.1) 0.008 -2.1 (-5.1, 0.8) 0.16 -1.3 (-2.7, 0.1) 0.068
Model 2c 0.3 (-1.1, 1.6) 0.71 -2.3 (-5.2, 0.5) 0.11 -1.1 (-2.4, 0.3) 0.12
Model 3d 0.1 (-1.4, 1.5) 0.93 -2.4 (-6.2, 1.3) 0.21 0.1 (-2.3, 2.5) 0.93
Diastolic BP, mmHg
Model 1b 0.8 (-0.2, 1.7) 0.11 -1.7 (-3.8, 0.5) 0.12 -1.5 (-2.5, -0.5) 0.004
Model 2c -0.6 (-1.6, 0.3) 0.20 -2.1 (-4.2, 0.0) 0.047 -1.4 (-2.3, -0.4) 0.006
Model 3d -0.4 (-1.5, 0.6) 0.42 -1.7 (-4.4, 1.0) 0.21 -1.0 (-2.6, 0.7) 0.27
Abbreviations: BP, blood pressure; FFQ, food-frequency questionnaire. a Estimates have been corrected for random 
error as explained in the text. b Adjusted for age and sex. c Model 1 covariates plus body mass index (kg/m2), hig-
hest completed education (low, intermediate, high), smoking status (never, former, current), physical activity (0-200, 
>200-≤400, >400 min/week), and alcohol intake (for men: 0, >0-≤20, >20 g/d; for women: 0, >0-≤10, >10 g/d). d Model 2 
covariates plus potassium intake based on the method by which sodium intake was assessed, and urinary creatinine 
for estimates based on two 24-h urine collections and total energy intake for estimates based on web-based 24-h 
recalls and food-frequency questionnaire. 
SUPPLEMENTAL TABLE 2. Association between different assessments of potassium intake and blood pressure in 
694 Dutch participants with complete 24-h urine collections
  Two 24-h urine collectionsa Two web-based 24-h recallsa FFQ
β per 1 g/d 
increment (95% CI)
P   β per 1 g/d 
increment (95% CI)
P β per 1 g/d 
increment (95% CI)
P
Systolic BP, mmHg
Model 1b -0.8 (-2.1, 0.5) 0.24 -1.2 (-3.2, 0.9) 0.28 -2.1 (-3.3, -1.0) <0.001
Model 2c -1.1 (-2.4, 0.2) 0.10 -0.7 (-2.8, 1.3) 0.49 -1.8 (-2.9, -0.7) 0.001
Model 3d -1.6 (-3.0, -0.2) 0.028 -0.2 (-3.0, 2.6) 0.89 -2.6 (-4.3, -0.8) 0.004
Diastolic BP, mmHg
Model 1b -1.4 (-2.3, -0.4) 0.006 -1.2 (-2.7, 0.3) 0.12 -1.7 (-2.5, -0.9) <0.001
Model 2c -1.6 (-2.5, -0.7) <0.001 -0.9 (-2.3, 0.6) 0.23 -1.5 (-2.2, -0.7) <0.001
Model 3d -1.7 (-2.7, -0.7) 0.001 -0.2 (-2.2, 1.8) 0.82 -1.7 (-2.9, -0.4) 0.010
Abbreviations: BP, blood pressure; FFQ, food-frequency questionnaire. a Estimates have been corrected for random 
error as explained in the text. b Adjusted for age and sex. c Model 1 covariates plus body mass index (kg/m2), hig-
hest completed education (low, intermediate, high), smoking status (never, former, current), physical activity (0-200, 
>200-≤400, >400 min/week), and alcohol intake (for men: 0, >0-≤20, >20 g/d; for women: 0, >0-≤10, >10 g/d). d Model 2 
covariates plus sodium intake based on the method by which potassium intake was assessed, and urinary creatinine 
for estimates based on two 24-h urine collections and total energy intake for estimates based on web-based 24-h 
recalls and food-frequency questionnaire.
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High sodium intake and low potassium intake are known to elevate blood pressure (BP), a 
major risk factor for cardiovascular diseases (CVD). Little is known about the effects of these 
minerals on other vascular outcomes. In this thesis the BP effects of sodium and potassium 
intake were investigated in the broader context of cardiovascular health, focusing on various 
BP measures, endothelial (dys)function, arterial stiffness, body fluid balance and heart rate. 
Methods used in this thesis include a human randomized controlled trial (RCT) with 
a cross-over design in which diet was fully controlled, a meta-analysis of RCTs and an 
epidemiological analysis of a cross-sectional study. A major strength of our trial is that the 
effects of supplemental sodium and potassium were examined simultaneously, in the same 
setting and in the same individuals. Effects can therefore be directly compared. Another 
strength is the fully controlled diet, which strongly reduces the intra-individual variability 
resulting from dietary influences thereby increasing statistical power to demonstrate effects 
that are exclusively attributable to sodium and potassium intake. The power is furthermore 
strengthened by its design as a cross-over study, allowing analysis of paired samples. 
The experimental part of the thesis is based on apparently healthy Dutch men and women, 
aged 40−80 years, with a fasting systolic BP between 130 and 159 mmHg. These individuals 
represent a large segment of the middle-aged and older population. In the Netherlands, 58% 
of men and 40% of women aged 40−49 years, and ~90% of men and women aged 70 years or 
older have systolic BP values over 130 mmHg [1].
Table 1 gives an overview of the findings of this thesis. In this final Chapter the main findings 
for sodium and potassium are described and put in context. After that, the implications for 
public health are discussed. 
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TABLE 1. Overview of the main findings on the vascular effects of sodium and potassium intake in this thesis
Study 
(Chapter)
Population Exposure Outcome Main findings
RCT 
(Chapter  2)
36 Dutch 
individuals with an 
untreated SBP of 
130−159 mmHg
Supplemental 
sodium of 3 g/d 
and supplemental 
potassium of 3 g/d, 
each for 4 weeks, on 
top of a relatively low 
sodium, low potassium 
diet
• Serum sodium and 
potassium
• Office BP and heart 
rate
• 24-h BP and heart 
rate 
• Measures of arterial 
stiffness
During sodium supplementation: 
• Non-significant effect on serum sodium 
(0.39 mmol/L) 
• Decrease in serum potassium of 0.10 
mmol/L
• Increase in office BP of 7.5/3.3 mmHg
• Increase in 24-h BP of 7.5/2.7 mmHg 
• No effect on office and 24-h heart rate
• No effect on pulse wave velocity and 
augmentation index 
During potassium supplementation:
• Decrease in serum sodium of 0.68 
mmol/L
• Increase in serum potassium of 0.13 
mmol/L
• Decrease in 24-h BP of 3.9/1.6 mmHg
• Increase in 24-h heart rate of 2.6 bpm
• Non-significant effect on pulse wave 
velocity (-0.35 m/s) 
• No effect on augmentation index
RCT 
(Chapter 3)
Idem Idem • Flow-mediated 
dilation
• Circulating 
endothelial and 
inflammatory 
markers
During sodium supplementation: 
• No effect on flow-mediated dilation
• Increase in plasma endothelin-1 of 0.24 
pg/ml
• No effect on other endothelial or 
inflammatory biomarkers
During potassium supplementation: 
• Increase in flow-mediated dilation of 
1.16%
• No effect on endothelial and 
inflammatory biomarkers
RCT 
(Chapter 4)
Idem Idem • Plasma parameters 
of body fluid balance
During sodium supplementation: 
• Reduction in plasma renin and 
aldosterone
• Increase in plasma copeptin, NT-proBNP 
and MR-proANP
During potassium supplementation: 
• Reduction in plasma MR-proANP 
• Increase in plasma copeptin, renin, 
aldosterone and serum urea
Meta-
analysis 
of 22 
randomized, 
placebo-
controlled 
trials 
(Chapter 5)
Healthy adults Potassium 
supplementation
Heart rate • No overall effect of increased potassium 
intake on heart rate (0.19 bpm; P=0.56)
• No evidence for dose-response 
relationship
• No significant effects in subgroups
Cross-
sectional 
study 
(Chapter 6)
993 Dutch adults 
not treated with 
antihypertensive 
medication
Dietary sodium and 
potassium intake 
assessed from 2 non-
consecutive 24-h urine 
samples, validated 
180-item FFQ and 2 
non-consecutive web-
based 24-h recalls
Office BP For sodium intake:
• No association with BP 
For potassium intake:
• Estimated from urinary excretions: 
inverse significant association (-1.6 
mmHg per g/d increment) with systolic 
BP 
• Estimated from FFQ: inverse, borderline 
significant association (-1.4 mmHg per 
g/d increment; P=0.057)
• Estimated from web-based 24-h recalls: 
no association
Abbreviations: bpm, beats per minute; BP, blood pressure; FFQ, food-frequency questionnaire; MR-proANP, midregional pro-atrial 
natriuretic peptide; NT-proBNP, N-terminal pro b-type natriuretic peptide; RCT, randomized-controlled trial.
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VASCULAR EFFECTS OF SODIUM INTAKE
Sodium Intake and BP
The causal relationship of sodium with BP has repeatedly been demonstrated in RCTs. We 
performed a randomized double-blind cross-over study of 36 untreated (pre)hypertensive 
individuals on a recommended sodium level (~2 g/d). We showed that increasing sodium 
intake by ~3.0 g/d increased 24-h urinary sodium by 98 mmol (equals 2.2 g), and increased 
office BP by 7.5/3.3 mmHg and 24-h BP by 7.5/2.7 mmHg, compared to placebo. Assuming 
a linear relation, this is equivalent to an effect in systolic BP of 0.7−0.8 mmHg per 10 mmol 
change in 24-h urinary sodium, which is comparable to the result of a meta-analysis of 
randomized trials with a minimum duration of 4 weeks, in which a 75 mmol reduction in 
24-h urinary excretion decreased systolic BP by 5.4 mmHg (0.7 mmHg per 10 mmol/24h) in 
untreated hypertensives [2]. Meta-analyses [2-4] and RCTs [5, 6] have shown that sodium 
reduction affects BP in a dose-response fashion, meaning that each reduction in sodium 
intake will benefit BP.
The well-established relation between sodium intake and BP was not confirmed in our cross-
sectional analysis of 993 Dutch individuals from the Nutritional Questionnaire plus study. In 
this study, sodium intake was estimated from 2 non-consecutive 24-h urine samples, 2 non-
consecutive web-based 24-h recalls, and a validated 180-item food-frequency questionnaire 
(FFQ). In observational studies, accurate assessment of habitual dietary intake is challenging. 
Averaging multiple timed 24-h urinary excretions with checks for completeness of collections 
is considered as the most accurate method to assess habitual sodium intake, as it includes 
discretionary salt and it takes into account the high day-to-day variation of sodium intake 
[7]. In our study, we had to rely on only 2 24-h urine samples (approximately 1 year apart), 
which may have been too imprecise for estimating an individual’s habitual intake. Moreover, 
the web-based 24-h recalls and FFQ used to estimate sodium intake did not include a 
question about discretionary salt, and these self-report methods are prone to error due the 
underreporting and reliance on food composition tables that may be incomplete, not up to 
date, or not accurately capturing the highly variable content of sodium in similar foods of 
different brands [8, 9].
Besides inaccurate assessment of sodium intake, other methodological constraints, 
including limited range of sodium intake, small study population and issues related to the 
cross-sectional design (e.g. reverse causality and residual confounding), may explain the 
lack of finding in our study. Methodological errors and biases have also been reported to be 
responsible for the inconsistent findings in observational studies relating sodium intake to 
cardiovascular disease [8, 9]. When evaluating the effect of sodium intake on cardiovascular 
health, results obtained from observational studies should thus be interpreted with caution.
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Sodium Intake and Endothelial Function
We found no effect of 4 weeks of increased sodium intake on brachial artery flow-mediated 
dilation (FMD), which suggests that supplemental sodium can affect BP without altering 
endothelial function. Other randomized cross-over studies with intervention durations of 
2−6 weeks reported improvements in FMD of 1.5−2.4% after sodium restriction [10-12]. In an 
RCT with 17 middle-aged and older subjects with pre-hypertension (5 on antihypertensive 
medication), FMD improved by 2.4% after 4 weeks of sodium restriction [12]. In an RCT in 29 
overweight and obese subjects with systolic BP between 95 and 138 mmHg, a 2-week low-
sodium diet improved FMD by 1.5% compared to the normal-sodium diet [10]. The same 
researchers showed in 25 overweight and obese subjects with a systolic BP < 139 mmHg that 
FMD improved by 2.1% after a modest sodium restriction for 6 weeks [11]. In RCTs that showed 
an FMD response for sodium, ‘background’ urinary sodium ranged from 1.5−2.6 g/24h and 
sodium doses from 1.4−2.3 g/d. The ‘background’ urinary sodium of 2.5 g/24h in our study is 
in the range of other studies and our dose of 3.0 g/d is even higher, and hence both cannot 
explain why we had a null finding for sodium and FMD. It should be noted, however, that RCTs 
of nutritional factors and FMD are burdensome and that drop-out rates may be as high as 
50% [6], possibly giving biased results. Even in the case of significant effects on FMD, findings 
from these RCTs should be interpreted with caution.
In our study, potassium intake was reduced and therefore ‘background’ urinary potassium 
(~2 g/24h) was lower than in studies showing an FMD response for sodium (~3 g/24h) [5-
7], but whether this difference in potassium intake can explain the discrepancy in results 
is not clear. Also, subjects in our study had on average a higher baseline brachial artery 
diameter and a lower FMD than subjects in studies showing effects on FMD. Important to 
note is that although FMD is considered the best available measure of endothelial function, 
it is a sensitive measurement which can be influenced by minor changes in methodology 
such as placement of the cuff/probe and duration of the cuff inflation, or by external factors 
(e.g. exercise and caffeine intake) [13]. In our study, FMD measurements were done in fasting 
subjects according to a strict protocol, adhering to 2 commonly used guidelines for FMD 
measurements [14, 15]. We were able to detect significant changes in FMD after increased 
potassium intake (discussed below). Therefore, we consider it unlikely that measurement 
flaws account for our null findings for sodium intake.
Besides FMD, we measured blood biomarkers involved in cellular adhesion, coagulation and 
low-grade inflammation. We also observed no effects of increased sodium intake on these 
biomarkers, except for an increase of 0.24 pg/ml in vasoconstrictor endothelin-1, considered 
to be a biomarker of endothelial function. In 2 studies by other research groups that showed 
an effect on FMD also the effects of sodium restriction on endothelial blood biomarkers 
were assessed [11, 12]. One study showed a decrease of 0.20 pg/ml in endothelin-1 and no 
changes in adhesion molecules after moderate sodium restriction for 6 weeks [11], in line 
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with our findings. The other study showed, in contrast, higher endothelin-1 levels after 4 
weeks of sodium restriction, but this effect was not significant [12]. 
Sodium Intake and Other Outcomes
Arterial stiffness is an indicator of vascular health and closely linked to BP [16, 17]. In our 
RCT, 4 weeks of supplemental sodium had no effect on arterial stiffness, which was non-
invasively assessed by measuring augmentation index and pulse wave velocity using 
applanation tonometry. The 4-week duration may have been too short to induce changes 
in arterial stiffness. Nevertheless, in other trials with a 4−6 week duration, dietary sodium did 
affect pulse wave velocity, a direct measure of arterial stiffness, in (pre)hypertensive subjects 
[18-20], but not in normotensive subjects [11, 21]. It has been hypothesized that short-term 
interventions may affect arterial stiffness by influencing functional mechanisms, such as 
vascular tone and endothelial function rather than vascular structure [22]. 
In a post-hoc analysis we examined the effects of sodium intake on fluid balance, a key 
factor in BP regulation. For increased sodium intake, we found increases in estimated 
glomerular filtration rate (eGFR), plasma natriuretic peptides, and decreases in plasma renin 
and aldosterone, in line with previous findings [23, 24]. The increase in eGFR likely reflects 
induced hyperfiltration, which is associated with increased intraglomerular pressure [25, 26]. 
The stimulation of release of plasma natriuretic peptides allows for increased natriuresis, 
and the suppression of renin-angiotensin-aldosterone system (RAAS) results in a decreased 
tendency for sodium reabsorption. These physiological changes indicate that compensatory 
responses are stimulated upon deranged fluid status. These compensatory responses are 
known to be more pronounced with sudden and large changes in sodium intake and much 
smaller or minimal with a longer term modest change in sodium intake [2]. Hence these 
effects seen in our trial after a 4-week increase in sodium intake are likely to attenuate over 
time, but were not examined in our study. We also investigated the effects of sodium intake 
on plasma copeptin, which is part of the precursor of arginine vasopressin [27]. Copeptin was 
found to be a reliable surrogate for arginine vasopressin that is more stable ex vivo and easier 
to measure [28, 29]. Secretion of vasopressin is stimulated by hypovolemia and increased 
osmolarity [30]. We found that supplemental sodium for 4 weeks increased plasma copeptin 
concentrations. This was also observed in another RCT and based on this finding the authors 
suggested that the sodium-induced increase of osmolarity is a more potent stimulus for 
vasopressin secretion than sodium-induced increase of blood volume, as the latter would 
inhibit vasopressin release [30].
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VASCULAR EFFECTS OF POTASSIUM INTAKE
Potassium Intake and BP
We found that supplemental potassium of ~3 g/d on top of the relatively low-sodium diet 
increased 24-h urinary potassium by 63 mmol (equals 2.5 g) and lowered 24-h BP by 3.9/1.6 
mmHg. In a meta-analysis of 21 RCTs of at least 4 weeks duration, increased potassium reduced 
systolic BP by 3.5 mmHg. When stratified by hypertension status, systolic BP was reduced by ~5 
mmHg in people with hypertension, but unaffected in people with normal BP (with the latter 
based on 3 studies) [4]. Subgroup analysis in our trial showed, however, that supplemental 
potassium reduced 24-h systolic BP by 6 mmHg in subjects with a normal BP (see Table 2). We 
established a high contrast in potassium intake and other dietary factors were fully controlled. 
In the meta-analysis of Aburto et al. [4], largest improvements in BP were found for achieved 
potassium intakes of 3.5 to 4.7 g/d, without a clear dose-response association. However, in a 
meta-analysis of 15 RCTs in which subjects were not on antihypertensive treatment, a dose-
response association was found between increased urinary potassium excretion and the 
reduction in BP [31], indicating that each increment in potassium intake would improve BP. 
The meta-analysis of Aburto et al. [4] also suggested that potassium may be more effective 
in reducing BP at higher levels of sodium consumption: systolic BP was reduced by 7 mmHg 
for sodium intake of > 4 g/d and by 2 mmHg for sodium intake of 2−4 g/d, although these 
estimates were not significantly different. In our trial, subjects consumed a relatively low-
sodium diet (2.2 g/d). It is possible that the effect of increased potassium intake on BP in 
individuals with Western, high-salt diets are greater than observed in our study in which the 
‘background’ sodium intake was reduced. 
TABLE 2. Effects of potassium supplementation on BP and heart rate by pre-treatment systolic BP
  Values after 4 weeks of interventiona   Treatment effectb
  Potassium Placebo   Potassium vs placebo P 
SBP < 140 mmHg (n=11)
24-h SBP, mmHg 118.2 ± 6.5 124.5 ± 11.2 -6.0 (-11.4, -0.5) 0.033
24-h DBP, mmHg 73.4 ± 4.9 77.3 ± 5.4 -3.8 (-6.6, -1.1) 0.008
24-h HR, bpm 70.6 ± 8.6 68.1 ± 9.4 2.5 (-0.5, 5.6) 0.10
SBP ≥ 140 mmHg (n=25)
24-h SBP, mmHg 128.9 ± 14.3 131.6 ± 14.9 -2.7 (-6.3, 0.8) 0.13
24-h DBP, mmHg 75.6 ± 8.8 76.2 ± 9.3 -0.6 (-2.4, 1.3) 0.54
24-h HR, bpm 67.5 ± 8.6 64.9 ± 9.4   2.6 (0.8, 4.4) 0.005
Abbreviation: BP, blood pressure; bpm, beats per minute; DBP, diastolic blood pressure; HR, heart rate; SBP, systolic 
blood pressure. a Unadjusted mean ± SD. b Mean differences (95% CI) obtained from linear mixed-effects model for 
repeated measurements using the compound symmetry covariance structure.
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The inverse relation between potassium intake and BP was also observed in our cross-
sectional analysis of 993 apparently healthy Dutch individuals not on antihypertensive 
medication from the Nutritional Questionnaire plus study. Each 1 g/d increase in potassium 
intake, based on 2 24-h urine samples, was associated with a 1.6/1.5 mmHg lower systolic/
diastolic BP. Potassium intake estimated by FFQ showed a similar, though borderline 
significant, association with systolic BP (-1.4 mmHg per 1 g/d increment), and a significant 
association with diastolic BP (-1.1 mmHg per 1 g/d increment). These BP estimates for 
potassium are in the order of magnitude as observed in our RCT (i.e. 1.3 mmHg decrease in 
24-h systolic BP per gram of potassium) and other RCTs [32]. However, no association was 
observed for potassium intake estimated from 2 web-based 24-h recalls. The tool is based on 
the 5-step multiple pass method, a proven technique to increase the accuracy of recalls [33-
36]. The web-based method as such, however, has not yet been validated. Based on these 
results, it seems that 2 24-h urinary collections and a FFQ are appropriate for studying the 
association between potassium intake and BP in cross-sectional studies. 
Potassium Intake and Endothelial Function
In our trial, potassium supplementation improved FMD by 1.2% and tended to lower IL-8 
(a biomarker of inflammation), without affecting other blood biomarkers of endothelial 
function and inflammation. Another RCT in untreated hypertensives investigating the 
effects of potassium chloride supplements and potassium bicarbonate supplements, each 
for 4 weeks, showed for ~45 mmol/24h higher urinary potassium increases in FMD of 2.7% 
and 1.5%, respectively [37]. In contrast, increasing potassium intake for 6 weeks through 
potassium citrate supplements and fruit and vegetables with a maximum increase in urinary 
potassium excretion of 27 mmol/24h caused no change in FMD in early hypertensives [38]. 
Possibly, a minimum potassium dose is required to affect FMD. We examined the effect of 
potassium supplementation on FMD while dietary sodium was reduced, i.e. urinary sodium 
excretion of 2.2 g/d. In the other FMD studies ‘background’ urinary sodium ranged from 2.7 to 
3.1 g/d. Since the difference in sodium are only small, we cannot draw conclusions about the 
relevance of the ‘background’ sodium diet. 
Although not as comprehensively assessed as in our trial, other RCTs demonstrated no effect 
of potassium on endothelial biomarkers [38-40], or the inflammatory marker C-reactive 
protein [38, 40]. To our knowledge, other studies have not addressed the effects on other 
inflammatory markers than C-reactive protein. Since in our study the effect on IL-8 was no 
longer significant after the exclusion of intervention periods in which subjects were non-
compliant, and other cytokines were not affected, we consider increased potassium intake 
unlikely to have a major impact on low-grade inflammation in the short-term. 
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Potassium Intake and Other Outcomes
In our RCT, augmentation index, the indirect measure of arterial stiffness, was unaffected 
by supplemental potassium. The effect of potassium on pulse wave velocity (-0.35 m/s), the 
direct measure of arterial stiffness, was not statistically significant. A recent meta-analysis of 
6 RCTs including ours showed also no effect of potassium on augmentation index [41]. Pulse 
wave velocity in the meta-analysis was unlikely to be affected by potassium (pooled estimate: 
-0.34 m/s, P=0.39), but the authors noted that the small number and heterogeneity of studies 
made it difficult to draw a definite conclusion [41]. Four weeks of supplemental potassium 
in an RCT in 42 untreated hypertensives [37] and 6 weeks of supplemental potassium in 
40 subjects at increased CVD risk [40] significantly reduced pulse wave velocity by 0.8 and 
0.4 m/s, respectively. Both studies used a potassium dose of 2.5 g/d, which is comparable 
to the dose in our study. A trial in 48 early hypertensives with lower doses of potassium, 
found no effect [38]. Our study showed a reduction in pulse wave velocity, but may have 
been underpowered to detect a statistically significant effect. More studies are needed to 
determine whether potassium supplementation affects pulse wave velocity. 
Potassium is thought to exert a BP lowering effect, at least in part, through stimulation of 
natriuresis [42, 43]. To gain more insight in the effects on fluid balance, we investigated 
the effect of potassium intake on body fluid balance parameters. We found that 4 weeks of 
potassium supplementation decreased plasma MR-pro-ANP and increased plasma copeptin, 
renin, aldosterone and 24-h heart rate. Our findings suggest that increased potassium intake 
decreases effective circulating volume and cardiac output to such an extent that counter 
regulatory mechanisms (i.e., increased secretion of vasopressin, stimulation of RAAS, and 
increased heart rate) are activated to maintain volume homeostasis. Limited studies have 
addressed the effect of potassium intake on fluid balance. The stimulation of the RAAS 
was also found in an RCT of subjects at moderate cardiovascular risk after 6 weeks of 2.5 
g/d potassium supplementation [40], but not in an RCT of untreated hypertensives with a 
similar dose for 4 weeks [37]. To our knowledge, no other study has investigated the effects 
of potassium intake on copeptin. Most likely, vasopressin was increased to raise extracellular 
volume towards normal by stimulation of water reabsorption. Changes in body weight in our 
trial were not a good indicator of fluid retention because of the fully controlled dietary setting 
in which we adjusted individuals’ energy intake to keep body weight constant. 
We found a 2.6-bpm increase in ambulatory heart rate during potassium, but no effect on 
office heart rate. To further investigate whether heart rate was affected by potassium intake 
we performed a meta-analysis of 22 randomized, placebo-controlled trials in healthy adults. 
Results indicated that potassium supplementation of 2−3 g/d for a minimum duration of 
2 weeks is not expected to affect heart rate in apparently healthy adults. Besides our RCT, 
only 3 other RCTs studied the effect of potassium on 24-h heart rate [38, 39, 44]. Subgroup 
analyses suggested a pooled estimated for 24-h ambulatory heart rate of 0.99 beats/min, 
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but results were not significant (P=0.26) and the analysis relied heavily on our trial. Other 
stratified analyses (e.g. by duration and potassium dose) yielded also no significant effects 
of potassium intake on heart rate in subgroups, and there was no evidence for a dose-
response relationship in meta-regression analyses. Overall, we conclude that potassium 
supplementation in the normal range of dietary intakes is unlikely to have a persistent effect 
on heart rate in apparently healthy individuals.
Conclusion Based of Main Findings and Directions for Future Research
From the findings presented in this thesis, we can conclude that increasing sodium intake 
from the recommended maximum target to a level that is common in Western societies 
strongly raises BP in individuals with an untreated mildly elevated BP. We cannot draw a 
definite conclusion about the effects of sodium on endothelial function. Where previous 
studies indicated that sodium intake affects endothelial function, our study indicated based 
on a comprehensive assessment no effect. Because the number of studies is still limited and 
results are inconsistent, more RCTs are needed to determine whether sodium intake affects 
endothelial function, and whether the effect could depend on ‘background’ potassium 
intake. A high-sodium diet likely deranges fluid status and elicits RAAS suppression and other 
compensatory responses to maintain volume homeostasis. Longer-term RCTs are required 
to investigate whether these effects in fluid parameters attenuate over time, reaching a new 
steady-state.
Increasing potassium intake lowers BP, even when people are on a relatively low-sodium 
diet. The BP response is likely accompanied by an improvement in endothelial function as 
assessed by FMD, but without changes in other indicators of endothelial function or low-
grade inflammation. Since we found an effect on FMD, one may argue whether we measured 
the best biomarkers of endothelial function. Endothelial function is a complex process 
involving a number of factors and it needs to be determined which factors are directly 
related to potassium intake-induced changes in FMD. We cannot conclude whether the 
improvement in endothelial function preceded or followed BP reduction, or whether these 
changes are independent. Dose-response studies are required to explore whether there may 
be a threshold minimum dose above it is unlikely to detect an effect, because an RCT with a 
lower dose of potassium did not find an effect on FMD. 
Supplemental potassium during a relative low-sodium diet is likely to decrease effective 
circulating volume to such an extent that several mechanisms (i.e. increased secretion 
of vasopressin, stimulation of RAAS, and increased heart rate) are activated to maintain 
volume homeostasis. Since the available evidence is scarce and inconclusive, more studies 
are warranted. Although in our RCT ambulatory heart rate was increased after potassium 
supplementation, our meta-analysis showed that increasing potassium intake by 2−3 g/d for 
at least 2 weeks is unlikely to affect heart rate in apparently healthy adults. Based on the work 
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presented in this thesis, we cannot conclude whether sodium and potassium affect arterial 
stiffness in relative healthy individuals with untreated elevated BP. Larger and longer-term 
RCTs in healthy and patient populations are needed to investigate whether these minerals 
could be meaningful for improving vascular compliance. 
In the present thesis a number of physiological pathways have been described, but there may 
be more mechanisms that could explain effects of sodium and potassium on BP and vascular 
health. These could involve the sympathetic nervous system, glucose metabolism and the 
immune system [45, 46]. Since these outcomes have been implicated in the pathogenesis of 
hypertension it would be worthwhile investigating whether they are modulated by sodium 
and potassium intake. Potential outcome measurements in future studies include plasma 
and/or urinary catecholamines, serum cortisol, serum insulin, glucose and HbA1c, and T 
helper cells [45].
PUBLIC HEALTH IMPLICATIONS
Impact on Cardiovascular Disease
As much as 18% of global deaths can be attributed to elevated BP [47]. In a meta-analysis 
of individual data, each 20-mmHg increment in systolic BP was associated with 51% greater 
risk of stroke mortality and 43% greater risk of ischemic heart disease mortality in European 
individuals aged 40−89 years [48]. These estimates highlight the importance of interventions 
to reduce BP. 
We demonstrated that a 7.5-mmHg lower systolic BP can be achieved by reducing salt intake 
from the level common in Western societies (12−13 g/d) to the recommended level (5−6 g/d). 
Furthermore, when subjects adhere to the recommended level for salt intake, increasing 
potassium intake can lower BP even further by 3−4 mmHg. Thus, lowering salt intake and 
increasing potassium intake can lower systolic BP by 11 mmHg in untreated individuals. If 
we extrapolate the findings of the meta-analysis to our findings, a reduction of 11 mmHg 
in office systolic BP would be associated with a 32% lower risk of stroke mortality and 27% 
lower risk of ischemic heart disease mortality [48]. This estimated impact on mortality risk 
is based on office BP. Since ambulatory BP, a measure used in our study, is suggested to be 
prognostically superior to office BP, risk reductions may be even greater [49]. For comparison, 
the systolic BP reduction that we observed for a low sodium, high potassium intake is of the 
same magnitude as may be achieved with antihypertensive medication in individuals with 
a systolic BP of 120−140 mmHg [50]. Systolic BP reductions ranging from 2 to 9 mmHg were 
achieved when angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers 
and/or calcium channel blockers were used as antihypertensive medication [50].
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Apart from BP, changes in FMD may be predictive for CVD. In meta-analyses each 1% increase 
in FMD was associated with an 8−13% lower risk of cardiovascular events [51, 52]. The 
improvement in FMD by 1.2% found for an increased potassium intake could theoretically 
lead to a CVD risk reduction of 10−16%. A comparable impact may be expected from 
potassium-induced changes in systolic BP of 4 mmHg, i.e. 13% lower stroke mortality risk 
and 11% lower ischemic heart disease mortality risk [48]. 
Strategies for Lowering Sodium and Increasing Potassium Intake
In the present thesis, the effects of increasing the intake of salt from 5−6 to 12−13 g/d and 
potassium from 2−3 to 5−6 g/d were studied. These intakes are within the range of intake 
commonly consumed, and hence the doses used in our study are achievable in real-life 
settings. Around the world people consume on average 9−12 g of salt on a daily basis, 
which is far beyond the recommended maximum intake of 5−6 g per day. Main strategies 
to reduce sodium intake include 1) the consumers’ selection of low-sodium foods instead 
of high-sodium foods by reading food labels and avoiding processed foods, 2) use of less 
salt in cooking and at the table, and 3) lowering the sodium content by reformulation of 
industrially produced foods. Since in Western societies 80% of daily salt intake comes from 
salt in processed foods rather than from table salt [53] and consumers may not be able to 
change their dietary behavior, reformulation of foods may be the most effective means to 
reduce sodium intake [54]. Hendriksen et al. [55] estimated that reducing the level of sodium 
intake in processed foods to a technologically feasible minimal level may cut down median 
sodium intake by 38% in the general Dutch population (e.g. from 3.0 g/d to 1.9 g/d in adult 
men). Governments worldwide, with the help of advocacy groups, put pressure on the food 
industry to add less salt to foods [54]. A few countries have set mandatory limits for specific 
food products (e.g. bread) [54].
In most populations potassium intakes are below recommendations [56]. Potassium is 
abundantly available in unrefined foods such as fruits and vegetables, legumes, whole grains 
and dairy products and promoting the intake of these foods will increase potassium intake. 
To illustrate, the intake of a glass of milk, a kiwi and a banana provides 1 gram of potassium 
[57]. Potassium-rich unrefined food products are included in guidelines for healthy diets. 
Adherence to the DASH eating plan will result in a potassium intake of 4.7 g/d [58]. The latest 
versions of the DASH diet as advised by the Dietary Guidelines for Americans are also low 
in sodium (menus available for sodium levels of 1.5 and 2.3 g/d) [58]. This diet is based on 
the DASH-sodium trial [6] and is similar to our trial with regard to the targets for sodium and 
potassium intake. A difference is that the changes in sodium and potassium intake in the 
DASH-sodium trial are established by means of a food-based approach and in our trial by 
the use of supplements. Since potassium-rich foods, like fruits and vegetables, may have 
additional beneficial effects on health besides the potassium-induced effects, increasing 
potassium intake by the consumption of foods instead of supplements is preferred. Examples 
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of other nutrients that contribute to the health effects of fruits, vegetables and other plant 
foods are fibers, polyphenols and magnesium [59]. 
 
Under normal physiological conditions the body is able to excrete excess amounts of 
potassium, mainly through urine [60], and hence the high potassium intake (5 g/d) as 
achieved in our trial does not pose the general population at risk for adverse health effects. 
However, in clinical practice, some individuals may be more vulnerable to undesirable effects 
of high potassium intake. These include patients with impaired kidney function, especially 
those with a glomerular filtration rate of less than 20 ml/min/1.73 m2, and patients using 
potassium-sparing diuretics or medication that affect the RAAS (e.g. angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers). In these patients, changes in serum 
potassium after high potassium intake may pose them at risk for hyperkalemia and cardiac 
arrhythmias [61]. The value of increasing potassium intake, either through healthy diet, salt 
substitutes, or supplements, in patients who use cardiovascular medication and in patients 
with impaired kidney function warrants more research. As common in medical practice, 
medication is the primary choice of antihypertensive treatment, after which dietary advice 
may follow. Clinical studies are needed in which diet is changed first, and medication 
adopted accordingly, to find out how BP and vascular health could benefit from changes in 
potassium (and sodium) intake in vulnerable patient groups. 
OVERALL CONCLUSIONS
In this thesis we examined the BP effects of sodium and potassium intake in the broader 
context of cardiovascular health, focusing also on endothelial (dys)function, arterial stiffness, 
body fluid balance and heart rate. Based on the results of this thesis we conclude that 
increasing sodium intake from a recommended level to a level that is common in Western 
societies strongly raises BP. The results for endothelial function and arterial stiffness are 
inconclusive, and more (longer-term) studies are warranted. Increasing the intake of 
potassium lowers BP and may improve endothelial function, also in people already adhering 
to the dietary guideline for sodium. Both sodium and potassium intake affected fluid 
parameters, likely indicating that compensatory responses are stimulated to maintain body 
fluid balance. Evidence for the effects of potassium on endothelial function and fluid balance 
parameters, however, is limited and further research is needed. Based on the work presented 
in this thesis, it is unlikely that increasing potassium intake in the normal range of dietary 
intakes affects heart rate in apparently healthy adults. When evaluating the effect of sodium 
and potassium interventions on cardiovascular health, results obtained from observational 
studies should be interpreted with caution, particularly for sodium intake. Around the world 
people consume on average 9−12 g of salt and 2−4 g of potassium on a daily basis. A more 
optimal intake of sodium and potassium can be achieved through adherence to dietary 
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guidelines and product reformulation by food industry. This could reduce BP by more than 
10 mmHg and lower the number of cardiovascular deaths by at least one-quarter in Western 
populations. 
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Cardiovascular diseases (CVD) are the main cause of death worldwide. Annually, about 17.5 
million people die from CVD, accounting for ~30% of deaths worldwide. Elevated blood 
pressure (BP) is a major risk factor for CVD and the largest single contributor to global 
mortality. BP is a modifiable risk factor that is largely determined by lifestyle factors, including 
diet. Dietary minerals, in particular sodium and potassium, play an important role in BP 
regulation. While adverse effects of sodium and beneficial effects of potassium on BP have 
repeatedly been shown in human intervention studies, evidence on other vascular effects of 
these dietary minerals is still scarce. Therefore, we investigated the BP effects of sodium and 
potassium intake in healthy humans in a broader (patho)physiological context, focusing also 
on endothelial function, arterial stiffness, fluid regulation and heart rate.
In Chapter 2, the effects of sodium and potassium supplementation on BP and arterial 
stiffness were examined by means of a randomized placebo-controlled crossover trial. Thirty-
six untreated Dutch individuals with mildly elevated BP on a fully controlled diet that was 
relatively low in sodium (2−3 g/d) and potassium (2−3 g/d) received capsules with sodium (3 
g/d), potassium (3 g/d) or placebo, for 4 weeks each, in random order. After each intervention, 
fasting office BP, 24-h ambulatory BP and measures of arterial stiffness were assessed. 
The results of this study showed that increased sodium intake strongly raised office and 
ambulatory systolic BP (7−8 mmHg) whereas increased potassium intake lowered systolic BP 
(3−4 mmHg). Potassium supplementation increased ambulatory heart rate, but office heart 
rate was not affected. Measures of arterial stiffness were not materially affected by increased 
sodium or potassium intake, possibly due to the relatively short intervention period.
In the same study we investigated the effects of increased sodium and potassium intake 
on the functional measure of endothelial function (flow-mediated dilation), and on a 
comprehensive set of biomarkers of endothelial dysfunction and low-grade inflammation 
(Chapter 3). Four weeks of supplemental sodium had no effect on brachial flow-mediated 
dilation, or on the blood biomarkers of endothelial dysfunction and low-grade inflammation, 
except for an increase in serum endothelin-1 (a biomarker of endothelial dysfunction). 
Potassium supplementation improved flow-mediated dilation by 1.2% and tended to 
lower the low-grade inflammation marker interleukin-8. This suggests that potassium may 
beneficially influence vascular health by improving endothelial function. 
In a post-hoc analysis of the same study in 35 untreated individuals, the humoral effects 
of supplemental sodium and potassium were assessed using a panel of markers that are 
involved in osmoregulation and volume regulation (Chapter 4). Results showed that 
supplemental sodium increased plasma natriuretic peptides and plasma copeptin, and 
suppressed the renin-angiotensin system. Supplemental potassium decreased plasma MR-
pro-ANP, increased plasma copeptin, and stimulated the renin-angiotensin system. These 
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findings suggest that the mineral-induced changes in BP elicit several counter regulatory 
mechanisms to maintain volume homeostasis.
In Chapter 5, the effect of potassium supplementation on heart rate was assessed in a meta-
analysis of 22 randomized, placebo-controlled trials in healthy adults. Overall, increasing 
potassium intake by 2−3 g/d for at least two weeks did not affect resting heart rate. Twenty-
four-hour ambulatory heart rate was not significantly affected in subgroup analysis of 4 
RCTs, including ours. Other subgroup analyses for characteristics of the study and study 
population also showed no significant effects, and there was no evidence for a dose-
response relationship. These results suggest that increasing potassium intake is not expected 
to adversely affect heart rate in apparently healthy adults.
In Chapter 6, BP associations for sodium and potassium intake using different dietary 
assessment methods were examined. Data of 993 healthy Dutch adults not on antihypertensive 
medication were analyzed using a cross-sectional approach. Sodium and potassium intake 
were estimated from two non-consecutive 24-h urinary samples (considered as the gold 
standard), two non-consecutive web-based 24-h recalls, and a validated 180-item food 
frequency questionnaire (FFQ). This study showed no significant associations of sodium 
intake with BP, regardless of the dietary assessment method used. Potassium intake estimated 
from 24-h urine and FFQ was inversely associated with BP (~1.5 mmHg reduction per 1 g/d 
increment). This suggests that dietary assessment methods in cross-sectional studies may 
be inadequate for estimating the association of sodium intake with BP, but may yield reliable 
results for potassium intake.
As discussed in Chapter 7, the studies presented in this thesis indicate that increasing sodium 
intake from a recommended level to a level that is common in Western societies for four 
weeks strongly raises BP in individuals with an untreated mildly elevated BP. The results 
for endothelial function and arterial stiffness are inconclusive, and hence more (longer-
term) studies are warranted. Increasing the intake of potassium lowers BP and improves 
endothelial function, even in individuals on a relatively low-sodium diet. Both sodium and 
potassium intake affected fluid parameters, likely indicating that compensatory responses 
are stimulated to maintain body fluid balance. Although in our RCT ambulatory heart rate 
was increased after supplemental potassium, the meta-analysis showed that increasing 
potassium intake is unlikely to affect heart rate in apparently healthy adults. When evaluating 
the effectiveness of sodium and potassium intake on cardiovascular health, results obtained 
from observational studies should be interpreted with caution, particularly for sodium intake. 
Around the world people consume on average 9−12 g of salt and 2−4 g of potassium on a daily 
basis. A more optimal intake of sodium and potassium can be achieved through adherence 
to dietary guidelines and product reformulation by food industry. This could reduce BP by 
more than 10 mmHg and lower the number of cardiovascular deaths by at least one-quarter 
in Western populations. 
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